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 2 
 
Pgi 
PrH 
QAT 
SAL 
SGZ 
SPT 
nucleus paragigantocellularis 
nucleus prepositus hypoglossi 
quinine aversion test 
saline 
subgranular zone 
saccharin preference test 
TMS 
TrkB 
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Outline of the thesis 
 
Chapter 1 provides a general introduction on epilepsy and depression, two highly prevalent disorders 
that occur together very frequently. Etiology, diagnostic criteria, classification and treatment options 
are highlighted. Furthermore, this chapter discusses the use of vagus nerve stimulation (VNS) for the 
treatment of refractory epilepsy and depression. Several aspects of VNS including the anatomy of the 
vagus nerve, the implantation procedure, safety and tolerability, stimulation parameters and efficacy 
are highlighted.  
Chapter 2 describes the research aims and the rationale of this thesis. Furthermore, the animal 
models and behavioral tests used in this thesis are discussed. 
Chapter 3 comprises three studies. The first study is a proof-of-concept study where the 
antidepressant potential of VNS is assessed in an animal model for temporal lobe epilepsy and 
comorbid depression. The second study investigates whether the locus coeruleus plays an important 
role in the antidepressant-like mechanism of action of VNS. The third literature study resulted in a 
review on the putative antidepressant mechanism of action of VNS, focusing on two major 
hypotheses in depression research: the monoaminergic hypothesis and the neural plasticity 
hypothesis of major depressive disorders. 
Chapter 4 focuses on the optimization of the stimulation parameters and comprises three studies. 
The first study investigates the effect of various VNS output current intensities on cortical excitability 
in the motor cortex stimulation rat model. The hypothesis that low output current intensities are 
sufficient to affect cortical excitability, is tested. The second and third study consist of two 
translational studies. The goal of these experiments is to determine whether laryngeal motor-evoked 
muscle potentials or LMEPs can be recorded in a minimally invasive way in chronically VNS-implanted 
rats and patients. The ultimate goal of these studies is to investigate whether LMEPs can be used to 
optimize the stimulation parameters and as an indicator of effective delivery of electrical current to 
the vagus nerve. In a first phase, the technique is optimized in chronically VNS-implanted rats. In a 
second phase, we aim at translating this technique to clinical practice. 
 
Chapter 5 starts with the general conclusion by answering the questions listed in the aims in chapter 
2. This is followed by the discussion and future perspectives. 
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Epilepsy 
 
With a worldwide prevalence of approximately 0.5-1.0%, epilepsy is the second most common 
neurological disorder following neurovascular diseases [1]. The International League against epilepsy 
(ILAE) defines epilepsy as a chronic neurological condition, characterized by recurrent epileptic 
seizures. An epileptic seizure manifests itself as a transient occurrence of signs and/or symptoms 
which may include alterations of consciousness, motor, sensory, autonomic or psychic events and 
results from abnormal excessive or synchronous neuronal activity in the brain [2]. Two epileptic 
seizures are separated in time by a period without seizures, which is defined as the interictal period. 
Although no overt signs of epilepsy may be visible during the interictal period, there might be some 
abnormalities such as interictal spikes [3]. 
 
According to the classification of the ILAE, seizures are divided into two main categories depending 
on their onset in the brain: partial and generalized seizures. Partial or focal seizures result from an 
abnormal paroxysmal discharge originating in one of the cerebral hemispheres. The clinical 
expression and the severity of these seizures is dependent on the region of onset (e.g. motor or 
visual symptoms when the motor or the visual cortex is involved respectively). These seizures are 
further subdivided into simple and complex seizures referring to the retention and the impairment or 
complete loss of consciousness respectively. Both types of partial seizures can develop into 
secondary generalized seizures when the epileptic activity spreads to the contralateral hemisphere. 
Primary generalized seizures result from abnormal paroxysmal discharges arising in both cerebral 
hemispheres. These seizures are further subdivided into tonic-clonic, tonic, clonic, atonic, absence 
and myoclonic seizures according to the clinical and electroencephalographic (EEG) characteristics. 
Tonic-clonic seizures are characterized by a sudden tonic contraction of muscles followed by clonic 
convulsions and subsequent muscle relaxation. During this type of seizures, there is loss of 
consciousness from seizure onset to the late phase of recovery. As their name suggests, tonic and 
clonic seizures only consist of the tonic or clonic phase respectively. Atonic seizures on the other 
hand, are characterized by a sudden loss of muscle tone and subsequently often result in falling. 
Absence seizures are characterized by a sudden interruption of ongoing activities, a blank stare and a 
sudden end. These seizures are associated with typical bursts of bilateral synchronous spike-wave 
discharges on the EEG. Children between the age of 4-12 years are most susceptible to this type of 
seizures. Myoclonic seizures present as involuntary single or multiple sudden, brief, shock-like 
contractions of muscles or muscle groups and are not associated with loss of consciousness [4, 5]. 
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The diagnosis of epilepsy is made when two or more unprovoked seizures have occurred and is 
primarily based on the medical history of the patient and on EEG recordings. Furthermore, additional 
investigations including a neuropsychological evaluation, magnetic resonance imaging, single photon 
emission computed tomography, positron emission tomography and magnetoencephalography can 
be used to investigate the etiology, to determine the affected brain region and to subclassify the 
epilepsy syndrome. 
 
 
Etiology 
In the normal brain, a constant equilibrium is maintained between excitation and inhibition. In an 
epileptic brain on the other hand, this balance is disturbed and inhibition fails to counteract sudden 
hyperexcitable and/or synchronous electrical activity. This may result from changes in mechanisms 
intrinsic to neurons such as changes in conductance of ion channels, second messenger systems and 
protein expression or from mechanisms extrinsic to neurons such as changes in amounts of 
neurotransmitters [6]. The potential causes of epilepsy are heterogeneous, ranging from genetic 
defects, structural abnormalities, metabolic diseases, infections of the central nervous system, 
neurodegenerative disorders, brain injury, stroke to brain tumors [7]. According to the underlying 
cause, symptomatic, idiopathic and cryptogenic epilepsy syndromes were defined by the ILAE [8]. 
Symptomatic epilepsy syndromes are caused by structural or metabolic abnormalities in the brain, 
which can either be acquired (e.g. infections or brain trauma), endogenous (e.g. cortical dysplasia) or 
genetic (e.g. tuberous sclerosis) in origin. Idiopathic epilepsy syndromes present without a structural 
abnormality and are believed to have a strong underlying genetic basis. Cryptogenic epilepsy 
syndromes are epilepsy syndromes with unknown etiology [8]. The ILAE has proposed a new 
categorization of these epilepsy syndromes based on their etiology. In this new classification, the 
epilepsy syndromes are divided into genetic, metabolic/structural and of unknown cause [2]. 
 
Standard treatment 
Pharmacotherapy - antiepileptic drugs 
Antiepileptic drugs are the standard first-line treatment for epilepsy. The mechanism of action of 
different antiepileptic drugs varies, but the main mechanisms are based on restoring the disturbed 
excitation/inhibition equilibrium within the brain through (1) blockade of voltage-gated ion channels, 
(2) stimulation of the inhibitory GABA-ergic system and (3) inhibition of the excitatory glutamatergic 
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system [9]. Initially, one antiepileptic drug is started at a low dose and is slowly up-titrated. In case 
no optimal response is achieved due to side effects or ongoing seizures, a second monotherapy is 
started. When two first-line monotherapy trials fail, the chance to render a patient seizure free with 
a third monotherapy drops to 5% and a combination of two or more antiepileptic drugs is 
administered [5]. Common adverse events of antiepileptic drugs are somnolence, dizziness, 
blurry vision and cognitive problems [10]. 
 
Prognosis and alternative treatments 
Although the majority of epileptic patients experience a significant reduction in seizure frequency 
with antiepileptic drugs, more than 30% of patients suffer from uncontrolled seizures or intolerable 
side effects despite an adequate treatment [11]. These patients suffer from refractory epilepsy, 
which is associated with excess injury, mortality, significant cognitive impairment and economic costs 
[12]. The ILAE defines refractory epilepsy as: “the failure of adequate trials of two tolerated and 
appropriately chosen and used antiepileptic drug schedules (whether as monotherapy or in 
combination) to achieve sustained seizure freedom” [13]. For patients suffering from refractory 
epilepsy, alternative treatments are necessary and include phase 3 trials with newly developed 
antiepileptic drugs, epilepsy surgery, dietary treatments, immunological treatments and 
neurostimulation modalities [14]. 
 
Phase 3 trials with newly developed antiepileptic drugs 
The administration of newly developed antiepileptic drugs leads to 50% seizure frequency reduction 
and seizure freedom in only 21% and 6% of refractory patients respectively [15]. Furthermore, 
patients who are included in consecutive phase 3 trials often experience a poor quality of life [16]. 
 
Epilepsy surgery 
Epilepsy surgery is a neurosurgical procedure where the area of the brain involved in seizure 
generation is either resected or disconnected. Resective surgery consists of the removal of brain 
tissue that is responsible for provoking habitual seizures in an individual patient (e.g. lobectomy, 
lesionectomy or hemispherectomy). Disconnective surgery involves the disconnection of nerve fibers 
through which abnormal epileptic activity spreads to the adjacent tissue (e.g. callosotomy, multiple 
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subpial transections or gamma-knife surgery) [17]. Epilepsy surgery results in seizure freedom in up 
to 85% of the patients depending on the localization of the seizure focus [18].  
 
Dietary treatments 
Dietary treatments involve the ketogenic and the Atkins diet. The ketogenic diet, which is very high in 
fat and low in carbohydrates, is thought to simulate the metabolic effects of starvation by forcing the 
body to use fat as a primary fuel source, thereby creating ketones. These ketones are then used in 
the brain as an alternative energy source, which is associated with a significant (>90%) seizure 
reduction and complete seizure freedom in 30% and 10-15% of patients respectively [19]. Despite 
the substantial seizure reduction, the diet is often discontinued because of side effects such as 
constipation, sleepiness and nausea. Furthermore, the ketogenic diet is not typically offered to adults 
due to the significant lifestyle alterations needed for its use. The Atkins diet is also based on the 
intake of fat and the restriction of carbohydrates, but the daily allowed amount of proteins is higher 
compared to the ketogenic diet. Half of the patients experience a seizure frequency reduction of 50-
90%, while 28% of patients even report a seizure frequency reduction of more than 90% [14]. 
Nevertheless, a substantial part of the patients also stop the Atkins’ diet because of inefficacy, side 
effects and restrictiveness [20, 21].  
 
Immunological treatments 
Immune system dysfunction may play a role in epilepsy by triggering or maintaining epileptic 
seizures. Therefore, immunological treatments may have a beneficial effect on epileptic seizures. In 
approximately half of patients, seizure frequency can be reduced with 50% [22]. However, this 
treatment is associated with significant side effects including electrolyte disturbances, glucose 
intolerance, hypertension, increased susceptibility for infections, osteoporosis, myopathy and 
cardiomyopathy [14]. 
 
Neurostimulation modalities 
Neurostimulation is a treatment modality in which electrical pulses are administered directly to or in 
the neighborhood of nerve tissue in order to manipulate a pathological substrate and to achieve a 
symptomatic or even curative therapeutic effect. The different types of neurostimulation differ in the 
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part of the nervous system affected and in the way the stimulation is administered [23] and include 
repetitive transcranial magnetic stimulation, transcranial direct current stimulation, trigeminal nerve 
stimulation, deep brain stimulation and (transcutaneous) vagus nerve stimulation. The responder 
rate for these neurostimulation treatements ranges from 23% to 43%, depending on the type of 
stimulation and the duration of the treatment [24, 25]. A full discussion on all techniques is beyond 
the scope of the thesis and is given elsewhere [23, 25, 26]. However, as vagus nerve stimulation is 
the main topic of this thesis, detailed information on clinical efficacy can be found below (see p. 21).  
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Depression 
 
The World Health Organization estimates that by 2020, major depressive disorders (MDD) will 
become the second largest cause of global disease problems in the world, immediately following 
ischemic heart disease [27]. The lifetime prevalence for MDD is reported to be as high as 17% and 
the 12-month prevalence is estimated to be 4-8% [28, 29]. The disease appears to develop 
independent of ethnicity, education or income and is usually associated with substantial symptom 
severity and role impairment. The resulting disability and burden do not only affect the individual in 
terms of decreased productivity, but the level of health care utilization and suicide is also increased 
[30].  
 
According to the diagnostic and statistical manual of mental disorders (DSM-V) [31] , MDD manifests 
with a heterogeneous set of symptoms, both at the psychological and behavioral level as well as at 
the physiological level. A depressive episode requires the presence of one or two of the following 
core symptoms for at least two weeks: (1) depressed mood most of the day, nearly every day, as 
indicated by either subjective report (e.g. feeling sad or empty) or observation made by others (e.g. 
appears tearful). Note: In children and adolescents, can be irritable mood and (2) markedly 
diminished interest or pleasure in all, or almost all activities that usually would be enjoyed and this 
most of the day, nearly every day (anhedonia) (as indicated by either subjective account or 
observation made by others). In addition, four of the following symptoms must be present (three if 
both core symptoms are present):  
(1) Significant weight gain or weight loss when not dieting (e.g. a change of more than 5% in 
body weight in a month), or decrease or increase in appetite nearly every day. Note: In 
children, consider failure to make expected weight gains; (2) insomnia or hypersomnia nearly 
every day; (3) psychomotor agitation or retardation nearly every day (observable by others, 
not merely subjective feelings or restlessness or being slowed down); (4) fatigue or loss of 
energy every day; (5) feelings of worthlessness or excessive, inappropriate guilt (which may 
be delusional) nearly every day (not merely self-reproach or guilt about being sick); (6) 
diminished ability to think or concentrate, or indecisiveness, nearly every day (either by 
subjective account or as observed by others) and (7) recurrent thoughts of death (not just 
fear of dying), recurrent suicidal ideation without a specific plan or a suicide attempt or a 
specific plan for committing suicide [31, 32]. 
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The symptoms cause clinically significant distress or impairment in social, occupational or other 
important areas of functioning. Furthermore, the symptoms are not caused by the direct 
physiological effects of a substance (e.g. a drug of abuse or a medication) or a general medical 
condition (e.g. hyperthyroidism) and cannot result from bereavement (e.g. after the loss of a loved 
one) .  
 
The diagnosis and the evaluation of response to treatment is based on clinical observations and the 
results from depression rating scales. These scales differ according to the observer (self-rating versus 
observer rating scales), the symptoms investigated, the number of items and the criteria used. The 
most commonly used depression rating scales are the Hamilton depression Rating scale, the 
Montgomery-Asberg depression rating scale, and the Beck depression inventory [33].  
 
 
 
Etiology 
Depression is a disease with plenty of risk factors including environmental, genetic and psychological 
ones. The multifaceted character of depression renders its etiology challenging to study. In this 
regard, a lot of pathological processes have been identified including overactivity of the 
hypothalamic-pituitary-adrenal axis, increased neuroinflammation, impaired endogenous opioid 
function, imbalances in several neurotransmitter systems, reduced neural plasticity and dysfunction 
of specific brain structures and circuits [34-36]. The abundance of pathological processes has led to 
the emergence of several hypotheses of MDD, two very important ones being the monoamine and 
the neural plasticity hypothesis of MDD. The monoamine hypothesis postulates that the 
pathophysiological basis of depression is the deficient activity of the monoamines - mainly serotonin 
and noradrenaline - in the central nervous system. Indeed, almost all currently available 
antidepressants are based on enhancing the serotonergic and/or noradrenergic system (see below) 
[34, 37]. The main assumption in the neural plasticity hypothesis of MDD is that reduced neural 
plasticity plays a major role in the pathophysiology of depression, and that its restoration represents 
a critical mechanism underlying antidepressant efficacy [35]. 
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Standard treatment 
Pharmacotherapy – antidepressant drugs 
Antidepressant drugs and psychotherapy are the standard treatments for MDD. The mechanism of 
action of most antidepressant drugs is based on increasing the concentration of serotonin and 
noradrenaline in the synaptic cleft via (1) inhibition of their reuptake (tricyclic antidepressants, 
selective serotonin reuptake inhibitors, noradrenaline reuptake inhibitors and serotonin-
noradrenaline reuptake inhibitors), (2) antagonism of inhibitory presynaptic autoreceptors and (3) 
inhibition of monoamine oxidases (monoamine oxidase inhibitors), which are the enzymes for 
monoamine degradation [34, 37].  
 
Psychotherapy 
The conceptualization of depression as a psychological disorder has inspired the development of 
various forms of psychotherapy [38]. The two main types of psychotherapy for the treatment of MDD 
are cognitive behavioral therapy and interpersonal therapy. Cognitive behavioral therapy attempts to 
change dysfunctional patterns of thinking in order to prevent the development and maintenance of 
depressive symptoms [39]. Interpersonal therapy assists patients in analyzing 
their interpersonal relationship modes, correlating their relational states with their mood and 
learning to use better communication [40].  
 
Prognosis and alternative treatments 
In the majority of patients, depressive symptoms can be effectively treated with pharmacotherapy, 
psychotherapy or the combination of both interventions [41]. Nevertheless, up to 30% of patients fail 
to respond to these standard interventions and hence suffer from refractory depression [42]. Even 
more problematic is the fact that the disease tends to recur, with greater than 75% of patients 
experiencing more than 1 episode in a 10-year period [43, 44]. The lack of success with the standard 
therapies highlights the importance of optimizing alternative therapies for patients suffering from 
refractory depression. Similar as in refractory epilepsy, neurostimulation modalities including 
electroconvulsive therapy, repetitive transcranial magnetic stimulation, transcranial direct current 
stimulation, trigeminal nerve stimulation, deep brain stimulation and (transcutaneous) vagus nerve 
stimulation are used for the treatment of refractory depression [38].  
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Comorbidity of epilepsy and depression 
 
The risk of developing MDD is approximately five times higher in refractory epilepsy patients than 
among the general population [45-47]. On the other hand, major depressive episodes and suicide 
attempts independently increase the risk of developing unprovoked seizures and epilepsy [48, 49]. 
Traditionally, epilepsy-related depression was believed to result from the psychosocial burden of 
having a chronic debilitating neurologic disorder and the stigma related to epilepsy, which are still 
the major reasons why depression remains underdiagnosed in the epileptic population [50]. 
However, the bidirectional relationship suggests that this comorbidity is more than a psychosocial 
phenomenon and that the two disorders likely share common pathogenic mechanisms [45, 47, 48, 
51]. These mechanisms might include a hyperactive hypothalamic–pituitary–adrenal axis and its 
neuroanatomic and neuropathologic complications, as well as disturbances in serotonergic, 
noradrenergic, GABA-ergic and glutamatergic neurotransmitter systems, all of which may be 
interrelated [52]. Furthermore, increased neuroinflammation [36, 53] and changes in neural plasticity 
[54, 55] are abnormalities found both in epilepsy and depression and might therefore also be 
involved in the comorbidity of these disorders.  
 
As depressive symptoms have a more profound impact on an epileptic patient’s quality of life than 
seizure severity or frequency [56-59], it is key to diagnose and treat these symptoms as well. Current 
pharmacological treatment options for patients suffering both from epilepsy and depression are 
limited by the fact that antiepileptic drugs can contribute to mood disturbances, while 
antidepressant drugs can increase seizure susceptibility [60, 61]. The lack of success with current 
pharmacological interventions for patients suffering both from refractory epilepsy and depression, 
highlights the importance of further optimizing alternative neuromodulatory treatments. These 
treatments include repetitive transcranial magnetic stimulation, transcranial direct current 
stimulation, deep brain stimulation and vagus nerve stimulation (VNS) [25, 38]. As VNS is the main 
topic of this thesis, this treatment modality will be discussed in detail below.  
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VNS for the treatment of epilepsy and depression 
 
Historical background 
The historical basis of peripheral stimulation for the treatment of seizures dates back to the sixteenth 
and seventeenth century, when physicians described the use of a ligature around the limb in which a 
seizure commences to arrest its progress [62]. This method was described by the ancient Greek 
author Pelops for whom this observation was proof that epileptic fits originate in the limb itself. This 
hypothesis was reviewed in the beginning of the nineteenth century, when Odier and Brown-Sequard 
showed that ligatures are equally efficacious in arresting seizures caused by organic brain disease e.g. 
a brain tumor [63]. At the end of this century, Gowers attributed these findings to a raised resistance 
in the sensory and motor nerve cells corresponding to the limb involved. This would in turn arrest the 
spread of the discharge. Gowers also reported several other ways by which sensory stimulation could 
prevent seizures from spreading e.g. pinching of the skin and inhalation of ammonia [64]. Almost a 
hundred years later, Rajna and Lona demonstrated that afferent sensory stimuli can abort epileptic 
paroxysms in humans [62, 65]. The vagus nerve became a point of interest among neurologists in the 
nineteenth century when it was thought that seizures could be aborted by applying pressure to the 
this nerve via the carotid artery located in the neck [66]. Subsequently, early research in animal 
models confirmed that electrical stimulation of the vagus nerve decreases the frequency and severity 
of epileptic seizures [67, 68]. Since then, numerous preclinical studies have confirmed the 
antiepileptic effect of VNS (reviewed in [69]).  
 
Indications 
VNS was approved for the treatment of refractory epilepsy in 1994 and 1997 in Europe and the 
United States respectively. Mood improvements in epilepsy patients treated with VNS, irrespective of 
the effects on seizure frequency [46, 70], provided the initial rational for using VNS for the treatment 
of refractory depression. Subsequently, VNS was approved in 2001 in Europe and Canada for the 
treatment of non-psychotic unipolar and bipolar depressed patients that had failed to respond to at 
least four antidepressant trials. Four years later - in July of 2005 - the treatment was approved for 
refractory depression by the Food and Drug Administration (FDA) in the United States as well [71-74]. 
Since the first patient was implanted in 1988 [75], over 100.000 VNS devices have been implanted in 
more than 75.000 patients worldwide [76]. As the vagus nerve innervates and thereby influences 
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virtually the whole body (see below), it is not surprising that VNS is currently under investigation for 
the treatment of several other diseases including chronic heart failure, Alzheimer’s disease, pain, 
tinnitus, obesity and anxiety disorders [77-79]. 
 
Anatomy – efferent and afferent projections 
The tenth cranial nerve or vagus nerve is the longest of the cranial nerves and extends from the brain 
stem to the abdomen. Its complex anatomical distribution has earned the vagus nerve its name, as 
vagus is the Latin word for wanderer [80]. The left vagus nerve comprises approximately 100.000 
axons, 20% of which are efferent (motor) fibers and 80% of which are afferent (sensory) fibers. Figure 
1 gives a schematic overview of the main efferent and afferent projections.  
 
Figure 1: Schematic representation of the efferent and afferent projections of the vagus nerve. 
Adapted from Vonck et al. 2007 [80]. 
The efferent fibers of the vagus nerve originate from the dorsal motor nucleus and the nucleus 
ambiguus. A fraction of these fibers of the vagus nerve provides parasympathetic innervation to the 
lungs and the abdominal viscera, while another fraction contributes to the recurrent laryngeal nerve, 
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which branches off from the vagus nerve and carries low-threshold vagal motor neurons to the 
larynx, pharynx and vocal cords. The afferent fibers of the vagus nerve originate from the ganglion 
nodosum and jugularis and convey somatosensory information of the ear, taste information and 
visceral information to the brain [80, 81]. At the cervical level, the vagus nerve mainly consists of 
small diameter unmyelinated C-fibers (65–80%) and of a smaller portion (35-20%) of intermediate 
diameter myelinated B-fibers and large-diameter myelinated A-fibers [62]. As the upstream afferent 
projections within the brain are considered to be key in the mechanism of action of VNS, these 
connection will be discussed later in detail (see chapter 3-3). 
 
Implantation procedure 
VNS is an extracranial form of 
neurostimulation which consists of 
electrically stimulating the left vagus nerve 
through an implanted electrode and a pulse 
generator (figure 2 [82]). The surgical 
procedure should be carried out by a 
neurosurgeon familiar with the surgical 
approach for carotid endarterectomy 
because of the location of the vagus nerve in 
the neck within the carotid sheath, where the 
vagus nerve is running between the carotid 
artery and the internal jugular vein [62]. The 
insertion of the device is usually performed under general anesthesia and involves 2 incisions. The 
first incision is made at the level of the neck, where the platysmal and subplatysmal cervical fascia 
are dissected until the carotid sheath is exposed. The vagus nerve is identified within the sheath and 
at least 2.5 cm of the nerve is exposed. The bipolar electrode consisting of two silicone helical coils, is 
then wrapped around the vagus nerve, with the cathode and the anode placed rostrally and caudally 
respectively. A third helical coil is located further caudally to tether the lead to the vagus nerve. 
Subsequently, the lead from the electrode to the pulse generator is tunneled through the 
subcutaneous fat layer into the left chest area where the second incision is made. There, a 
subcutaneous pocket in the anterior chest wall is made for the insertion of the pulse generator [83].  
 
Figure 2: VNS generator, lead and bipolar 
electrode location in chest wall. 
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Stimulation parameters 
Electrical pulses applied in VNS are defined by the following stimulation parameters: output current, 
frequency, pulse width and ON/OFF time or duty cycle [84]. The programming of the stimulation 
parameters is performed using an external wand that is connected to a handheld computer. The 
pulse generator is usually turned on 2 weeks postoperatively to allow wound healing. Typically, the 
output current is set at 0.25 mA at the start of the therapy and is gradually ramped-up in steps of 
0.25-0.50 mA every 2-4 weeks according to the individual tolerance level of the patient or to a 
maximum of 3.5 mA. The frequency and the pulse width of the stimulation pulse are typically set at 
20-30 Hz and 250-500 μs respectively. The standard duty cycle is 30 s ON/ 5 min OFF. The choice of 
intermittent stimulation is based upon safety studies with regard to the stimulation of neural tissue 
[85], efficacy studies showing that the effect of stimulation outlasts the stimulus duration [67, 86] 
and the knowledge that intermittent stimulation is associated with a longer battery life. All 
parameter settings can be modified in order to reach maximum therapeutic efficacy, while 
minimizing stimulation-related side effects and preserving battery life. Table 1. shows the range of 
possible settings, the programming steps, the recommended initial values and the typical target 
values. 
 
stimulation 
parameters 
  
programmable  
range 
  
programming  
steps 
  
recommended 
inital values 
typical target 
values 
        
output current 
 
0-3.5 mA 
 
0.25 mA 
 
0.25 mA 1.00-2.00 mA 
frequency 
 
1-30 Hz 
 
1, 2, 5, 10, 15, 20, 25, 30 Hz 20-30 Hz 20-30 Hz 
pulse width 
 
130-1000 µs 
 
130, 250, 500, 750, 1000 µs 250-500 µs 250-500 µs 
duty cycle 
 
10-100% 
 
function of signal ON, OFF times 10% 10% 
signal ON time 
 
7-60 s 
 
7, 14, 21, 30, 60 s 30 s 30 s 
signal OFF time 0.2-180 min 
 
5–60 min, 5-min steps 5 min 5 min 
    
60–180 min, 30-min steps 
            
 
Table 1: Adapted from Labiner et al. 2007 [87, 88]. 
 
The stimulation parameters used currently in clinical practice and in experimental studies 
are based on what is known to be safe and tolerable and are therefore not evidence-based 
but rather empirically determined. However, optimizing the stimulation paradigm is an 
indispensable step towards the achievement of a better clinical outcome. Therefore, the 
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research presented in chapter 4 of this thesis will aim at optimizing the stimulation 
parameters. 
 
Safety and tolerability 
Side effects due to VNS can be subdivided into surgery- and stimulation-related side effects. Surgery-
related side effects are rare but include fluid accumulation at the generator site, incisional infections, 
vocal cord paresis, lower facial weakness and bradycardia [89]. Rare cases of ventricular asystole 
have also been reported when the device is tested during the implantation procedure in the 
operating room. However, no long-term negative outcomes resulted in these cases [84, 90]. 
Concerning cosmetic adverse events, several generator models have been developed with each 
successive model having smaller dimensions to improve cosmetic outcome (see figure 3) [91].  
 
Figure 3: Different types of VNS generators. The size and 
volume of the generators have been reduced over time, 
thereby reducing cosmetic adverse events. 
 
 
The most frequent stimulation-related side effects are tingling sensations in the throat and 
hoarseness or voice alterations [84, 89]. The tingling sensations in the throat results from the 
secondary afferent stimulation of the superior laryngeal nerve, which branches off from the vagus 
nerve superior to the location of the implanted electrode and carries sensory fibers to the laryngeal 
mucosa. Hoarseness and voice alterations on the other hand, result from the efferent stimulation of 
the recurrent laryngeal nerve which branches off distally from the location of the electrode and 
carries motor fibers to the laryngeal muscles [92]. The stimulation-related side effects generally 
disappear when the stimulation parameters are adapted e.g. when the output current, the frequency 
or the pulse width are reduced. Therefore, VNS-related side effects are in general mild and short-
lived and subsequently, VNS is considered to be a safe and well-tolerated treatment [89]. With 
regard to other side effects related to the stimulation of vagal efferents, the effect on the heart rate 
has been a major concern. In this regard, left VNS is preferred over right VNS, owing to the fact that 
the left vagus nerve has fewer efferent projections into the heart, thereby reducing the risk of 
cardiac side effects, such as bradycardia [93]. However, the stimulation parameters used to suppress 
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seizures in patients and experimental animals do not maximally activate the high-threshold, 
unmyelinated vagal C-fibers [94]. Activation of these C-fibers is necessary to induce bradycardia [95], 
but not to reduce seizure severity [96]. Indeed, previous studies in non-human primates have 
demonstrated that right-sided VNS does not induce detectable cardiac effects [68]. Furthermore, it 
was shown that right-sided VNS is as effective as left-sided VNS in reducing epileptic seizures in rats 
[97] and pigs [98]. In patients as well, right-sided VNS was shown to be safe and to have antiepileptic 
effects in subjects that were previously successfully treated with left-sided VNS but had to 
discontinue the treatment due to nerve injury [99-101]. Therefore, right-sided VNS could be 
proposed as an alternative treatment for refractory epilepsy. Nevertheless, future trials on bigger 
patient samples, including electrocardiogram monitoring to detect the presence of possible cardiac 
side effects, are needed to confirm this hypothesis. 
 
Compared to antiepileptic and antidepressant pharmacological treatments, VNS has several 
advantages. First of all, non-compliance with drug treatments remains a big problem. A significant 
portion of patients do not take their medication as prescribed or even do not take it at all [102]. 
Moreover, most patients will stop the treatment as soon as they are feeling better [103]. As VNS 
occurs continuously through an implanted device, compliance is not an issue with this therapy. 
Furthermore, the typical drug-induced side effects such as cognitive impairment and somnolence, 
are not reported in patients treated with VNS [89]. On the contrary, VNS-induced cognitive 
improvements and increased alertness have been observed in patients suffering from both refractory 
epilepsy and depression [104]. Due to the nature of the treatment, VNS therapy can be combined 
with currently available pharmacologic treatments without the risk of drug interactions. 
Furthermore, when used as an adjunctive therapy, VNS results in a better control of seizures and 
depressive symptoms at smaller doses of antiepileptic or antidepressant medications, consequently 
resulting in decreased dose-dependent side effects of these pharmacological treatments [105]. In 
contrast to many pharmacological compounds, treatment tolerance does not develop with VNS 
therapy [80]. Contrary to pharmacological treatments, efficacy tends to increase with a longer 
duration of the treatment [71, 80, 106, 107]. Another advantage of VNS is the fact that the patient or 
caregiver is provided with a magnet, which allows additional stimulation when an aura or a seizure 
occurs [108]. On the other hand the patient can stop the stimulation in situations where it may cause 
discomfort, e.g. during public speaking [91]. Therefore, the use of this magnet gives the patients a 
feeling of control over their situation, thereby reducing stress [109]. In contrast to ablative 
neurosurgical interventions, VNS has the advantage of being reversible as the stimulation can be 
stopped or the explantation of the device can be easily performed in case the patient wants to 
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discontinue the treatment. Furthermore, the surgical procedure for a VNS implantation involves a 
lower risk and fewer complications than for ablative surgery [93, 110]. 
 
 
Efficacy and predictors of response 
Epilepsy  
The earliest studies demonstrated that one third of patients has a significant improvement in seizure 
control with a reduction in seizure frequency of at least 50% (responders), one third of patients 
experiences a worthwhile reduction in seizure frequency between 30% and 50% (partial responders) 
and the remaining third of patients experiences little or no effect (non-reponders). More recent large 
series of patients, both in children [111] and in adults [112], with long-term follow-up of over 5 years 
have been reported and demonstrate that up to 60% of patients become responders. A recent meta-
analysis of VNS efficacy in epilepsy revealed that VNS produces an average reduction in seizure 
frequency of 45%, with 36% seizure reduction at 3-12 months after surgery and 51% seizure 
reduction after more than one year of therapy. Furthermore, at the last follow-up, seizures were 
shown to be reduced by 50% or more in approximately 50% of the patients [113]. The meta-analysis 
revealed that patients with generalized epilepsy and children benefit significantly from VNS despite 
their exclusion from initial approval of the device. Furthermore, posttraumatic epilepsies and 
tuberous sclerosis were shown to be positive predictors of a favorable outcome [109, 113]. In a study 
by Janszky et al., the absence of bilateral interictal epileptiform discharges and the presence of 
malformations of cortical development were associated with a seizure-free outcome [114]. A recent 
study by Acros et al. demonstrated that a temporal lobe discharge is an indicator of an early 
response and that the presence of a lesion indicates a late response. Furthermore, patients with 
fewer rates of seizures were found to have a better prognosis in the latter study [115]. 
 
Depression 
As only a limited number of trials on the antidepressant effect of VNS have been performed to date 
[116], a meta-analysis is not yet available. Open label studies have demonstrated a steadily 
increasing improvement of depressive symptoms with full benefit after 6 to 12 months, sustained for 
up to two years (for an overview, see [117, 118]). These studies reported response rates (defined as a 
> 50% decrease in depression severity) up to 53% and remission rates up to 39% after 3-24 months of 
treatment [117-119]. Unfortunately, the only blinded sham-controlled clinical trial was inconclusive, 
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because the output current in some patients had not been adequately ramped-up and these patients 
did therefore not receive the full therapy [116]. Although responder identification studies are lacking, 
it was shown that the history of treatment resistance is predictive of VNS outcome. That is, patients 
who have never received electroconvulsive therapy, are 3.9 times more likely to respond to VNS. 
Thus, VNS appears to be most effective in patients with low to moderate, but not extreme 
antidepressant resistance [117, 120].  
 
The comorbidity of epilepsy and depression 
Several studies have demonstrated VNS-induced mood improvements in patients suffering from 
epilepsy and comorbid depressive symptoms [70, 121-123]. Surprisingly, only one study [122] has 
found an association between seizure reduction and mood improvement. This may indicate 
additional effects of VNS on mood, independent of improved seizure control and therefore 
independent of epilepsy. Although the results from these studies are promising, future randomized 
controlled trials are needed to confirm the hypothesis that VNS has antidepressant effects in patients 
suffering from epilepsy and comorbid depression. 
 
Mechanism of action  
As for many drugs, the clinical application of VNS preceded the research into its mechanism of action. 
The initial hypothesis on the mechanism of action was based on the knowledge that the tenth cranial 
nerve afferent fibers have numerous projections within the central nervous system and that in this 
way, action potentials generated in vagal afferent fibers have the potential to affect the entire 
organism [124]. Clues on the mechanism of action of VNS have arisen from electrophysiological 
studies, functional imaging studies, neuropsychological studies and behavioral studies both in 
humans [80, 125] and in experimental animals [69, 126]. Despite the abundance of experimental 
studies, the precise mechanism of action remains to be elucidated. As a full review of all studies is 
beyond the scope of this thesis and is given elsewhere [69, 91, 126], only a brief summary will be 
given on the putative mechanism of action VNS.  
 
Epilepsy 
As epileptic seizures are characterized by an increase in cortical excitability and synchronous firing of 
populations of neurons, it was hypothesized that VNS suppresses seizures by reducing cortical 
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excitability and desynchronizing neuronal activity. Subsequently, experimental animal studies were 
conducted demonstrating that VNS indeed decreases interictal epileptiform EEG discharges [127-
129] and reduces cortical excitability [130, 131]. Furthermore, VNS was shown to induce an increase 
both in EEG synchronization and desynchronization, depending on the frequency of the stimulation 
[128, 132]. Interestingly, numerous studies have found that VNS reduces cortical excitability and/or 
seizures in a wide range of experimental animal models (reviewed in [69]). In these models, seizures 
are originating from different cortical sites, e.g. from the hippocampus or amygdala in the 
hippocampal and amygdala kindling model respectively or from the motor cortex in the cortical 
stimulation model [130, 131, 133-135]. This suggests that the sites at which VNS controls neuronal 
excitability are widely distributed, which is consistent with the widespread afferent projections of the 
vagus nerve in the central nervous system. Based both on clinical and experimental animal studies, it 
is assumed that effective VNS is mediated through the activation of the afferent myelinated A- and B-
fibers and not of the small unmyelinated C-fibers [96, 136-139]. These afferent A- and B-fibers 
project to the nucleus tractus solitarius (NTS). In turn, the NTS has widespread projections to virtually 
the whole brain, including areas important for epileptogenesis such as the amygdala, the 
hippocampus and the thalamus [140]. Consistent with this knowledge, functional neuroimaging 
studies have demonstrated widespread VNS-induced metabolic changes in brain regions implicated 
in seizure generation including the thalamus, cerebellum, orbitofrontal cortex, limbic system, 
hypothalamus and medulla (reviewed in [125]). Further work by Naritoku and colleagues [141] 
examined the molecular biological effects of VNS on multiregional neuronal activities in the 
brainstem and cerebral cortex. This group found VNS-induced increases in the expression of neuronal 
c-fos - a marker for increased metabolic activity - in the medullary vagal complex, the locus coeruleus 
and several thalamic and hypothalamic nuclei. The changes in neuronal activity in these diffuse 
cortical networks can most likely be explained by the VNS-induced changes in neurotransmitter 
concentrations. That is, the intracranial effect of VNS may be based on VNS-induced increases in the 
concentration of the inhibitory neurotransmitter GABA or decreases in the concentration of the 
excitatory neurotransmitters glutamate and aspartate [142-151]. Furthermore, the mechanism of 
action of VNS may involve other modulatory neurotransmitters that are known to have antiepileptic 
effects, such as serotonin and noradrenaline [133]. The relevant anatomy, the effects of VNS on the 
dorsal raphe nucleus and the locus coeruleus – which are the main sources of serotonin and 
noradrenaline respectively - and the subsequent release of serotonin and noradreanline in the brain, 
will be discussed in detail in the review on the putative antidepressant mechanism of action of VNS 
(see below, chapter 3-3). Apart from the known effects of VNS on GABA, glutamate, aspartate 
serotonin and noradrenaline, a growing body of evidence suggests that the therapeutic effects of 
VNS are mediated by acetylcholine release through the activation of the nucleus basalis [152, 153]. 
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To summarize, the exact antiepileptic mechanism of action of VNS remains to be elucidated, but 
research has demonstrated that stimulation of the left vagus nerve induces inhibitory effects on 
neuronal excitability in a wide range of cortical structures. These changes could potentially result 
from the VNS-induced changes in neurotransmitter concentrations including GABA, glutamate, 
aspartate, serotonin, noradrenaline and acetylcholine. The molecular changes underlying the 
neurotransmitter-induced alterations in cortical excitability are incompletely understood to date, but 
a growing body of evidence suggests that neuroplastic [55, 154-157] and neuroimmunomodulatory 
[53, 158-161] effects might be the missing link.  
 
Depression 
As for epilepsy, the exact mechanism of action of VNS for depression remains to be elucidated. A 
review on the putative antidepressant mechanism of action of VNS can be found in chapter 3-3, a 
summary of which is given in the following paragraph.  
Consistent with the monoamine theory of depression, serotonin and noradrenaline were identified 
as key players in the antidepressant mechanism of action of VNS [133, 145, 156, 162-167]. However, 
VNS induces an acute elevation of the monoamines, while its antidepressant effect in patients is only 
established after long-term treatment. In this regard, a growing body of evidence suggests that 
neuroplastic changes might be the missing link [154-157, 168]. In other words, we hypothesize that 
VNS exerts its antidepressant effects through a rapid increase in the concentration of the 
monoamines, which then enhances neuronal plasticity in the hippocampus. Newborn cells could then 
functionally integrate and restore disturbed cortico-limbic networks in depressed subjects. Processes 
such as increased dendritic complexity and the formation of new synapses could further strengthen 
these networks [155]. The latter processes take several weeks to months to be completed, which 
provides an explanation for the therapeutic lag. 
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Aims and rationale of the thesis 
VNS is a well-established, safe and effective add-on therapy for patients suffering from refractory 
epilepsy [1]. Mood improvements in epilepsy patients treated with vagus nerve stimulation (VNS), 
provided the initial rationale for using VNS for the treatment of refractory depression [2-4]. However, 
randomized controlled trials confirming the antidepressant effect of VNS in epilepsy patients are 
lacking. Furthermore, the mechanism of action is still unknown, optimal stimulation parameters 
remain elusive and about one third of patients do not benefit from the treatment. Therefore, the aim 
of this thesis is (1) to perform a proof-of-concept study and to unravel the antidepressant mechanism 
of action of VNS and (2) to optimize the stimulation parameters in order to improve clinical outcome. 
 
More specifically, this thesis addresses the following research questions: 
Proof-of-concept and mechanism of action 
1. Does VNS have and antidepressant-like effect in the kainic acid rat model for temporal lobe 
epilepsy and comorbid anhedonia, the latter being a key symptom of major depression. 
2. Does the locus coeruleus play a key role in the antidepressant-like mechanism of action of VNS? 
 
Optimization of stimulation parameters 
1. Are low VNS output current intensities sufficient to reduce cortical excitability in the motor cortex 
stimulation rat model? 
2. Can VNS-induced laryngeal muscle-evoked potentials or LMEPs be measured in chronically VNS-
implanted rats in a minimally invasive way? 
3. Can LMEPs be used to determine optimal stimulation parameters, to identify non-responders and 
to individualize post-operative recovery periods? 
4. Can this technique be translated to clinical practice? 
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Proof-of-concept and mechanism of action (chapter 3) 
 
Study 1: The antidepressant potential of VNS in the kainic acid (KA) model for temporal lobe 
epilepsy and comorbid anhedonia 
Depressive disorders are the most common type of psychiatric comorbidity in epileptic patients, 
especially in individuals suffering from refractory temporal lobe epilepsy. Despite the availability of a 
variety of both antiepileptic and antidepressant drugs, up to 30% of patients fail to respond 
adequately to standard medication. Furthermore, current treatment options for patients suffering 
both from epilepsy and depression are limited by the fact that anticonvulsant drugs can contribute to 
mood disturbances, while antidepressant drugs can increase seizure susceptibility [5-7]. The lack of 
success with current pharmacological interventions for patients suffering from both epilepsy and 
depression, highlights the importance of optimizing non-pharmacological, neuromodulatory 
treatments such as VNS for this patient population. The initial rationale for using VNS to treat 
refractory depression was fueled by the observation that VNS induces mood improvements in 
epilepsy patients, irrespective of the effect on seizure frequency [2-4]. However, there are no 
randomized controlled trials confirming the antidepressant effect of VNS in epileptic patients. Studies 
on the antidepressant effect of VNS in a clinical population are confounded by multiple factors, 
including concomitant antiepileptic drug therapy, psychosocial and intellectual effects. The use of 
animal models overcomes this problem and is important in unraverling the mechanism of action of 
VNS for the treatment of epilepsy-related depression. Therefore, we wanted to perform a proof-of-
concept study to assess the antidepressant potential of VNS in an animal model for epilepsy and 
comorbid anhedonia, a key symptom of major depression. For this purpose the effect of VNS on the 
hedonic state was assessed in the the post status epilepticus KA rat model for temporal lobe epilepsy 
and comorbid anhedonia, using the saccharin preference and the quinine aversion test. 
The post status epilepticus KA rat model is a validated model for temporal lobe epilepsy. KA is a 
potent neuroexcitatory amino acid that acts by activating receptors for glutamate, the principal 
excitatory neurotransmitter in the central nervous system. When KA is injected systemically in rats, it 
rapidly produces epileptic seizures, which are characterized by by the following phenomena: stage 1: 
immobility, eye closure, twitching of vibrissae, facial clonus, wet dog shakes; stage 2: head nodding, 
chewing, severe facial clonus, wet dog shakes; stage 3: clonus of one forelimb; stage 4: rearing, 
bilateral forelimb clonus; stage 5: rearing, bilateral forelimb clonus, loss of balance and falling [8-10]. 
These seizures typically last for several hours without complete recovery in between, and can 
therefore be considered a status epilepticus. This status epilepticus is followed by a latent period, 
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during which epileptogenic changes (e.g. hippocampal cell loss, mossy fiber sprouting and dentate 
gyrus cell dispersion [11, 12]) occur in the brain. These epileptogenic changes result in spontaneous, 
frequently secondarily generalized seizures [9], thereby closely resembling temporal lobe epilepsy in 
humans [10]. Furthermore, it was recently shown that KA rats display anhedonia, a key symptom of 
major depression [13].  
In animal research, anhedonia can be assessed using the saccharin preference test. This validated 
test is based on the rewarding properties of sweet substances, such as dilute saccharin solutions. 
Healthy animals have a strong inherent taste preference towards these sweet solutions, while 
depressed animals show a significantly reduced saccharin preference. This loss of taste preference 
reflects a decrease in reward sensitivity, i.e. anhedonia, which can be reversed by an antidepressant 
treatment [14-18]. In the saccharin preference test, the cage of the animal is supplied with two 
identical preweighed drinking bottles. One of the bottles contains regular water while the other 
contains a 0.1% saccharin solution. The animal is presented with the bottles for a certain period of 
time, typically ranging from 1 hour to 24 hours. At the end of the test, both bottles are removed and 
reweighed. Saccharin preference is calculated as the volume of the saccharin solution consumed 
divided by the total fluid volume (saccharin solution plus regular water) consumed and expressed as 
a percentage [19, 20]. To exclude the possibility that differences in saccharin preference are caused 
by alterations in taste perception, the quinine aversion test can be performed. This test consists of 
the same procedure, except for the fact that the 0.1% saccharin solution is replaced by a 0.05% 
quinine solution. Quinine is a bitter tasting substance, which is highly aversive to rats with a normal 
taste perception [21]. 
 
Study 2: The role of the locus coeruleus in the antidepressant mechanism of action of VNS 
 
Although VNS is already used in clinical practice for the treatment of refractory depression, the 
antidepressant mechanism of action of this neuromodulatory treatment remains to be elucidated. A 
better understanding of the mechanism of action is indispensable to identify potential responders 
prior to surgery and may guide the search for optimal stimulation parameters, finally improving 
clinical efficacy. Previously, it was shown that VNS has an antidepressant-like effect in the rat forced 
swim test [22]. The mechanism of action underlying this effect is incompletely understood, but there 
is a large body of evidence suggesting that the LC – which is the main source of noradrenaline in the 
brain - might play an important role. Therefore, we wanted to test the hypothesis that the VNS-
induced antidepressant-like effect in the forced swim test is mediated through activation of the LC. 
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For this purpose, LC neurons were lesioned using DSP-4 [N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine hydrochloride], a highly selective neurotoxin for the noradrenergic axons 
originating from the LC. 
The forced swim test is one of the most commonly used and validated animal models for behavioral 
despair. In this test, the animal is placed in a water-filled cylinder from which it cannot escape. 
Initially, the animal will be very mobile in trying to escape, but eventually it gives up and adopts an 
immobile posture (see figure 1).  
 
 
 
 
 
Figure 1: The left and right side of the figure show mobile, escaping directed and immobile, passive 
behavior respectively. 
This immobile posture is interpreted as the behavioral correlate of despair. The standard test as first 
described by Porsolt et al. [23], consists of two swimming exposures. The first exposure consists of a 
15-minute swim session and the second exposure, which is the actual test phase, is performed 24 
hours to 1 week later and consists of a 5-minute swim session of which the mobility and immobility 
time are assessed. During the 24 hours to 1 week between the two swim sessions, a potential 
antidepressant manipulation is performed. A reduction in passive immobile behavior in the 5-minute 
swim session is a validated measure for an antidepressant-like effect of the manipulation, provided it 
does not increase general locomotor activity, which could generate a false positive result [24]. To 
assess potential differences in locomotor activity, an open field test can be performed.  
To rule out the possibility that the effects in the forced swim test are caused by an overall change in 
locomotor activity, an open field test can be performed. This test is performed in an open field arena 
with walls to prevent escaping. The floor of the arena is divided into equal squares. During the test, 
the animal is placed in the center or one of the four corners of the open field arena and is allowed to 
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explore the apparatus for five minutes (see figure 2). The number of squares crossed with all four 
paws during the 5-minute trial is a validated measure for the locomotor activity [25]. 
 
 
 
 
 
 
 
 
Figure 2: Schematic top view of the open field test arena. The trace on the floor of the arena 
represents the path of the rat during the 5-minute test. 
 
 
 
Study 3: Review on the antidepressant mechanism of action of VNS: evidence from preclinical 
studies 
 
The third literature study of chapter 3 consist of a review that provides an overview of the preclinical 
VNS studies in view of two major hypotheses in depression research: the monoaminergic and the 
neural plasticity hypothesis of MDD. 
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Optimization of the stimulation parameters (chapter 4) 
Study 4: Intensity-dependent modulatory effects of VNS on cortical excitability 
 
As stated above, the optimal stimulation parameters for effective VNS are still unknown. However, 
optimizing the stimulation paradigm is an indispensable step towards the achievement of a better 
clinical outcome. The stimulation parameters used currently in experimental studies and in clinical 
practice are based on what is known to be safe and tolerable and are therefore not evidence based 
but rather empirically determined. As the efficacy of VNS is dependent on the adequate activation of 
the vagal A- and B-fibers [26-28], the stimulation parameters should be optimized to activate these 
fibers. The activation threshold of the A- and B-fibers is lower than the output currents used in 
experimental settings and in clinical practice and therefore we hypothesize that VNS output currents 
lower than those used today, are sufficient and at least equally effective in reducing cortical 
excitability as VNS at higher output currents.  
This hypothesis was tested in the motor cortex stimulation rat model, which is a validated model for 
cortical excitability. In this model, the effect of a potential seizure-suppressing treatment on cortical 
excitability can be determined. This is done by applying a ramp-shaped pulse to the motor cortex of 
awake rats, through implanted epidural electrodes. The stimulation is stopped by the observer when 
a motor response (retraction of the head and/or forelimb) is elicited. The threshold for eliciting a 
motor response is a validated measure for cortical excitability. If the threshold increases due to an 
intervention, this intervention can be considered to decrease cortical excitability, as more current is 
required to excite the neurons of the motor cortex [29-31] . 
 
Study 5: Laryngeal motor-evoked potentials as an indicator of effective vagus nerve activation: a 
preclinical study 
Two major problems in VNS therapy are that (1) optimal stimulation parameters are unknown and 
(2) about one third of patients do not benefit from the treatment (non-responders). It is possible that 
the vagus nerve of some non-responders is not adequately activated, for multiple reasons such as 
lead failure, poor electrode contact or nerve damage. To date, there is no tool to test this hypothesis 
in an experimental set-up. Previous studies from our lab have shown that activation of the Aα-motor 
fibers of the recurrent laryngeal nerve, as measured by LMEPs, is reflective of the activation of the 
vagus nerve [32, 33]. Therefore, LMEPs could provide us with valuable information to deduct optimal 
 38 
 
stimulation parameters and to identify ineffective stimulation of the vagus nerve leading to non-
response. The techniques used in previous studies [32, 33] required invasive surgery or the use of 
special VNS electrodes for simultaneous stimulation and recording. The aim of the study described in 
this thesis was to investigate the feasibility and reliability of LMEP recordings using a minimally 
invasive, easy-to-use tool in a chronic experimental setting. 
  
Study 6: Laryngeal motor-evoked potentials as an indicator of effective vagus nerve activation: a 
clinical pilot trial 
In clinical practice as well, one third of patients are non-responders and optimal stimulation 
parameters required to effectively activate the vagus nerve are still unknown [34, 35]. The 
therapeutically applied stimulation intensity is typically the highest output current tolerated by the 
individual patient. This is obviously not an evidence-based way to determine the individual, optimal 
output current for vagal fiber activation. Research should therefore be directed towards finding a 
non-invasive method that can guide individual titration of the stimulation parameters. Such 
biomarker for effective delivery of VNS pulses to the nerve could support the choice for individual 
stimulation parameters in a more rational way. To date, no such technique is available for clinical use 
in chronically VNS-implanted patients. In a previous study from our lab, it was shown that it is 
feasible to record VNS-induced laryngeal muscle-evoked potentials or LMEPs in chronically VNS-
implanted experimental rats using a non-invasive electromyography technique [36]. LMEPs are 
indicative of the effective delivery of electrical current to the cervical fibers of the vagus nerve and 
could subsequently be used to identify non-responders due to ineffective activation of the nerve and 
to determine individual optimal stimulation parameters to activate the vagal fibers. The aim of the 
presented study was to translate this technique to clinical practice. 
 
 
 
  
 39 
 
References 
[1] Ben-Menachem E. Vagus nerve stimulation, side effects, and long-term safety. J Clin Neurophysiol 2001; 18: 415-8. 
[2] Harden CL. Depression and anxiety in epilepsy patients. Epilepsy Behav 2002; 3: 296. 
[3] Elger G, Hoppe C, Falkai P, Rush AJ, and Elger CE. Vagus nerve stimulation is associated with mood improvements in 
epilepsy patients. Epilepsy Res 2000; 42: 203-10. 
[4] Klinkenberg S, Majoie HJ, van der Heijden MM, Rijkers K, Leenen L, and Aldenkamp AP. Vagus nerve stimulation has a 
positive effect on mood in patients with refractory epilepsy. Clin Neurol Neurosurg 2012; 114: 336-40. 
[5] Hesdorffer DC and Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? Epilepsia 2009; 
50: 978-86. 
[6] Judge BS and Rentmeester LL. Antidepressant overdose-induced seizures. Neurol Clin 2011; 29: 565-80. 
[7] Kanner AM and Nieto JC. Depressive disorders in epilepsy. Neurology 1999; 53: S26-32. 
[8] Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin 
Neurophysiol 1972; 32: 281-94. 
[9] Hellier JL, Patrylo PR, Buckmaster PS, and Dudek FE. Recurrent spontaneous motor seizures after repeated low-dose 
systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy. Epilepsy Res 1998; 31: 73-84. 
[10] Levesque M and Avoli M. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev 2013; 37: 2887-99. 
[11] Ben-Ari Y and Dudek FE. Primary and secondary mechanisms of epileptogenesis in the temporal lobe: there is a before 
and an after. Epilepsy Curr 2010; 10: 118-25. 
[12] Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SJ, Kleinrok Z, and Turski L. Limbic seizures produced by pilocarpine in 
rats: behavioural, electroencephalographic and neuropathological study. Behav Brain Res 1983; 9: 315-35. 
[13] Tchekalarova J, Pechlivanova D, Atanasova T, Markova P, Lozanov V, and Stoynev A. Diurnal variations in depression-
like behavior of Wistar and spontaneously hypertensive rats in the kainate model of temporal lobe epilepsy . Epilepsy Behav 
2011; 20: 277-85. 
[14] Harkin A, Houlihan DD, and Kelly JP. Reduction in preference for saccharin by repeated unpredictable stress in mice and 
its prevention by imipramine. J Psychopharmacol 2002; 16: 115-23. 
[15] Forbes NF, Stewart CA, Matthews K, and Reid IC. Chronic mild stress and sucrose consumption: validity as a model of 
depression. Physiol Behav 1996; 60: 1481-4. 
[16] Jayatissa MN, Bisgaard C, Tingstrom A, Papp M, and Wiborg O. Hippocampal cytogenesis correlates to escitalopram-
mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology 2006; 31: 2395-404. 
[17] Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and 
evaluation. Psychopharmacology (Berl) 1997; 134: 319-29. 
[18] El Yacoubi M, Bouali S, Popa D, Naudon L, Leroux-Nicollet I, Hamon M, Costentin J, Adrien J, and Vaugeois JM. 
Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl 
Acad Sci U S A 2003; 100: 6227-32. 
[19] Strekalova T, Spanagel R, Bartsch D, Henn FA, and Gass P. Stress-induced anhedonia in mice is associated with deficits 
in forced swimming and exploration. Neuropsychopharmacology 2004; 29: 2007-17. 
[20] Mazarati A, Siddarth P, Baldwin RA, Shin D, Caplan R, and Sankar R. Depression after status epilepticus: behavioural and 
biochemical deficits and effects of fluoxetine. Brain 2008; 131: 2071-83. 
[21] Berridge KC and Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive 
salience? Brain Res Brain Res Rev 1998; 28: 309-69. 
[22] Krahl SE, Senanayake SS, Pekary AE, and Sattin A. Vagus nerve stimulation (VNS) is effective in a rat model of 
antidepressant action. J Psychiatr Res 2004; 38: 237-40. 
[23] Porsolt RD, Anton G, Blavet N, and Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant 
treatments. Eur J Pharmacol 1978; 47: 379-91. 
[24] Slattery DA and Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc 
2012; 7: 1009-14. 
[25] Gronli J, Murison R, Fiske E, Bjorvatn B, Sorensen E, Portas CM, and Ursin R. Effects of chronic mild stress on sexual 
behavior, locomotor activity and consumption of sucrose and saccharine solutions. Physiol Behav 2005; 84: 571-7. 
[26] Zagon A and Kemeny AA. Slow hyperpolarization in cortical neurons: a possible mechanism behind vagus nerve 
simulation therapy for refractory epilepsy? Epilepsia 2000; 41: 1382-9. 
[27] Evans MS, Verma-Ahuja S, Naritoku DK, and Espinosa JA. Intraoperative human vagus nerve compound action 
potentials. Acta Neurol Scand 2004; 110: 232-8. 
[28] Krahl SE, Senanayake SS, and Handforth A. Destruction of peripheral C-fibers does not alter subsequent vagus nerve 
stimulation-induced seizure suppression in rats. Epilepsia 2001; 42: 586-9. 
[29] Buffel I, Meurs A, Raedt R, de Herdt V, Decorte L, Bertier L, Delbeke J, Wadman W, Vonck K, and Boon P. The effect of 
high and low frequency cortical stimulation with a fixed or a poisson distributed interpulse interval on cortical excitability in 
rats. Int J Neural Syst 2014; 24: 1430005. 
[30] Voskuyl RA, Dingemanse J, and Danhof M. Determination of the threshold for convulsions by direct cortical stimulation. 
Epilepsy Res 1989; 3: 120-9. 
[31] Voskuyl RA, Hoogerkamp A, and Danhof M. Properties of the convulsive threshold determined by direct cortical 
stimulation in rats. Epilepsy Res 1992; 12: 111-20. 
 40 
 
[32] Mollet L, Raedt R, Delbeke J, El Tahry R, Grimonprez A, Dauwe I, V DEH, Meurs A, Wadman W, Boon P, and Vonck K. 
Electrophysiological responses from vagus nerve stimulation in rats. Int J Neural Syst 2013; 23: 1350027. 
[33] El Tahry R, Mollet L, Raedt R, Delbeke J, De Herdt V, Wyckhuys T, Hemelsoet D, Meurs A, Vonck K, Wadman W, and 
Boon P. Repeated assessment of larynx compound muscle action potentials using a self-sizing cuff electrode around the 
vagus nerve in experimental rats. J Neurosci Methods 2011; 198: 287-93. 
[34] American Psychiatric Association APATFoDSMIV, Diagnostic and statistical manual of mental disorders : DSM-IV-TR. 
2000, Washington, DC: American Psychiatric Association. 
[35] Boon P, De Herdt V, Vonck K, and Van Roost D. Clinical experience with vagus nerve stimulation and deep brain 
stimulation in epilepsy. Acta Neurochir Suppl 2007; 97: 273-80. 
[36] Annelies Grimonprez RR, Leen De Taeye, Lars Emil Larsen, Jean Delbeke, Paul Boon, Kristl Vonck. Laryngeal motor-
evoked potentials mark vagus nerve activation: a preclinical study. in preparation 2015. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
 
 
 
 
 
 
 
Chapter 3 
Proof-of-concept and mechanism of action 
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Chapter 3 – study 1 
Vagus nerve stimulation has antidepressant effects in the kainic acid 
model for temporal lobe epilepsy 
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Study 1: Proof-of-concept 
Depressive disorders are the most common type of psychiatric comorbidity in epileptic patients, 
especially in individuals suffering from refractory temporal lobe epilepsy. Despite the availability of a 
variety of both antiepileptic and antidepressant drugs, up to 30% of patients fail to respond 
adequately to standard medication. Furthermore, current treatment options for patients suffering 
both from epilepsy and depression are limited by the fact that anticonvulsant drugs can contribute to 
mood disturbances, while antidepressant drugs can increase seizure susceptibility. The lack of 
success with current pharmacological interventions for patients suffering both from epilepsy and 
depression, highlights the importance of optimizing non-pharmacological, neuromodulatory 
treatments such as VNS for this patient population. The initial rationale for using VNS to treat 
refractory depression was fueled by the observation that VNS induces mood improvements in 
epilepsy patients, irrespective of the effect on seizure frequency. However, there are no randomized 
controlled trials confirming the antidepressant effect of VNS in epileptic patients. Studies on the 
antidepressant effect of VNS in a clinical population are confounded by multiple factors, including 
concomitant antiepileptic drug therapy, psychosocial and intellectual effects. The use of animal 
models overcomes this problem and is important in unraveling the mechanism of action of VNS for 
the treatment of epilepsy-related depression. Therefore, a proof-of-concept study was performed to 
assess the antidepressant potential of VNS in an animal model for epilepsy and comorbid anhedonia, 
a key symptom of major depression. For this purpose the effect of VNS on the hedonic state was 
assessed in the the post status epilepticus kainic acid rat model for temporal lobe epilepsy and 
comorbid anhedonia, using the saccharin preference and the quinine aversion test. 
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Abstract 
Background: Depression is the most common psychiatric comorbidity in epilepsy patients. The lack of 
success with current pharmacological interventions for this patient population, highlights the 
importance of optimizing non-pharmacological neuromodulatory treatments such as vagus nerve 
stimulation (VNS). Studies on the antidepressant effect of VNS in epilepsy patients may be 
confounded by concurrent antiepileptic drug therapy. To date, studies in epilepsy models 
overcoming this problem are lacking.  
Objective: We investigated whether VNS affects anhedonia, a key symptom of major depression, in 
the kainic acid rat model for temporal lobe epilepsy.  
Methods: Anhedonia was assessed in kainic acid (KA) and saline (SAL) injected rats using the 
saccharin preference test (SPT). To exclude differences in taste perception, the quinine aversion test 
(QAT) was performed. Both groups were randomly subdivided in a VNS and a SHAM group, yielding 4 
experimental arms: KA-VNS, KA-SHAM, SAL-VNS and SAL-SHAM. Both VNS groups received 2 weeks 
of VNS, while the SHAM groups were not stimulated. Thereafter, the SPT and QAT were repeated.  
Results: Saccharin preference was significantly reduced in the KA compared to the SAL rats (p<0.05), 
without differences in quinine aversion. Two weeks of VNS significantly increased the saccharin 
preference in the KA-VNS group (p<0.05), while it had no effect on quinine aversion. No effects of 
VNS or SHAM were found in the other groups.  
Conclusion: The KA rats displayed anhedonia which was significantly decreased by VNS, indicating 
that this neuromodulatory treatment could likewise diminish depressive symptoms in patients 
suffering from temporal lobe epilepsy and comorbid depression. 
 
Keywords: Vagus nerve stimulation, temporal lobe epilepsy, depression, anhedonia, kainic acid 
model 
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Introduction 
Depressive disorders are the most common type of psychiatric comorbidity in patients with epilepsy 
[1-3], especially in individuals suffering from refractory temporal lobe epilepsy [4-8]. Despite the 
availability of a variety of both antiepileptic and antidepressant drugs, up to 30% of the patients fail 
to respond adequately to standard medication [9]. Furthermore, current treatment options for 
patients suffering both from epilepsy and depression are limited by the fact that anticonvulsant 
drugs can contribute to mood disturbances, while antidepressant drugs can increase seizure 
susceptibility [4, 10, 11]. The lack of success with current pharmacological interventions highlights 
the importance of optimizing non-pharmacological neuromodulatory treatments such as vagus nerve 
stimulation (VNS).  
VNS consists of electrically stimulating the left vagus nerve at the cervical level by means of 
implanted electrodes and a programmable pulse generator. It is a well-established, safe and effective 
add-on therapy for the treatment of refractory epilepsy [12]. Clinical trials reported response rates 
(defined as the fraction of patients with >50% reduction in seizure frequency) of 20-40% in the first 
year of treatment [13, 14]. This response rate was shown to increase with time [15, 16]. 
Furthermore, the antiepileptic effect of VNS has been shown in numerous animal models for epilepsy 
[17-29].  
The initial rationale for using VNS for the treatment of refractory depression was based on mood 
improvements in epilepsy patients treated with VNS, irrespective of the effects of VNS on seizure 
frequency [5, 30, 31]. The therapeutic effect of chronic VNS for treatment-resistant depression has 
been assessed in several open-label and long-term clinical studies in depressed patients without 
epilepsy [32-43]. VNS produced steadily increasing improvement of depressive symptoms with full 
benefit after 6-12 months and sustained efficacy during 2 years of follow-up [44]. Furthermore, these 
studies reported response rates (defined as the fraction of patients with >50% decrease in 
depression severity) of 30-40% and a remission rate of 15-17% after 3-24 months of treatment [45]. 
Unfortunately the only blinded sham-controlled clinical trial was inconclusive because some patients 
had not been adequately ramped-up and therefore did not receive the full therapy [32]. As for 
animal research, it has been shown that both acute [46] and chronic [47] VNS produce 
antidepressant-like effects in the rat forced swim test model [48]. 
To date, studies specifically addressing the antidepressant effects of VNS in epilepsy patients are 
lacking. Furthermore, such studies could be confounded by multiple factors, including antiepileptic 
drug therapy, psychosocial, socio-economic and intellectual effects [8]. The use of animal models 
overcomes this problem and may be useful in identifying potential therapies for the treatment of 
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depression in epileptic patients. This study aims at investigating the antidepressant potential of VNS 
in the kainic acid model for temporal lobe epilepsy with comorbid anhedonia.  
Anhedonia, or the inability to experience pleasure [49], is a key symptom of major depression. 
Because pleasure is a subjective feeling, the DSM-IV operationally defines anhedonia as a diminished 
interest or pleasure in response to stimuli that were perceived as rewarding during the premorbid 
state [50]. In animal research, anhedonia can be assessed using the saccharin or sucrose preference 
test. This validated test for anhedonia is based on the rewarding properties of sweet substances, 
such as saccharin or sucrose solutions. Healthy animals have a strong inherent taste preference 
towards these sweet solutions, while animal models for depression show a significantly reduced 
saccharin or sucrose preference. This loss of taste preference reflects a decrease in reward 
sensitivity, i.e. anhedonia, which can be reversed by treatment with antidepressants [51-55]. To 
exclude the possibility that the reduced saccharin preference in our experiments is caused by a loss 
of taste due to the kainic acid, the induced status epilepticus or the subsequent neuronal loss, the 
quinine aversion test was performed. 
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Methods 
A schematic overview of the study design is shown in figure A.1. Rats were implanted with a VNS 
electrode and electroencephalogram  (EEG) recording electrodes. After one week of recovery, half 
of the animals received intraperitoneal injections with kainic acid (KA) to induce status epilepticus. 
The other half of the animals was injected with matched volumes of saline (SAL). Both the KA group 
and the SAL group were randomly subdivided in a VNS group and a SHAM group, yielding 4 
experimental arms: KA-VNS, KA-SHAM, SAL-VNS and SAL-SHAM. Anhedonia was evaluated 5 weeks 
after KA or SAL injections using the saccharin preference test. To control for loss of taste due to KA-
induced status epilepticus, the quinine aversion test was performed. After this baseline testing, the 
VNS groups (KA-VNS and SAL-VNS) received 2 weeks of VNS, the SHAM groups (KA-SHAM and SAL-
SHAM) were also connected to the set-up but were not stimulated. Subsequently, the saccharin 
preference test and the quinine aversion test were repeated in all animals. All procedures are 
discussed in detail below. 
 
Figure A.1: Schematic representation of the study design. S: surgery; R: recovery; SAL: saline; KA: 
kainic acid; SPT: saccharin preference test; QAT: quinine aversion test; VNS: vagus nerve stimulation. 
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Animals 
Forty-five male Sprague Dawley rats (Harlan, The Netherlands) weighing 250–300 g were used. 
Animals were treated according to the guidelines approved by the European Ethics Committee 
(decree 86/609/EEC). The study protocol was approved by the Animal Experimental Ethical 
Committee of Ghent University Medical department (ECP 13/33). All animals were kept under 
environmentally controlled conditions: 12 h light/dark cycles with artificially dimmed light (4-6 Lux in 
the rat home cages), lights went on at 8:00 AM and off at 8:00 PM. Temperature and relative 
humidity were kept at 20-23°C and 50% respectively and food and water were provided ad libitum. 
 
Surgery 
The animals were anesthetized with a mixture of Isoflurane (5% for induction, 2% for maintenance) 
and medical O2. To minimize post-operative pain, buprenorphine (0.025 mg/kg) (Schering-Plough, 
New Jersey, USA) was administrated intramuscularly 30 minutes prior to surgery. An incision was 
made over the anterior cervical region. The skin and muscles were retracted and the left vagus nerve 
was carefully dissected from the aortic sheet. Subsequently, the custom-made silicone cuff electrode 
was wound around the nerve with the anode placed caudally. The leads of the electrodes were 
tunneled subcutaneously to an incision in the scalp. Details on the construction of the vagal 
electrode are described elsewhere [56]. Furthermore, rats were implanted with two epidural EEG 
recording electrodes through the os frontale and an epidural reference electrode through the os 
occipitale, close to the sutura lambdoidea. A bipolar depth EEG recording electrode consisting of two 
polyimide coated stainless steel wires (Bilaney, Germany) was stereotactically implanted in the left 
hippocampus (coordinates relative to bregma: anteroposterior -5.6 mm; mediolateral -4.6 mm; 
dorsoventral -4.6 mm). The leads of the EEG recording electrodes were assembled together with the 
leads of the VNS electrode to a connector in a head cap on the skull of the rat using acrylic cement. 
Xylocaine gel (2%) was applied to the incision wounds to minimize pain. Animals were allowed to 
recover from surgery during 1 week. 
 
Induction of status epilepticus 
One week after surgery, half of the animals were intraperitoneally injected with KA (Tocris 
bioscience, USA) to induce status epilepticus. KA injections (5 mg/kg/h in a volume of 1.5 ml/kg) were 
administered until the animal displayed a self-sustained status epilepticus for at least 3 hours, 
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according to the protocol of Hellier et al. [57]. During status epilepticus, video-EEG monitoring was 
performed continuously and behavioral seizures were scored according to a modified version of 
Racine's scale: stage 1: immobility, eye closure, twitching of vibrissae, facial clonus, wet dog shakes; 
stage 2: head nodding, chewing, severe facial clonus, wet dog shakes; stage 3: clonus of one 
forelimb; stage 4: rearing, bilateral forelimb clonus; stage 5: rearing, bilateral forelimb clonus, loss of 
balance and falling [58]. The length of the status epilepticus was defined as the time between the 
first epileptic spike on the EEG and the moment the EEG spike activity dropped below a frequency of 
1 Hz for more than one hour. The SAL group was injected with matched volumes of sterile saline 
(vehicle). 
 
Saccharin preference test and quinine aversion test 
Anhedonia was evaluated using the saccharin preference test. In this test, each cage was supplied 
with two identical drinking bottles filled with water, to avoid place preference in the rats (habituation 
phase). On the day of the experiment, the water bottles were replaced by two new bottles with 
known weight. One of the bottles contained water while the other contained a 0.10% saccharin 
(Sigma Aldrich, the Netherlands) solution. The location of the bottle of saccharin solution relative to 
the water bottle was counterbalanced across the rats. The experiment started at 1:00 PM and ran for 
20 hours. At the end of the test, both bottles were removed and weighed. Saccharin preference was 
calculated as the volume of the saccharin solution consumed divided by the total fluid volume 
(saccharin solution plus regular water) consumed and expressed as a percentage. We assessed 
saccharin preference over a time period of 20 hours because short term testing (for example 2 hours) 
can be influenced by many factors that are not related to the hedonic state (e.g. subtle stressors at 
the moment of the test). Furthermore, longer measurements increase the accuracy, as the error can 
be very high during a short sampling period. Another reason for test prolongation was to minimize 
potential neophobic reactions to the taste of the saccharin solution [59]. In order to minimize the 
influence of metabolic factors, we did not apply food and water deprivation in our experiment.On 
the next day, the same procedure was repeated with a bitter tasting 0.05% quinine (Sigma Aldrich, 
The Netherlands) solution. 
 
Vagus nerve stimulation 
The rats were connected to a constant-current stimulator via a spring-covered cable. An electrical 
swivel allowed the rats to move freely within their cage. The animals in the KA-VNS and the SAL-VNS 
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group received 2 weeks of VNS with an output current intensity that was gradually ramped up: 0.25 
milliampere (mA) during the first 3 days, 0.50 mA during the next 4 days and 1.00 mA during the final 
7 days, to minimize stimulus-related side effects. Electrical pulses with a pulse width of 250 µs, were 
delivered at a frequency of 30 Hz. The stimulator was programmed to deliver VNS for 24 hours per 
day with a duty cycle of 7 s ON/18 s OFF. This duty cycle was chosen based on previous experiments 
from our group demonstrating the potency to affect intracerebral neurotransmitter release [17]. The 
animals in the KA-SHAM and the SAL-SHAM groups were also connected to the stimulation set-up, 
but the output current was set to 0.00 mA. The impedance of the VNS electrodes was measured daily 
using a square wave pulse with an amplitude of 1.00 mA. All impedances remained low throughout 
the experiment (< 10 kOhm). After two weeks of SHAM or VNS, behavioral testing was repeated.  
 
Histology 
Animals were euthanized with an intraperitoneal excess dose of sodium pentobarbital (180 mg/kg). 
The brains were fixed in paraformaldehyde (4%), cryoprotected in 30% sucrose at 4°C, snap-frozen in 
ice-cold isopentane and subsequently stored at -20°C. Coronal frozen sections (70 µm) were made 
using a cryostat (Leica). Electrode positions were identified on the brain sections. 
 
Statistics 
Nonparametric tests were performed because the data was not normally distributed. All results are 
expressed as median and interquartile range (between brackets). The duration of the status 
epilepticus and the dose of KA in the KA groups (KA-SHAM and KA-VNS) and the outcome parameters 
in the saccharin preference and quinine aversion test at five weeks after KA or SAL injections, were 
compared using Kruskal-Wallis tests followed by Mann–Whitney U post hoc tests with Bonferonni 
corrections. To assess the effects of SHAM and VNS treatment on the outcome parameters in the 
saccharin preference and quinine aversion test, Wilcoxon matched pairs signed ranks tests were 
used. 
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Results 
 
Status epilepticus 
Sixteen out of twenty-five animals survived the KA-induced status epilepticus. In the surviving 
animals, the median duration of the status epilepticus was 11.3 h (1.4 h) and the median dosage of 
KA was 12.5 mg/kg (0.3 mg/kg). There were no differences in the duration of status epilepticus and 
the dosage of KA between the KA-SHAM and the KA-VNS group: 10.9 h (2.2 h) versus 11.6 h (0.5 h) 
and 12.5 mg/kg (0.0 mg/kg) versus 12.5 mg/kg (1.25 mg/kg) respectively (p>0.05 in both cases). None 
of the animals in the SAL group developed status epilepticus. 
 
Hedonic outcome five weeks after SAL or KA injection 
 
Figure A.2: Outcomes in the saccharin preference and quinine aversion test 5 weeks after KA or SAL 
injections. Panel a, b and c depict the saccharin preference (in %), saccharin consumption (in g) and 
water consumption (in g) respectively in the saccharin preference test. Panel d, e and f depict the 
quinine aversion (in %), quinine consumption (in g) and water consumption (in g) respectively in the 
quinine aversion test. Boxplots depict the median (full line), the interquartile range (box boundaries) 
and the 5-95th percentile (whiskers). Each dot represents a value of an individual animal (SAL-SHAM: 
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n = 8, SAL-VNS: n = 7, KA-SHAM: n=7, KA-VNS: n = 7). * p<0.05, Kruskal-Wallis test followed by Mann–
Whitney U post hoc tests.  
 
In the saccharin preference test, the KA groups showed a significantly lower saccharin preference 
compared to the SAL groups: 19.4% (60.0%), 10.3% (7.0%), 97.5% (5.0%) and 97.2% (4.0%) for the 
KA-SHAM, KA-VNS, SAL-SHAM and SAL-VNS group respectively (p<0.05, see figure A.2.a). This 
significant reduction in saccharin preference resulted from both a significantly lower saccharin 
consumption and a significantly higher water consumption in the KA groups compared to the SAL 
groups (p<0.05, see figure A.2.b and c respectively). Combined, the results from the saccharin 
preference test show that the KA animals display anhedonia. 
No differences in aversion towards quinine were found across the groups: 6.3% (4.0%), 8.0% (18.2%), 
6.7% (8.4%) and 7.7% (18.6%) for the KA-SHAM, KA-VNS, SAL-SHAM and SAL-VNS group respectively 
(p>0.05, see figure A.2.d). This results from an equal consumption of quinine and water in the KA and 
the SAL groups (p>0.05, see figure A.2.e and f respectively). Combined, the results from the quinine 
aversion test show that taste perception was not compromised after KA-induced status epilepticus. 
 
Effects of two weeks of VNS or SHAM on the hedonic state 
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Figure A.3: The effect of two weeks of VNS or SHAM treatment in the saccharin preference and 
quinine aversion test in SAL and KA animals. Panel a, b and c depict the saccharin preference (in %), 
saccharin consumption (in g) and water consumption (in g) respectively in the saccharin preference 
test. Panel d, e and f depict the quinine aversion (in %), quinine consumption (in g) and water 
consumption (in g) respectively in the quinine aversion test. Boxplots depict the median (full line), 
the interquartile range (box boundaries) and the 5–95th percentile (whiskers). Each dot represents 
the saccharin preference or quinine aversion of an individual animal (SAL-SHAM group: n = 8; SAL-
VNS group:n = 7; KA-SHAM group: n = 7; KA-VNS group: n = 7). *p<0.05, Wilcoxon matched pairs 
signed ranks test. 
 
Two weeks of VNS significantly increased the saccharin preference in the KA-VNS group: from 10.3% 
(7.0%) before treatment to 71.1% (81.0%) after treatment (p<0.05, see figure A.3.a). This significant 
increase in saccharin preference resulted from both a significant increase in saccharin consumption 
(p<0.05, see figure A.3.b) and a significant reduction in water consumption after two weeks of VNS in 
the KA-VNS group (p<0.05, see figure A.3.c). Combined, the results from the saccharin preference 
test show that VNS significantly decreases anhedonia in KA rats. 
No differences in saccharin preference were found in the other groups before vs. after VNS or SHAM 
treatment: 97.5% (5.0%) versus 98.5% (3.0%), 97.2% (4.0%) versus 98.4% (17.0%) and 19.4% (60.0%) 
versus 12.5% (15.0%), for the SAL-SHAM, SAL-VNS and KA-SHAM group respectively (p>0.05 in all 
cases, see figure A.3.a). Accordingly, no differences in saccharin consumption and water 
consumption in the saccharin preference test before vs. after VNS or SHAM treatment were found in 
these three groups (p>0.05, see figure A.3.b and c respectively). 
No differences in quinine aversion were found before vs. after VNS or SHAM treatment: 6.7% (8.4%) 
versus 7.9% (4.0%), 7.7% (18.6%) versus 2.9% (7.0%), 6.3% (4.0%) versus 13.3% (25.0%) and 8.0% 
(18.2%) versus 8.0% (14.0%) for the SAL-SHAM, SAL-VNS, KA-SHAM and KA-VNS group respectively 
(p>0.05, see figure A.3.d). Accordingly, VNS and SHAM treatment did not affect the amount of 
quinine consumption, nor did it affect the amount of water consumption in the quinine aversion test 
(p>0.05, see figure A.3.e and f respectively). 
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Discussion  
The KA rat model for temporal lobe epilepsy presents anhedonia, as demonstrated by a significant 
decrease in saccharin preference. The reduced saccharin preference in the KA group was not caused 
by an altered taste perception, as the aversion towards quinine was unaltered in the KA-treated rats. 
Two weeks of VNS decreased the anhedonic state in the KA rats, as indicated by a significant increase 
in saccharin preference. No effects were found in the other groups (KA-SHAM, SAL-VNS and SAL-
SHAM). Furthermore, VNS nor SHAM treatment had an effect on taste perception, as shown in the 
quinine aversion test. Our findings demonstrate the antidepressant effect of VNS in the KA model for 
temporal lobe epilepsy and comorbid anhedonia. 
Anhedonia, or the inability to experience pleasure, is an indicator of clinical depression and is present 
in the chronic mild stress model, the most widely used and validated animal model for depression 
[54, 60, 61]. As depressive symptoms are the most common type of psychiatric comorbidity in 
epilepsy patients, it is not surprising that anhedonia has also been found in rat models for both 
partial and generalized epilepsy [8, 62, 63]. In accordance with previous studies that demonstrated a 
significant decrease in saccharin preference in the pilocarpine model for temporal lobe epilepsy [49, 
64] and a significant decrease in sucrose preference in the KA model for temporal lobe epilepsy [65], 
we found a significant decrease in saccharin preference in KA-treated rats. This makes the model 
suitable for investigating the potential antidepressant effects of VNS.  
The frequent co-occurrence of epileptic seizures and anhedonia in chronic epilepsy models suggest 
that these symptoms may share common underlying pathological mechanisms. Although the specific 
mechanisms have not been identified to date, emerging evidence shows that there is a remarkable 
overlap in the abnormalities found in epilepsy and depression models, the most important ones 
being (i) imbalances in neurotransmitter systems [1], (ii) increased neuroinflammation [66, 67] and 
(iii) changes in hippocampal neurogenesis [68, 69]. 
It has been shown that the noradrenergic [70-72], serotonergic [15, 71-79], dopaminergic [65, 76, 80-
86], GABAergic [87-90] and glutamatergic [88, 91] neurotransmitter systems are disturbed both in 
the KA model for temporal lobe epilepsy and the chronic mild stress model for anhedonia. Increased 
neuroinflammatory markers such as altered levels of cytokines (i.e. IL-1α, IL-1β, IL-2 and TNF-α) have 
also been found in both models [75, 92, 93], providing another putative underlying mechanism for 
the anhedonia we observed in the KA model. Furthermore, significantly reduced or excessively 
increased progenitor proliferation in the granule cell layer of the hippocampus have been found in 
the chronic mild stress model for anhedonia [91, 94, 95] and the KA model for temporal lobe epilepsy 
[96-98] respectively. These changes contribute to disturbing neural networks important in the 
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pathophysiology of epileptic seizures and anhedonia. Therefore, it is likely that these changes further 
contribute to the development of the anhedonic state in the KA model. 
The exact mechanism of action of VNS remains to be elucidated, but VNS research has demonstrated 
potential in affecting all three of the above described brain abnormalities that may play a role in the 
common pathophysiological basis of epilepsy and depression. Previous research has demonstrated 
that VNS may exert its antidepressant and antiepileptic effects through correcting dysfunctional 
neurotransmitter systems. Electrophysiological [99-104] and neurochemical [17, 105-108] studies 
have demonstrated that VNS enhances the noradrenergic and serotonergic neurotransmission 
through activation of the locus coeruleus and the dorsal raphe nucleus, which are the two main 
sources of brain noradrenaline and serotonin respectively [109, 110]. In this study, antidepressant 
effects were found using a relatively intense stimulation protocol. Roosevelt and co-workers had 
previously reported a bilateral increase in noradrenaline levels in the cortex (39%) and the 
hippocampus (28%) in response to one hour of VNS using a stimulation protocol typically applied in 
clinical settings to control seizures (20 Hz, 1.00 mA, 500 µs, 30 s ON / 10 min OFF) [105]. In a previous 
experiment by our group, a more than two-fold higher increase (69%) in extracellular hippocampal 
noradrenaline was achieved by using a more intensive stimulation protocol: 30 Hz, 1.00 mA, 250 
µsec, 7 sec ON / 18 sec OFF [17], resulting in the delivery of a higher load of electrical pulses to the 
vagus nerve. The duty cycle used in our experiments (7 s ON / 18 s OFF) is referred to as ‘rapid 
cycling’ in clinical practice, and is sometimes used to treat patients in whom VNS with the standard 
duty cycle of 30 s ON / 10 min OFF, has no significant therapeutic effect [111, 112]. It remains to be 
demonstrated which duty cycles are optimal to achieve clinical efficacy while conserving battery life. 
Although VNS research has focused on the noradrenergic and serotonergic neurotransmission in the 
central nervous system, it should be noted that stimulation of the vagus nerve most likely induces a 
much more complex cascade of both central and peripheral neurochemical changes. Indeed, VNS 
was shown to affect the glutamatergic, GABAergic, dopaminergic and cholinergic systems [101, 113-
121]. Strong evidence suggests that VNS-induced neuroplastic changes are mediated by acetylcholine 
through activation of the nucleus basalis [122, 123]. Furthermore, VNS also has proven anti-
inflammatory effects, which may further contribute to the antidepressant and antiepileptic effects of 
VNS [124-133]. Interestingly, a growing body of evidence suggests that VNS could produce its effects 
through increasing hippocampal neurogenesis [134-137], thereby creating newborn cells which can 
functionally integrate and re-establish normal network activity. This hypothesis is supported by the 
fact that the time lag of the therapeutic effects of VNS corresponds to the time needed for the 
integration of newborn cells in the hippocampal granule cell layer into existing circuits. 
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Conclusion 
The intraperitoneal KA rat model for temporal lobe epilepsy presents anhedonia which is significantly 
decreased by two weeks of VNS treatment. These results provide evidence for the antidepressant 
effect of VNS in the KA model for temporal lobe epilepsy and indicate that VNS could likewise 
diminish depressive symptoms in patients suffering from temporal lobe epilepsy and comorbid 
depression. The promising results encourage further studies in this model in order to gain a better 
understanding of the underlying mechanism of action of VNS. This mechanism of action most likely 
results from a complex interplay between several mechanisms that underlie the pathophysiology of 
epilepsy and depression, i.e. the correction of dysfunctional neurotransmitter circuits, the induction 
of anti-inflammatory effects and the promotion of neurogenesis. 
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Chapter 3 - study 2 
The antidepressant-like effect of vagus nerve stimulation is mediated 
through the activation of the locus coeruleus 
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Study 2: Mechanism of action 
 
Although VNS is already used in clinical practice for the treatment of refractory depression, the 
antidepressant mechanism of action of this neuromodulatory treatment remains to be elucidated. A 
better understanding of the mechanism of action is indispensable to identify potential responders 
prior to surgery and may guide the search for optimal stimulation parameters, finally improving 
clinical efficacy. Previously, it was shown that VNS has an antidepressant-like effect in the rat forced 
swim test. The mechanism of action underlying this effect is incompletely understood, but there is a 
large body of evidence suggesting that the locus coeruleus (LC) – which is the main source of 
noradrenaline in the brain - might play an important role. Therefore, the hypothesis that the VNS-
induced antidepressant-like effect in the forced swim test is mediated through activation of the LC, 
was tested. For this purpose, LC neurons were lesioned using DSP-4 [N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine hydrochloride], a highly selective neurotoxin for the noradrenergic axons 
originating from the LC. 
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Abstract 
It has been shown that vagus nerve stimulation (VNS) has an antidepressant-like effect in the forced 
swim test. The mechanism of action underlying this effect is incompletely understood, but there is 
evidence suggesting that the locus coeruleus (LC) may play an important role. In this study, 
noradrenergic LC neurons were selectively lesioned to test their involvement in the antidepressant-
like effect of VNS in the forced swim test. 
Forced swim test behavior was assessed in rats that were subjected to VNS or sham treatment. In 
half of the VNS-treated animals, the noradrenergic neurons from the LC were lesioned using the 
selective neurotoxin DSP-4 [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride], yielding 
three experimental arms: sham, VNS and DSP-4-VNS (n = 8 per group). Furthermore, the open field 
test was performed to evaluate locomotor activity. A dopamine-β-hydroxylase immunostaining was 
performed to confirm lesioning of noradrenergic LC neurons.  
VNS significantly reduced the percentage of immobility time in the forced swim test compared to 
sham treatment (median: 56%, interquartile range: 41% vs. median: 75%, interquartile range: 12%). 
This antidepressant-like effect of VNS could not be demonstrated in the DSP-4-VNS group (median: 
79%, interquartile range: 33%). Locomotor activity in the open field test was not different between 
the three treatment arms. The absence of hippocampal dopamine-β-hydroxylase immunostaining in 
the DSP-4-treated rats confirmed the lesioning of noradrenergic neurons originating from the 
brainstem LC. 
The results of this study demonstrate that the noradrenergic neurons from the LC play an important 
role in the antidepressant-like effect of VNS. 
 
Keywords: Vagus nerve stimulation, depression, forced swim test, locus coeruleus, noradrenaline 
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Introduction 
Major depressive disorders are highly prevalent, widely distributed in the population and usually 
associated with substantial symptom severity and role impairment [1]. While depressive symptoms 
can be effectively treated with antidepressant drugs or psychotherapy in the majority of patients, up 
to 20% of patients fail to respond to standard interventions [2]. These drug-refractory patients are 
candidates for treatment with neurostimulation therapies such as vagus nerve stimulation (VNS). 
 
VNS is an extracranial neurostimulation technique, where the cervical region of the left vagus nerve 
is stimulated by means of a helical electrode, connected to a subclavicularly-implanted pulse 
generator. It is a well-established, safe and effective add-on therapy for refractory epilepsy [3]. The 
initial rationale for using VNS for the treatment of refractory depression was based on mood 
improvements observed in epilepsy patients treated with VNS, irrespective of the effects of VNS on 
seizure frequency [4, 5]. Several clinical studies have subsequently confirmed the therapeutic efficacy 
of VNS for treatment resistant depression [6-15], but the mechanism of action is still unknown.  
The forced swim test is one of the most commonly used and validated experimental assays to assess 
depression-like behavior in rodents. During the test, animals are placed in a cylinder filled with water 
from which they cannot escape. Mobile escape-related behavior (defined as forepaw movements 
along the side of the cylinder and swimming throughout the cylinder) and immobile passive behavior 
(defined as the lack of whole body movement, except for small efforts to keep the head above water) 
are scored blindly on videotaped images of the test. A reduction in immobile passive behavior is 
reflective of an antidepressant-like effect of the investigated intervention [16, 17]. To rule out the 
possibility that the effects in the forced swim test are caused by an overall change in locomotor 
activity, an open field test can be performed. Krahl et al. showed that VNS produces an 
antidepressant-like effect in the forced swim test in rats with the same efficacy as electroconvulsive 
shock therapy and the tricyclic antidepressant desipramine [18].  
Since the 1960s there has been a strong emphasis on the role of noradrenaline both in the 
pathogenesis of depressive disorders and in the mechanism of action of antidepressants [19, 20]. 
This largely results from the fact that many of the first generation antidepressants, the tricyclics, 
increase the synaptic concentration of noradrenaline [21]. There is extensive evidence demonstrating 
that VNS also enhances the noradrenergic neurotransmission through the activation of the LC [22-
30], which is the main source of cortical noradrenaline [31]. Therefore, we investigated the 
hypothesis that the VNS-induced antidepressant-like effect in the forced swim test is mediated 
through activation of the LC and subsequent release of noradrenaline. For this purpose LC neurons 
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were lesioned using DSP-4, a highly selective neurotoxin for the noradrenergic axons originating from 
the LC [32, 33].  
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Methods and materials 
A schematic overview of the study design is shown in figure 1. All procedures are described in detail 
below. 
 
Figure 1: Schematic representation of the study design. DSP-4, [N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine hydrochloride]; ip, intraperitoneal; mA, milliampere; VNS; vagus nerve 
stimulation. 
 
Animals 
Male rats (Harlan, The Netherlands) weighing 250–300 g were used. As in the study of Krahl, Wistar 
Kyoto rats were chosen because they are known to be sensitive to the depressogenic effects of the 
forced swim test [18]. Animals were treated according to the guidelines approved by the European 
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ethics committee (decree 86/609/EEC). The study protocol was approved by the animal experimental 
ethical committee of Ghent University medical department (ECP 13/33). All animals were kept under 
environmentally controlled conditions: 12 h light/dark cycles with artificially dimmed light, 
temperature and relative humidity at 20-23°C and 40-60% respectively. Food and water were 
provided ad libitum. 
 
Surgery 
The animals were anesthetized with a mixture of medical O2 and Isoflurane (5% for induction, 2% for 
maintenance). A dose of Buprenorphine (0.025 mg/kg, subcutaneously) was administered 
preoperatively. The skin of the ventral cervical region was shaved and disinfected and a midline 
incision was made. The skin and muscles were retracted and the left vagus nerve was carefully 
dissected from the aortic sheet. Subsequently, a custom-made bipolar silicone cuff electrode was 
wrapped around the nerve with the anode placed caudally. The leads of the electrode were tunneled 
subcutaneously up to an incision in the scalp and attached to the skull using anchor screws and 
acrylic cement. Xylocaine and Neobacitracine gel were applied to the incision wounds in order to 
minimize pain and reduce the risk of postoperative infections respectively. Furthermore, Metacam (1 
mg/kg, subcutaneously) was given to the animals postoperatively and every 24 hours after surgery 
for two days. The animals were assigned at random to one of the three treatment groups (sham, VNS 
or DSP-4-VNS, n = 8 per group) and were allowed to recover from surgery for two weeks. 
 
DSP-4 injections 
Rats in the DSP-4-VNS group were injected with DSP-4 twice. The first injection (60 mg/kg, ip, 
dissolved in a volume of 1 ml of sterile saline) was given on the first day of the recovery period, the 
second injection (50 mg/kg, ip, dissolved in a volume of 1 ml of sterile saline) was given on the 
seventh day of the recovery period (i.e. 14 and 7 days before the start of the forced swim test [34, 
35]). 
 
Forced swim test 
The forced swim test procedure was performed as described previously [18]. For all swimming 
procedures, the rats were placed in a glass cylinder (diameter: 26 cm; height: 65 cm) filled with tap 
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water (26.0-26.5°C) to a height of 40 cm. The animals could not support themselves by touching the 
bottom of the cylinder with the hind paws or tail. The test consisted of two sessions, following an 
established and validated method [18, 36]. The first session (day 1 of the testing week), called the 
pre-swim, consisted of placing the rats in the water for 15 minutes. The second session, the 5-minute 
swim test, took place three days after the pre-swim (day 4 of the testing week) [18]. The 5-minute 
swim test was videotaped and analyzed off-line by two independent investigators blinded for the 
group or treatment (AG and CB). In 5-s epochs, the investigators judged whether the rat was 
immobile or mobile. The number of epochs with immobile behavior was divided by the total number 
of epochs for each rat (60) and multiplied by 100 to determine the percentage of immobility time, as 
previously described by Krahl et al. [18]. After the swim sessions, the rats were removed from the 
cylinder and dried with paper towels. Between each swim session, the cylinder was washed with a 
soap solution and refilled with fresh water. 
 
Vagus nerve stimulation 
Animals in the VNS and the DSP-4-VNS group received one hour of VNS therapy on four consecutive 
days. The first session was administered immediately after the 15-minute pre-swim on day 1 of the 
testing week. In order to minimize stimulation-related side effects, the stimulator output current was 
initially low and ramped up every day in the following incremental steps: 0.20 milliampere (mA), 0.50 
mA, 0.60 mA and 0.70 mA on day 1, 2, 3 and 4 of the testing week respectively. The stimulus 
consisted of electrical pulses with a duration of 250 µs, delivered at a frequency of 30 Hz and a duty 
cycle of 7 s ON / 18 s OFF. This duty cycle was chosen based on previous experiments from our group 
demonstrating its antidepressant potential and the potency to affect intracerebral noradrenaline 
release [27, 37]. Animals in the sham group were also connected to the stimulation set-up, but the 
output current was set at 0.00 mA. On day 4 of the testing week, VNS or sham sessions were 
immediately followed by the 5-minute forced swim test. On day 5 of the testing week, the animals 
received an additional VNS session at 0.70 mA or a sham session at 0.00 mA, which was immediately 
followed by the open field test. The impedance of the VNS electrodes was measured daily and 
remained low throughout the experiment (< 10 kOhm).  
 
Open field test 
An open field test was performed after the fifth and last VNS or sham session (on day 5 of the testing 
week). This test was performed to assess spontaneous locomotor activity. The animals were placed 
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individually in the center of a wooden box (dimensions: 1 m (l) x 1 m (w) x 0.4 m (h)) with white walls 
and a white floor. On the floor of the wooden box, 49 equal squares (dimensions: 0.14 m x 0.14 m) 
were marked with black lines. The rats were allowed to explore the open field for 5 minutes. Sessions 
were videotaped and the number of squares crossed with four paws during the 5-minute trial was 
assessed offline by two independent investigators blinded for the group and treatment (AG and CB). 
After each test, the arena was cleaned thoroughly with a soap solution, rinsed with fresh water and 
dried with paper towels. 
 
Histology 
Animals were deeply anesthetized with an overdose of sodium pentobarbital (180 mg/kg, ip) and 
transcardially perfused with ice-cold paraformaldehyde (4%, pH 7.4). The brains were post-fixed in 
paraformaldehyde (4%, pH 7.4) for 24 hours and subsequently cryoprotected in 10%-20%-30% 
sucrose at 4°C, snap-frozen in ice-cold isopentane and stored at -20°C. Coronal frozen sections (40 
µm) were made using a cryostat (Leica). The sections were washed twice for five minutes in 
phosphate buffered saline (PBS) and subsequently incubated with 0.6% hydrogen peroxide for 
30 minutes at room temperature. After washing twice for five minutes in PBS, the sections were 
incubated with PBS containing 3% Donkey serum and 0.25% Triton-X for 30 minutes. The sections 
were then incubated with the primary anti-dopamine-β-hydroxylase antibody (1:1000, Merck 
Millipore, MAB308) diluted in PBS for one hour at room temperature and subsequently overnight at 
4 °C. Next day, the sections were washed twice during five minutes in PBS, followed by incubation 
with biotinylated donkey-anti-mouse antibody (1:1000, Jackson ImmunoResearch lab) diluted in PBS 
for two hours at room temperature. After two rinses in PBS, dopamine-β-hydroxylase in the sections 
was detected with the avidin–biotin conjugate (Vectastain ABC kit, Vector Laboratories) and revealed 
with 3,3-diaminobenzidine (DAB; brown precipitate). The slices were mounted on glass slides and 
cover slipped using Entellan.  
 
Statistical analysis 
Statistical analyses were performed using SPSS 21. Nonparametric tests were used because the data 
was not normally distributed. All results are expressed as median and interquartile range. To 
compare immobility in the forced swim test and locomotor activity in the open field test between the 
three groups, Kruskal–Wallis tests were used followed by Mann–Whitney U post hoc tests with 
adjusted p-values after Bonferroni correction. A Spearman correlation test was used to assess 
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possible correlations between the immobility in the forced swim test and the locomotor activity in 
the open field test. Graphs were drawn in Sigmaplot 11.0. Statistical significance was set at p<0.05. 
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Results 
 
Forced swim test and open field test 
The fraction of immobility in the forced swim test was significantly lower in the VNS group (median: 
56%, interquartile range: 41%) compared to the sham group (median: 75%, interquartile range: 12%) 
(p<0.05). This antidepressant-like effect of VNS was abolished in the DSP-4-VNS group (median: 79%, 
interquartile range: 33%), reflected by a level of immobility similar to the sham group (p>0.05) and 
significantly higher than the VNS group (p<0.05) (see figure 2.A). 
There were no significant differences in locomotor activity in the open field test between animals of 
the three groups; median: 59 squares, interquartile range: 55 squares, median: 52 squares, 
interquartile range: 68 squares and median 30 squares, interquartile range: 55 squares for the sham, 
VNS and DSP-4-VNS group respectively (p>0.05) (see figure 2.B). No correlation was found between 
the immobility in the forced swim test and the locomotion in the open field test (Spearman 
correlation coefficient= -0.0826, p>0.5, see figure 2.C). 
 
Figure 2: Results of the forced swim test and the open field test. A. Immobility in the forced swim 
test (in %). B. Locomotor activity in the open field test (in amount of squares crossed). C. Immobility 
in the forced swim test versus locomotor activity in the open field test. Boxplots depict the median 
(full line), the mean (dashed line), the interquartile range (box boundaries) and the 5-95th percentile 
(whiskers). Each dot represents a value of an individual animal (n = 8 per group). * p<0.05, Kruskal–
Wallis tests, followed by Mann–Whitney U post hoc tests with adjusted p-levels after Bonferroni 
correction. DSP-4, [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride]; VNS, vagus nerve 
stimulation.  
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Histology 
To validate the efficacy of the DSP-4 effect on the noradrenergic neurons, an immunostaining was 
performed using antibodies against the membrane-bound enzyme dopamine-β-hydroxylase. This 
enzyme converts dopamine to noradrenaline and is a specific marker for noradrenergic nerve 
terminals [38]. The lesion in the DSP-4-treated group was confirmed as the absence of dopamine-β-
hydroxylase-immunostained noradrenergic axons in the hippocampus (see figure 3). The 
hippocampus was chosen because the LC provides the sole source of noradrenaline for this structure 
[32]. 
 
Figure 3: Microscopic images of the dopamine-β-hydroxylase staining. A. Microscopic image of 
dopamine-β-hydroxylase-immunostained noradrenergic axons in the hippocampus of a naive rat and 
B. the absence of staining in a DSP-4-treated rat. DG, dentate gyrus; DSP-4, [N-(2-chloroethyl)-N-
ethyl-2-bromobenzylamine hydrochloride]; HIL, hilus.  
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Discussion 
In this study, we demonstrated that VNS has an antidepressant-like effect based on a significant 
reduction of the immobility time in the forced swim test. These findings are congruent with the 
results of a previous study by Krahl et al. [18]. In the present study, the antidepressant-like effect of 
VNS was completely abolished when the noradrenergic neurons arising from the LC were eliminated 
using the selective noradrenergic neurotoxin DSP-4. To rule out the possibility that the effects in the 
forced swim test were caused by an overall change in locomotor activity, the animals were tested in 
an open field. No significant difference in locomotor activity was found between groups. 
Furthermore, the immobility in the forced swim test did not correlate with the locomotor activity in 
the open field test, ruling out a mere locomotor effect as an explanation for the observed forced 
swim test results. Our findings demonstrate a key role for the noradrenergic LC neurons in the 
antidepressant-like mechanism of action of VNS. 
 
The LC and its neurotransmitter noradrenaline, are convincingly involved in the treatment of 
depression [20, 39]. On the one hand, direct electrical stimulation of the LC has been shown to 
produce an antidepressant-like effect in the forced swim test [40]. On the other hand, lesioning 
studies have shown that an intact LC is required to observe a therapeutic effect of antidepressant 
drugs [40-42]. Moreover, it was demonstrated that various classes of antidepressants influence the 
discharge rate of LC neurons [43-46]. It is well-known that VNS also influences the LC through the 
vagal afferent fibers. These fibers have their cell bodies in the nodose ganglion and predominantly 
project to the nucleus tractus solitarius. In turn, the neurons from the nucleus tractus solitarius 
project to the LC and support the VNS-induced increases in LC firing rate [22-25]. Furthermore, VNS 
was shown to significantly increase the percentage of LC neurons firing in bursts [22-24, 47], a firing 
mode that leads to greater release of noradrenaline compared to single pulses [29]. Moreover, 
chronic stimulation of the vagus nerve was shown to increase the number of spikes per burst and the 
burst length, contributing further to the increase in mean firing rate of the noradrenergic LC neurons 
[22, 24]. The results from these electrophysiological studies are consistent with several studies that 
have demonstrated VNS-induced increases in noradrenaline in brain structures involved in mood 
regulation, including the basolateral amygdala [30], the prefrontal cortex [28, 47] and the 
hippocampus [26, 27]. In the present study, a relatively intense duty cycle (7 s ON / 18 OFF) was 
used. This duty cycle is referred to as ‘rapid cycling’ in clinical practice, and is sometimes used to 
treat patients in whom VNS with the standard duty cycle (30 s ON / 300 s OFF), has no significant 
therapeutic effect [48, 49]. We have decided to use rapid cycling in this experiment for two reasons. 
First, we recently demonstrated that rapid cycling VNS has antidepressant effects in the kainic acid 
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model for temporal lobe epilepsy and comorbid depression [37]. Second, Roosevelt and colleagues 
have previously reported a bilateral increase in noradrenaline levels in the hippocampus (28% above 
baseline) in response to one hour of VNS, using the standard duty cycle [26]. However, in an 
experiment by our own group, a more than two-fold higher increase (69% above baseline) in 
extracellular hippocampal noradrenaline was achieved in response to one hour of rapid cycling VNS 
[27]. This large body of evidence on the VNS-induced enhancement of the LC noradrenergic system, 
combined with the findings of the present study and the established role of the LC and noradrenaline 
in the therapeutic effect of many antidepressants [20, 39, 40, 42], strongly supports the hypothesis 
that the antidepressant effect of VNS is mediated through the activation of the LC and subsequent 
release of noradrenaline.  
 
In previous LC lesioning studies, it was demonstrated that an intact LC is also required for the 
antiepileptic and the antinociceptive effects of VNS [50-53]. Considering the loss of therapeutic 
efficacy of VNS for several disorders after LC destruction, it could be hypothesized that the LC 
functions as a gateway structure, by primarily releasing noradrenaline which can then trigger other 
mechanisms important in several conditions, including depression, epilepsy and pain [50-53]. A 
hypothesis to consider for depression is the enhancement of other neurotransmitter systems such as 
the serotonergic [22, 47, 54] and dopaminergic [23, 55] neurotransmission, two monoaminergic 
systems which are implied in the pathophysiology and the treatment of depression [56, 57]. While 
noradrenergic system activation is already present after one hour of VNS [22, 24, 47], it was 
demonstrated that the effect of VNS on the serotonergic and dopaminergic neurons only appears 
after chronic stimulation (2 weeks of VNS). Indeed, it was shown that serotonin is implied in the 
antidepressant-like effect of chronic VNS (2 weeks of continuous stimulation) [58]. Manta et al. 
showed that the effect of VNS on serotonergic neuronal firing is indirect and mediated by the 
noradrenergic LC neurons through the enhanced activation of the excitatory α1-adrenoreceptors 
located on dorsal raphe nucleus serotonergic cell bodies [22]. Furthermore, it was shown that direct 
LC stimulation elicits burst firing of the dopaminergic ventral tegmental neurons through the 
excitatory α1-adrenoreceptors as well [59-61]. Consequently, it can be hypothesized that the effect 
of VNS on the dopaminergic system is also indirectly mediated through the activation of the LC 
noradrenergic system.  
 
Another plausible hypothesis is that VNS produces its antidepressant-like effect through increasing 
neuroplasticity in the hippocampus, a limbic structure involved in mood regulation. The term 
"neuroplasticity" encompasses an array of mechanisms, from the birth, survival, migration, and 
integration of new neurons (or neurogenesis), to neurite outgrowth, synaptogenesis and the 
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modulation of mature synapses [62]. The rationale for this hypothesis originates from the knowledge 
that stressful events such as forced swimming in rodents, lead to a significant reduction in 
hippocampal neuroplasticity, while the mode of action of several antidepressants involves increasing 
hippocampal neuroplasticity [63]. Airan et al. even showed that antidepressant efficacy in the forced 
swim test requires intact hippocampal neurogenesis [64]. A growing body of evidence suggests that 
VNS could produce its antidepressant effect through increasing hippocampal neuroplasticity as well 
[28, 65-68]. As the hippocampus is rich in LC noradrenergic innervation [69] and noradrenaline has 
proven neuroplastic effects [70-72], it is tempting to hypothesize that these effects of VNS are also 
indirectly mediated though the activation of the LC and subsequent release of noradrenaline in the 
hippocampus.  
 
In conclusion, this study demonstrates the key role of the LC in the antidepressant-like mechanism of 
action of VNS. Despite this, further research is required to unravel the upstream mechanisms by 
which the VNS-induced activation of the LC exerts its antidepressant effect. Hypotheses to consider 
are the enhancement of neurotransmitter systems involved in depression and/or the upregulation of 
hippocampal neuroplasticity. 
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Study 3: Review on the antidepressant mechanism of action of VNS 
 
The third literature study of chapter 3 consist of a review that provides an overview of the preclinical 
VNS studies in view of two major hypotheses in depression research: the monoaminergic and the 
neural plasticity hypothesis of major depression. 
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Abstract 
Vagus nerve stimulation (VNS) is a proposed neuromodulatory treatment for medically refractory 
major depression. Although VNS is already used in clinical practice, the underlying mechanism of 
action remains unknown. The present review provides an overview of the preclinical VNS studies in 
view of two major hypotheses in depression research: the monoaminergic and the neural plasticity 
hypothesis of depression.  
Keywords: vagus nerve stimulation, major depressive disorder, the monoaminergic hypothesis of 
major depressive disorder, the neural plasticity hypothesis of major depressive disorder. 
  
 89 
 
Introduction 
The World Health Organization estimates that by 2020, major depressive disorders (MDD) will 
become the second largest cause of global disease problems in the world, only behind ischemic heart 
disease [1]. The lifetime prevalence for MDD is reported to be as high as 17% and the 12-month 
prevalence is estimated to be 4-8% [2, 3]. Despite the availability of a variety of antidepressant 
agents and improved tolerance of new antidepressant medications, up to 20% of patients fail to 
respond adequately to standard antidepressant treatments [4]. This relative lack of efficacy 
significantly interferes with the psychosocial functioning and quality of life of refractory patients. In 
addition, it is well-recognized that the failure to reach full clinical remission after antidepressant 
treatment involves a high risk of relapse and recurrence in patients suffering from MDD [5]. The lack 
of success with current pharmacological interventions, highlights the importance of optimizing non-
pharmacological treatments for refractory patients.  
 
Among other neuromodulation modalities for refractory MDD, vagus nerve stimulation (VNS) is the 
electrical stimulation of the left vagus nerve at the cervical level, by means of implanted electrodes 
and a programmable pulse generator. It is also a well-established, safe and effective add-on therapy 
for refractory epilepsy [6]. The initial rationale for using VNS for the treatment of refractory 
depression, resulted from mood improvements in epilepsy patients treated with VNS, irrespective of 
the presence or absence of beneficial effects on seizure frequency [7-9]. A recent study from our 
laboratory confirmed the antidepressant effect of VNS in the kainic acid rat model for temporal lobe 
epilepsy and comorbid depression [10]. Of interest, MDDs are the most common type of psychiatric 
comorbidity in patients suffering from refractory epilepsy [11-13].  
The therapeutic effect of chronic VNS for treatment resistant depression has been assessed in 
several clinical studies [14-28]. VNS demonstrated steadily increasing improvement of depressive 
symptoms with full benefit after 6 to12 months, sustained for up to 2 years. These studies reported 
response rates of 30-40% and remission rates of 15-17% after 3 to 24 months of treatment [29]. 
Furthermore, a recent meta-analysis comparing 'VNS with treatment as usual’ (n = 1035) versus 
'treatment as usual alone' (n = 425), revealed that 'VNS with treatment as usual' results in greater 
response and remission rates that are more likely to persist in the long-term [30].  
Although VNS has proven to be effective in reducing depressive symptoms in several clinical trials, 
the optimal stimulation parameters and the mechanism of action remain elusive. A retrospective 
analysis by Muller et al., revealed that VNS at low-strength/high-frequency stimulation parameters is 
effective in reducing depressive symptoms, while VNS at high-strength/low-frequency stimulation 
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parameters is not [26]. Furthermore, a randomized, double-blind, multicenter VNS dosing study by 
Aaronson et al., compared the safety and effectiveness of different stimulation parameters, i.e. low, 
medium or high dose VNS. The results from the study showed that VNS induces significant, durable 
antidepressant effects, irrespective of the applied stimulation parameters. However, higher electrical 
dose parameters were shown to be associated with response durability [25]. Concerning the 
mechanism of action, functional brain imaging studies in humans have demonstrated 
that VNS causes immediate and longer-term changes in brain regions implicated in neuropsychiatric 
disorders. The regions affected by VNS include the thalamus, cerebellum, prefrontal cortex, limbic 
system, hypothalamus and medulla [27, 28, 31].  
Further unraveling the antidepressant mechanism of action of VNS may support the optimization of 
stimulation parameters and the identification of biomarkers to predict therapeutic response. The 
present review discusses the putative antidepressant mechanisms of VNS, in the context of two 
major hypotheses in MDD research: the monoaminergic and the neural plasticity hypothesis of MDD. 
 
VNS and the monoaminergic hypothesis of MDD 
The last 50 years of depression research have been dominated by the monoaminergic hypothesis. 
The main assumption in this hypothesis is that depression is caused by an impairment of central 
monoaminergic functioning. Monoamines are neurotransmitters containing one amino group that is 
connected to an aromatic ring by a two-carbon chain [32]. These neurotransmitters affect a wide 
range of normal brain functions related to mood control, such as sleep, motivation and hedonic state 
[33]. Decreased activity of the monoamines, due to decreased availability, impaired postsynaptic 
receptors and/or reduced sub-cellular messenger activity, is a pivotal pathogenic mechanism of 
depressive disorders and represents the main target for the development of antidepressant therapy 
[11, 33, 34]. Almost all currently available antidepressant drugs that reverse depressive symptoms 
are based on enhancing the monoaminergic neurotransmission, primarily the noradrenergic and/or 
serotonergic system. Most antidepressant agents increase the concentration of noradrenaline and/or 
serotonin in the synaptic cleft via 1) reuptake inhibition, 2) antagonism of inhibitory presynaptic 
autoreceptors or 3) inhibition of monoamine oxidases, which are the enzymes for monoamine 
degradation [33, 35]. Research on the antidepressant actions of drugs has mainly focused on the 
locus coeruleus (LC) and the dorsal raphe nucleus (DRN) due to their role in noradrenaline and 
serotonin release respectively. In the next paragraphs, we will describe how VNS can theoretically 
enhance the noradrenergic and serotonergic neurotransmission in the brain areas important in mood 
regulation such as the prefrontal cortex, the amygdala and the hippocampus. This will be based on 
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the neuroanatomical connections from the vagus nerve to the LC and the DRN and on evidence from 
experimental animal studies. 
The vagus nerve is best known for its efferent parasympathetic actions, such as autonomic control 
and regulation of the heart and the gastrointestinal system [36]. However, the nerve comprises 
approximately 80% afferent fibers, carrying information from the body to the brain (see figure 1, for 
a detailed review on the anatomy of the vagus nerve, see [37]). These fibers have their cell bodies in 
the nodose ganglion and predominantly project to the nucleus tractus solitarius, an important 
gateway nucleus for many primary afferents from cardiovascular, respiratory, gastrointestinal and 
other visceral sensory receptors [38]. In turn, the neurons of the nucleus tractus solitarius project to 
the LC through three disynaptic pathways: (i) GABAergic inhibitory neurons localized in the nucleus 
prepositus hypoglossi, acting primarily on the GABAA receptor subtypes in the LC neurons [39, 40], (ii)  
neurons localized in the nucleus paragigantocellularis containing excitatory amino acids [41, 42] and 
(iii) inhibitory GABAergic interneurons surrounding the LC [43]. 
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Figure 1: The afferent projections of the vagus nerve. Nodose ganglion: NG, nucleus tractus 
solitarius: NTS, locus coeruleus: LC, nucleus prepositus hypoglossi: PrH, nucleus paragigantocellularis: 
Pgi, dorsal raphe nucleus: DRN. 
 
The nucleus tractus solitarius afferents to the nucleus prepositus hypoglossi, the nucleus 
paragigantocellularis and the GABAergic interneurons are mainly glutamatergic [42, 44, 45]. Next to 
these disynaptic pathways, the nucleus tractus solitarius neurons also sends both excitatory and 
inhibitory monosynaptic projections to the LC [42, 45]. The latter pontine nuclues is the main source 
of noradrenaline in the central nervous system and provides widespread noradrenergic innervation 
of virtually the entire brain [37, 46]. These anatomical projections provide a pathway to the brain 
supporting the VNS-induced increases in the concentration of noradrenaline in structures important 
for mood regulation, including the amygdala, the prefrontal cortex and the hippocampus [47-51]. 
These structures are part of a corticolimbic circuit that is known to be disturbed in patients suffering 
from MDD [52]. Hassert and colleagues were the first to show an increase in noradrenaline 
concentration in the basolateral amygdala in rats (98% above baseline levels) [51]. In the study of 
Roosevelt et al., VNS significantly increased noradrenaline concentrations both in the cortex (39% 
above baseline levels) and the hippocampus (28% above baseline levels) [48]. Raedt et al., found 
even higher VNS-induced increases in hippocampal noradrenaline (69% above baseline levels) [47]. A 
similar increase in noradrenaline concentration was found by Follesa et al. in the medial prefrontal 
cortex (70% above baseline levels) [49]. Recently, Manta et al. have found a significant increase in 
noradrenaline in the prefrontal cortex (58% above baseline levels) and the hippocampus (14% above 
baseline levels) as well [50]. Moreover, Landau et al. recently demonstrated that VNS decreases α2-
adrenoceptor binding, further supporting the increased noradrenaline release in response to this 
treatment [53]. These neurochemical effects of VNS fit the results from electrophysiological studies 
in rats which have shown that VNS increases the firing rate of noradrenergic LC neurons [40, 54-56]. 
Furthermore, VNS significantly increases the percentage of LC neurons firing in bursts [40, 50, 54, 
55], a firing mode that leads to greater release of noradrenaline compared to single pulses [57]. 
Long-term stimulation of the vagus nerve was shown to increase both the number of spikes per burst 
and the burst length, contributing further to the increase in the mean firing rate of LC noradrenergic 
neurons [40, 54]. Manta et al. suggested that the effects of VNS on the LC are mediated through a 
greater facilitation of the excitatory pathways from the nucleus tractus solitarius to the LC compared 
to the inhibitory pathways [40]. In this hypothesis, it is assumed that VNS activates the nucleus 
tractus solitarius, which is indirectly supported by the recent finding that transcutaneous VNS 
increases the firing rate of the nucleus tractus solitarius neurons [58]. The decreased synaptic 
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efficacy observed in the nucleus tractus solitarius after vagotomy [59], provides further indirect 
evidence for this hypothesis. On the other hand, it has been shown that VNS at a frequency of 20 Hz 
evokes synaptic depression in the nucleus tractus solitarius neurons [60, 61], thereby suppressing the 
primarily inhibitory input from the nucleus prepositus hypoglossi and the GABAergic interneurons to 
the LC [43]. This results in a disinhibition of the LC neurons, leading to a subsequent increased firing 
rate and release of noradrenaline in the brain.  
Another important connection in the context of the monoaminergic hypothesis of MDD is the 
excitatory projection from the LC to the DRN [62], which is the major source of serotonin in the brain 
[63]. It has been shown that both exogenous noradrenergic agonists and endogenously released 
noradrenaline activate the excitatory α1-adrenoreceptors on the cell bodies of the serotonergic 
neurons in the DRN and consequently increase the firing rate of these neurons [40, 54, 64]. 
Furthermore, studies have found that administration of an α1-adrenoreceptor antagonist reduces the 
firing activity of serotonergic DRN neurons [40, 65, 66]. Consistent with this knowledge, it was shown 
that VNS also enhances the firing rate of the serotonergic neurons of the DRN, but only after 14 days 
of stimulation [40, 54]. Furthermore, a selective lesion of the noradrenergic LC neurons prevents the 
excitatory action of VNS on the serotonergic DRN neurons [40]. Based on these findings, Manta et al. 
suggested that the effect of VNS on the serotonergic neurons of the DRN is indirect and secondarily 
mediated through its robust effect on the noradrenergic neurons from the LC [40]. This hypothesis is 
further supported by the observation that VNS produces an acute activation of the LC neurons as 
revealed by an increase in c-fos, a nuclear protein which is expressed under conditions of high 
neuronal activity [67, 68], while only a delayed activation of the neurons in the DRN is shown by an 
increase in delta FosB after chronic treatment [67, 69]. The DRN in turn, also innervates the LC [62, 
70], creating the opportunity for cross-modulation between these two brainstem nuclei. 
To date, behavioral and mechanistic studies assessing the antidepressant actions of VNS with 
clinically relevant stimulation parameters in validated animal models for depression are scarce. In 
this regard, the forced swim test is one of the most commonly used experimental set-ups for 
assessing antidepressant-like behavior in rodents. The test involves the scoring of active mobile or 
passive immobile behavior when rodents are forced to swim in a cylinder from which they cannot 
escape. A reduction in passive behavior is reflective of an antidepressant-like effect of the therapy 
[71, 72]. Krahl et al. showed that short-term VNS (4 consecutive days, 30 minutes per day) produces 
an antidepressant-like effect in the forced swim test in rats with the same efficacy as 
electroconvulsive shock therapy and the tricyclic antidepressant desipramine [73]. Since the impact 
of VNS on the serotonergic neurons of the DRN is estimated to be minor after short-term stimulation 
[40, 54], this antidepressant-like effect was most likely mediated through increased noradrenergic 
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signaling of the LC neurons. This hypothesis was recently tested in our laboratory. Using a selective 
noradrenergic neurotoxin for the LC neurons, we confirmed the key role of the LC in the 
antidepressant-like mechanism of action of VNS [74].  
 
The question remains how VNS-induced noradrenaline and serotonin increases produce an 
antidepressant effect in subjects suffering from medically resistant depression, while drug-induced 
noradrenaline and serotonin increases remain without an effect in this patient population. Dorr et al. 
suggested that antidepressant agents and VNS enhance the noradrenergic and serotonergic 
neurotransmission in a different way [40]. Antidepressant drugs that increase the noradrenaline 
and/or serotonin concentrations, initially decrease the firing rate of the LC and/or the DRN neurons, 
due to binding of the neurotransmitters to the somatodendritic autoreceptors on these neurons [75]. 
Long-term treatment restores the firing activity back to baseline due to desensitization of these 
receptors while keeping high synaptic availability of noradrenaline and/or serotonin. Antidepressant 
treatments thus increase the efficacy of the noradrenergic and/or serotonergic neurotransmission 
via an increase in neurotransmitter release and altered sensitivity of inhibitory autoreceptors 
(reviewed in [76]). VNS on the other hand, enhances the noradrenergic and serotonergic 
neurotransmission by inducing an increase in the firing rate of both the LC and the DRN neurons 
above their baseline activity [40, 55]. Moreover, VNS represents the first antidepressant treatment 
able to induce increased firing activity of both serotonergic and noradrenergic neurons [54]. Dorr et 
al. have found that both the serotonergic 5-HT1A and the noradrenergic α1-somatodendritic 
autoreceptors are fully functional after long-term treatment with VNS [54]. The increase in firing rate 
is therefore not a result of a desensitization of the autoreceptors but rather of a distinct mechanism. 
A possibility considered by the authors is that VNS increases the release of noradrenaline and 
serotonin in the terminal regions such as the hippocampus and the medial prefrontal cortex, but not 
in the vicinity of the LC and the DRN [54]. Therefore, VNS probably exerts antidepressant activity 
through alternative mechanisms compared to conventional drugs. This may provide an explanation 
why VNS proves to be beneficial for patients with treatment resistant MDD [54].  
 
Although monoamines were convincingly shown to play a major role in the pathophysiology of MDD 
and its treatment, the monoamine hypothesis is incomplete and does not fully explain some 
important clinical observations. First, monoamine depletion in healthy individuals does not 
consistently produce depressive symptoms [77-79]. Secondly, antidepressant treatments produce a 
fast elevation of monoamine concentrations, while the antidepressant effects of these treatments 
are only established after chronic treatment in patients [80]. In this regard, growing body of evidence 
suggests that neuronal plasticity might be the missing link.  
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Vagus nerve stimulation and the neural plasticity hypothesis of MDD 
The neural plasticity hypothesis of depression postulates that reduced neural plasticity plays a major 
role in the pathophysiology of MDD, and that its restoration may represent a critical mechanism 
underlying antidepressant efficacy. The term "neural plasticity" encompasses an array of 
mechanisms, from the birth, survival, migration and integration of new neurons to neurite 
outgrowth, synaptogenesis and the modulation of mature synapses [81]. The rationale for this 
hypothesis originates from the observation that stress - which is the main cause of depression - can 
lead to significant atrophy, cell loss and changes in synaptic strength in limbic brain structures that 
are involved in mood regulation both in humans and in animals [82, 83]. In this regard, the 
subgranular layer of the hippocampal dentate gyrus, which is one of the only two regions where 
neurogenesis takes place in the adult brain, is of particular importance [84]. Neurogenesis is the 
process by which fully functional neurons are generated from neural stem and progenitor cells [85] 
(for a schematic overview see figure 2).  
 
Figure 2: Schematic overview of neural plasticity in the hippocampus. Subgranular zone: SGZ, granule 
cell layer: GCL, cornu ammonis layer 3: CA3, entorhinal cortex: EC, tropomyosin receptor kinase 
B:TrkB, mature granule cells are depicted in gray, proliferating granule cells are depicted in black. The 
boxes show the studies in which influences of VNS were shown. 
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This process takes place in the subgranular zone of the dentate gyrus, situated between the granule 
cell layer and the hilus. Neural progenitor cells proliferate and give rise to new cells that migrate into 
the granule cell layer and differentiate into mature granule cells. These new granule cells then 
integrate functionally into the existing granule cell layer by sending their axons to the pyramidal CA3 
neurons (mossy fiber pathway) and receiving input from the entorhinal cortex (perforant fiber 
pathway) [85]. It requires about seven weeks for newborn cells to become functionally 
indistinguishable from the older granule cell population [86, 87]. Several studies have reported 
hippocampal volume loss in patients suffering from MDD [88, 89]. Moreover, these hippocampal 
volume changes were shown to be correlated with the duration of the illness [88] and were reversed 
or prevented by chronic antidepressant treatment in MDD patients [90]. In animal models for 
depression, stress-induced suppression of hippocampal neurogenesis was shown to be normalized by 
chronic antidepressant treatment [83, 91-93]. These findings support the hypothesis that increased 
neurogenesis in the hippocampus may be a mechanism by which antidepressant treatments 
overcome the stress-induced atrophy and loss of hippocampal neurons. Increases in hippocampal 
neurogenesis can result from increased proliferation of neural stem/progenitors cells, from 
enhanced survival of newborn neural progenitors or neurons or from a combination of both [94, 95]. 
Morphological cellular changes such as up- or down regulation of synapse formation and spine 
density or extension and retraction of dendrites, further contribute to altered neural plasticity in the 
hippocampus [85]. Although this part of VNS research is still in its infancy, a growing body of 
evidence suggests that stimulation of the vagus nerve could produce its antidepressant effect 
through increasing neural plasticity by influencing these processes (table 1 gives an overview of the 
relevant studies). 
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 Table 1: Overview of the different stimulation paradigms used and the main results of studies on the 
effects of VNS on plasticity. Brain derived neurotrophic factor: BDNF, basic fibroblast growth factor: 
bFGF, cornu ammonis layer 3: CA3, Herz: Hz, milliampere: mA, tropomyosin receptor kinase B: TrkB. 
 
The effect of VNS on progenitor proliferation 
 
Revesz et al. have shown that short-term VNS in adult rats produces a significant 50% increase in 
hippocampal progenitor proliferation compared to SHAM stimulation. An inverted U-shaped dose-
dependent response to VNS was observed: moderate stimulation (0.75 mA) vs. high (1.5 mA) and low 
(0.5 mA) stimulation produced a significant and non-significant increase in progenitor proliferation 
compared to SHAM stimulation respectively [95]. Interestingly, this type of VNS dose dependency 
has previously been reported in experiments concerning learning and memory in rats [96-98] as well 
as in humans [99]. The authors suggest that the lower progenitor proliferation at the highest stimulus 
intensity (1.5 mA) results from a stress-induced decrease in hippocampal progenitor proliferation 
[95]. 
 
Biggio et al. found an increased progenitor proliferation using short-term (but not long-term) VNS 
with an output current of 1.5 mA [100]. The same study also assessed the effects of long-term VNS in 
the forced swim test and the elevated plus maze, to determine the behavioral correlates of despair 
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and anxiety respectively. However, the observed changes in the hippocampal neurons were not 
associated with evident behavioral alterations characteristic of an antidepressant or anxiolytic action 
[100]. In a recent study of Gebhardt et al., long-term VNS increased the number of newborn cells in 
the hippocampus of bulbectomized rats, which is a validated animal model for depression [101]. In 
this study, a restorative effect of VNS on the disturbed one-way active avoidance learning in the 
bulbectomized rats was found [101]. 
 
There are some contradictions among the results of the different studies which can most likely be 
attributed to methodological differences, such as the stimulation paradigm used and the definitions 
of ‘short-term’ and ‘long-term’ stimulation. Apart from the results found in the different studies 
discussed above, table 1 also gives an overview of the different stimulation paradigms used. 
 
The effect of VNS on cell survival and differentiation 
 
In the study of Revesz et al., VNS had no effects on cell survival, suggesting that the effects of VNS on 
hippocampal progenitors are merely proliferative in nature [95]. However, it was suggested by others 
that VNS promotes the survival of the newborn cells generated in the early phases of stimulation, 
rather than increasing cell proliferation indefinitely [100]. This suggestion is based on the observation 
that VNS robustly increases the expression of neurotrophic and growth factors such as brain derived 
neurotrophic factor (BDNF) and basic fibroblast growth factor (bFGF) [49, 100]. These factors are 
known to promote the differentiation and survival of neurons [102-105], thereby increasing 
neuroplasticity. It is well known that the levels of these factors are reduced in mood disorder [106-
108] and that antidepressants induce their upregulation [109-111]. Biggio et al. showed that long-
term VNS also induces long-lasting increases in the amount of BDNF immunoreactivity and the 
number of BDNF-positive cells both in the cell bodies and fibers of hippocampal neurons [100]. 
Likewise, Follesa et al. found that short-term VNS significantly increases the expression of BDNF and 
bFGF in the hippocampus and cerebral cortex [49]. An alternative way by which antidepressants 
enhance BDNF functioning is by increasing its signaling through phosphorylation and subsequent 
activation of its receptor, i.e. the tropomyosin receptor kinase B (TrkB) receptor [109, 112-114]. 
Moreover, Saarelainen et al. have found that signaling via the TrkB receptor is required for inducing a 
behavioral response typically induced by antidepressants [112, 114]. Furmaga et al. have shown that 
both long-term and short-term VNS in rats phosphorylate and thus activate the TrkB receptor [112].  
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The effect of VNS on cellular morphology 
 
A growing body of evidence suggests that mechanisms also other than cell proliferation, 
differentiation and survival may be responsible for structural remodeling of the hippocampal 
formation under circumstances of chronic stress or depression [115]. It has even been suggested that 
volumetric changes in the hippocampus of depressed subjects result from reduced dendritic 
complexity and not from the ablation of hippocampal neurogenesis [116]. At a cellular level, these 
changes can occur in the form of up- or down regulation of synapse formation and spine density or 
extension and retraction of dendrites [82, 117-119]. Interestingly, it was shown by Biggio et al. that 
both short-term and long-term VNS have an effect on the dendritic morphology of hippocampal 
neurons [100]. In particular, both types of VNS significantly increase the complexity of the 
hippocampal dendrites by increasing the number of intersections. Moreover, the length of the 
dendrites that project into the molecular layer of the hippocampus is significantly greater in rats 
subjected to long-term VNS than in those subjected to sham surgery [100].  
 
Although it is clear that VNS increases neuronal plasticity, it is problematic that only two animal 
studies have tried to correlate VNS-induced changes in neuroplasticity to antidepressant-like effects 
in behavioral testing paradigms. Only the study by Gebhardt et al. [101] found an association 
between the increased progenitor proliferation and the restorative effects on cognition. An 
association does not prove the causal relationship between the observed phenomena and therefore 
the results should be interpreted with caution. That is, the possibility exists that the neuroplastic 
effects of VNS are merely an epiphenomenon of other more important processes leading to 
sustained antidepressant effects. The dissociation between the presence of neuroplastic effects and 
the lack of behavioral effects in the study of Biggio et al. [100], supports this hypothesis. 
Alternatively, this dissociation could result from the fact that preclinical studies are of insufficient 
duration to investigate long-term effects of VNS. Clinical studies have demonstrated that VNS-
induced therapeutic effects are increasingly observed after several months of treatment [17]. A 
plausible hypothesis for this gradual increase in efficacy could be that it requires several weeks to 
months for newborn cells to become functionally indistinguishable from mature, fully functional 
hippocampal granule cells [86, 87] and subsequently to restore dysfunctional networks in depressed 
subjects. Current models of MDD hypothesize a dysregulation of several interconnected structures in 
the frontal and limbic circuitry. Key structures in this network do not only include the hippocampus, 
but also upstream structures such as the prefrontal cortex (medial, orbital and dorsolateral), 
amygdala, insular cortex, cingulate cortex, striatum, dorsal thalamus, and hypothalamus [120]. 
Functional imaging studies in depressed patients treated chronically with VNS, have demonstrated 
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that antidepressant response may be associated with gradual changes in the cerebral metabolic 
activity of these upstream structures [27, 31]. Therefore neuroplastic changes in the hippocampus 
may represent a first, early but indispensible step towards achieving therapeutic efficacy.  
Another shortcoming of the preclinical studies performed so far, is that none of them have 
investigated whether the newborn progenitor cells differentiate into mature neurons and integrate 
functionally into the hippocampal network. Therefore, future studies should determine the 
phenotype of the newborn cells using specific markers for mature neurons, such as NeuN (neuronal 
nuclei) or NSE (neuron specific enolase). Furthermore, connectivity studies should be performed to 
confirm the hypothesis that the newborn neurons restore the disturbed cortico-limbic networks in 
depressed subjects. 
 
The monoamine and the neural plasticity hypothesis of MDD meet again 
 
Albeit that the neural plasticity hypothesis of MDD has directed research away from the monoamines 
and towards the putative role of plasticity in the adult brain, both hypotheses might be more 
intertwined than it seems at first sight. The hippocampus is rich in noradrenergic and serotonergic 
innervation [121] and changes in these monoamine concentrations in the central nervous system 
have been shown to affect hippocampal plasticity. On the one hand, selective noradrenergic 
depletion decreases the number of proliferating progenitors in the dentate gyrus of the adult rat 
[122]. On the other hand, chronic monoaminergic antidepressant treatments, including serotonin 
and noradrenaline selective reuptake inhibitors and monoamine oxidase inhibitors increase neural 
plasticity in the rodent hippocampus [85]. Blockage of noradrenergic autoreceptors, which increases 
noradrenaline levels in the brain, also enhances the survival of progenitor cells in the hippocampus 
[123]. The neuroplastic effects of the monoamines could be mediated directly through binding to 
their receptors in the hippocampus, most likely to the β3-adrenergic [124] and 5-HT1A receptors [125, 
126] for noradrenaline and serotonin receptively. How the β3-adrenergic and 5-HT1A serotonergic 
receptor induce the proliferation of neural precursors is currently unknown. However, it is well-
known that these receptors are seven transmembrane proteins coupled to heterotrimeric G-proteins 
that can activate intracellular second messenger cascades. Given that binding of noradrenaline and 
serotonin to these receptors up-regulates the cAMP cascade [85] and that increases in the 
intracellular levels of cAMP regulate the proliferation of hippocampal precursors in vivo [127], it is 
possible that the receptor-driven activation of neural precursors may also utilize this cAMP-mediated 
signaling mechanism [124]. In addition, monoamines could also indirectly influence hippocampal 
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plasticity via the alteration of growth and neurotrophic factors. Duman et al. suggested that the 
effects of noradrenaline and serotonin on hippocampal plasticity are produced through the 
upregulation of BDNF gene expression of neurons containing noradrenergic and serotonergic 
receptors [85]. Furthermore, noradrenergic and serotonergic neurons also contain fibroblast growth 
factor-2 (FGF-2) [128], which is known to enhance adult hippocampal neurogenesis [129]. However, 
it has not yet been shown that FGF-2 is released from the noradrenergic or sertonergic neurons 
when the vagus nerve is stimulated. It is also worth mentioning that noradrenaline application in 
cultured hippocampal neurons is able to induce TrkB phosphorylation and downstream signaling via 
G-coupled receptor transactivation of TrkB [130], providing an additional link between the 
monoamine hypothesis and the neural plasticity hypothesis of depression. Altogether, these findings 
support the hypothesis that the observed increase in hippocampal plasticity after VNS could be 
mediated in part by changes in hippocampal noradrenergic and serotonergic activity. 
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Conclusion 
 
The present review provides an overview of the available preclinical VNS studies in view of two major 
hypotheses in depression research: the monoaminergic and the neural plasticity hypothesis of MDD. 
Consistent with the monoamine theory of depression, noradrenaline and serotonin were identified 
as key players in the antidepressant mechanism of action of VNS. VNS induces an acute elevation of 
the monoamine levels, while its antidepressant effect in patients is established typically after several 
weeks or months of treatment. In this regard, a growing body of evidence suggests that neuroplastic 
changes might be the missing link. In other words, we hypothesize that VNS exerts its antidepressant 
effects through a rapid increases in the concentration of the monoamines, which then enhance 
neuronal plasticity in the hippocampus. Newborn cells could then functionally integrate and restore 
the disturbed cortico-limbic networks in depressed patients. Furthermore, processes such as 
increased dendritic complexity and the formation of new synapses could further strengthen these 
networks. Indeed, current models of MDD hypothesize a dysregulation of several interconnected 
structures in the frontal an limbic circuitry, in which the hippocampus plays a major role. Other key 
structures in this network include the prefrontal cortex, amygdala, insular cortex, cingulate cortex, 
striatum, dorsal thalamus and hypothalamus. The fact that it requires several weeks to months for 
newborn cells to become functionally indistinguishable from mature, fully functional hippocampal 
granule cells [86, 87] and subsequently to restore the dysfunctional networks in depressed subjects, 
could provide an explanation for the therapeutic lag of VNS in the treatment of depression. 
Furthermore, other neuromodulatory changes requiring time to establish - including changes in 
receptor sensitivity within these networks - could be responsible for the therapeutic lag. Importantly, 
all evidence discussed in this review originates from preclinical animal studies. Future studies 
addressing the mechanism of action of VNS in humans will be required to confirm these hypotheses. 
 
Acknowledgements 
Annelies Grimonprez is supported by a PhD-grant from Ghent Institute for Neuroscience. Prof. Dr. 
Robrecht Raedt and Prof. Dr. Kristl Vonck are supported by a grant from the “Bijzonder 
Onderzoeksfond (BOF)” from Ghent University. Prof. Dr. Chris Baeken is supported by the Ghent 
University Multidisciplinary Research Partnership “The integrative neuroscience of behavioural 
control”. Prof. Dr. Paul Boon is supported by grants from FWO, grants from BOF and by the Clinical 
Epilepsy Grant from Ghent University Hospital.  
 103 
 
References 
[1] Murray CL, Lopez, AD. The Global Burden of Disease. Geneva, World Health Organisation. 2001. 
[2] Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, 
Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lepine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-
Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martinez-Alonso M, 
Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacin C, Romera B, Taub N, and Vollebergh WA. Prevalence of mental 
disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project . Acta 
Psychiatr Scand Suppl 2004: 21-7. 
[3] Kessler RC. Epidemiology of women and depression. J Affect Disord 2003; 74: 5-13. 
[4] Berlim MT and Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a 
review of current concepts and methods. Can J Psychiatry 2007; 52: 46-54. 
[5] Mendlewicz J. Towards achieving remission in the treatment of depression. Dialogues Clin Neurosci 2008; 10: 371-5. 
[6] Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002; 1: 477-82. 
[7] Harden CL. Depression and anxiety in epilepsy patients. Epilepsy Behav 2002; 3: 296. 
[8] Elger G, Hoppe C, Falkai P, Rush AJ, and Elger CE. Vagus nerve stimulation is associated with mood improvements in 
epilepsy patients. Epilepsy Res 2000; 42: 203-10. 
[9] Klinkenberg S, Majoie HJ, van der Heijden MM, Rijkers K, Leenen L, and Aldenkamp AP. Vagus nerve stimulation has a 
positive effect on mood in patients with refractory epilepsy. Clin Neurol Neurosurg 2012; 114: 336-40. 
[10] Grimonprez A, Raedt R, Dauwe I, Mollet L, Larsen LE, Meurs A, De Herdt V, Wadman W, Delbeke J, Vonck K, and Boon 
P. Vagus Nerve Stimulation has Antidepressant Effects in the Kainic Acid Model for Temporal Lobe Epilepsy. Brain Stimul 
2014. 
[11] Kanner AM and Balabanov A. Depression and epilepsy: how closely related are they? Neurology 2002; 58: S27-39. 
[12] Kanner AM. The complex epilepsy patient: intricacies of assessment and treatment. Epilepsia 2003; 44 Suppl 5: 3-8. 
[13] Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? 
Lancet Neurol 2012; 11: 1093-102. 
[14] Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, 
Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, and Cooke RG. Vagus nerve stimulation for treatment-
resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347-54. 
[15] Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, Nahas Z, Haines S, Simpson RK, Jr., and Goodman 
R. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000; 47: 276-86. 
[16] Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, Johnson CR, Seidman S, Giller C, Haines S, 
Simpson RK, Jr., and Goodman RR. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, 
and predictors of outcome. Neuropsychopharmacology 2001; 25: 713-28. 
[17] Nahas Z, Marangell LB, Husain MM, Rush AJ, Sackeim HA, Lisanby SH, Martinez JM, and George MS. Two-year outcome 
of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005; 66: 1097-104. 
[18] Schlaepfer TE, Frick C, Zobel A, Maier W, Heuser I, Bajbouj M, O'Keane V, Corcoran C, Adolfsson R, Trimble M, Rau H, 
Hoff HJ, Padberg F, Muller-Siecheneder F, Audenaert K, Van den Abbeele D, Stanga Z, and Hasdemir M. Vagus nerve 
stimulation for depression: efficacy and safety in a European study. Psychol Med 2008; 38: 651-61. 
[19] Bajbouj M, Merkl A, Schlaepfer TE, Frick C, Zobel A, Maier W, O'Keane V, Corcoran C, Adolfsson R, Trimble M, Rau H, 
Hoff HJ, Padberg F, Muller-Siecheneder F, Audenaert K, van den Abbeele D, Matthews K, Christmas D, Eljamel S, and Heuser 
I. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol 2010; 30: 273-
81. 
[20] Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, 
Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, and Barry JJ. Effects of 12 months of vagus nerve 
stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005; 58: 355-63. 
[21] George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, 
Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, and Goodnick P. A one-year comparison of vagus nerve stimulation 
with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005; 58: 364-73. 
[22] Marangell LB, Rush AJ, George MS, Sackeim HA, Johnson CR, Husain MM, Nahas Z, and Lisanby SH. Vagus nerve 
stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry 2002; 51: 280-7. 
[23] Cristancho P, Cristancho MA, Baltuch GH, Thase ME, and O'Reardon JP. Effectiveness and safety of vagus nerve 
stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year. J 
Clin Psychiatry 2011; 72: 1376-82. 
[24] Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, and Mischoulon D. Vagus nerve stimulation: 2-year outcomes 
for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry 2008; 64: 455-60. 
[25] Aaronson ST, Carpenter LL, Conway CR, Reimherr FW, Lisanby SH, Schwartz TL, Moreno FA, Dunner DL, Lesem MD, 
Thompson PM, Husain M, Vine CJ, Banov MD, Bernstein LP, Lehman RB, Brannon GE, Keepers GA, O'Reardon JP, Rudolph 
RL, and Bunker M. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-
resistant depression: acute and chronic effects. Brain Stimul 2013; 6: 631-40. 
[26] Muller HH, Kornhuber J, Maler JM, and Sperling W. The effects of stimulation parameters on clinical outcomes in 
patients with vagus nerve stimulation implants with major depression. J ECT 2013; 29: e40-2. 
 104 
 
[27] Conway CR, Chibnall JT, Gebara MA, Price JL, Snyder AZ, Mintun MA, Craig AD, Cornell ME, Perantie DC, Giuffra LA, 
Bucholz RD, and Sheline YI. Association of cerebral metabolic activity changes with vagus nerve stimulation antidepressant 
response in treatment-resistant depression. Brain Stimul 2013; 6: 788-97. 
[28] Conway CR, Sheline YI, Chibnall JT, Bucholz RD, Price JL, Gangwani S, and Mintun MA. Brain blood-flow change with 
acute vagus nerve stimulation in treatment-refractory major depressive disorder. Brain Stimul 2012; 5: 163-71. 
[29] Holtzheimer PE and Mayberg HS. Neuromodulation for treatment-resistant depression. F1000 Med Rep 2012; 4: 22. 
[30] Berry SM, Broglio K, Bunker M, Jayewardene A, Olin B, and Rush AJ. A patient-level meta-analysis of studies evaluating 
vagus nerve stimulation therapy for treatment-resistant depression. Med Devices (Auckl) 2013; 6: 17-35. 
[31] Kosel M, Brockmann H, Frick C, Zobel A, and Schlaepfer TE. Chronic vagus nerve stimulation for treatment-resistant 
depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex. Psychiatry Res 2011; 191: 153-9. 
[32] Maximino C and Herculano AM. A review of monoaminergic neuropsychopharmacology in zebrafish . Zebrafish 2010; 7: 
359-78. 
[33] Millan MJ. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review . 
Eur J Pharmacol 2004; 500: 371-84. 
[34] Gronli J, Murison R, Fiske E, Bjorvatn B, Sorensen E, Portas CM, and Ursin R. Effects of chronic mild stress on sexual 
behavior, locomotor activity and consumption of sucrose and saccharine solutions. Physiol Behav 2005; 84: 571-7. 
[35] Moret C and Briley M. The importance of norepinephrine in depression. Neuropsychiatr Dis Treat 2011; 7: 9-13. 
[36] Park MC, Goldman MA, Carpenter LL, Price LH, and Friehs GM. Vagus nerve stimulation for depression: rationale, 
anatomical and physiological basis of efficacy and future prospects. Acta Neurochir Suppl 2007; 97: 407-16. 
[37] Ruffoli R, Giorgi FS, Pizzanelli C, Murri L, Paparelli A, and Fornai F. The chemical neuroanatomy of vagus nerve 
stimulation. J Chem Neuroanat 2011; 42: 288-96. 
[38] Andresen MC and Kunze DL. Nucleus tractus solitarius--gateway to neural circulatory control. Annu Rev Physiol 1994; 
56: 93-116. 
[39] Ennis M and Aston-Jones G. GABA-mediated inhibition of locus coeruleus from the dorsomedial rostral medulla. J 
Neurosci 1989; 9: 2973-81. 
[40] Manta S, Dong J, Debonnel G, and Blier P. Enhancement of the function of rat serotonin and norepinephrine neurons 
by sustained vagus nerve stimulation. J Psychiatry Neurosci 2009; 34: 272-80. 
[41] Ennis M and Aston-Jones G. Activation of locus coeruleus from nucleus paragigantocellularis: a new excitatory amino 
acid pathway in brain. J Neurosci 1988; 8: 3644-57. 
[42] Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, Shiekhattar R, Akaoka H, Drolet G, 
Astier B, and et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 
1991; 88: 47-75. 
[43] Aston-Jones G, Zhu Y, and Card JP. Numerous GABAergic afferents to locus ceruleus in the pericerulear dendritic zone: 
possible interneuronal pool. J Neurosci 2004; 24: 2313-21. 
[44] Kihara M and Kubo T. Immunocytochemical localization of glutamate containing neurons in the ventrolateral medulla 
oblongata and the nucleus tractus solitarius of the rat. J Hirnforsch 1991; 32: 113-8. 
[45] Van Bockstaele EJ, Peoples J, and Telegan P. Efferent projections of the nucleus of the solitary tract to peri-locus 
coeruleus dendrites in rat brain: evidence for a monosynaptic pathway. J Comp Neurol 1999; 412: 410-28. 
[46] Krahl SE. Vagus nerve stimulation for epilepsy: A review of the peripheral mechanisms. Surg Neurol Int 2012; 3: S47-52. 
[47] Raedt R, Clinckers R, Mollet L, Vonck K, El Tahry R, Wyckhuys T, De Herdt V, Carrette E, Wadman W, Michotte Y, 
Smolders I, Boon P, and Meurs A. Increased hippocampal noradrenaline is a biomarker for efficacy of vagus nerve 
stimulation in a limbic seizure model. J Neurochem 2011; 117: 461-9. 
[48] Roosevelt RW, Smith DC, Clough RW, Jensen RA, and Browning RA. Increased extracellular concentrations of 
norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat. Brain Res 2006; 1119: 124-32. 
[49] Follesa P, Biggio F, Gorini G, Caria S, Talani G, Dazzi L, Puligheddu M, Marrosu F, and Biggio G. Vagus nerve stimulation 
increases norepinephrine concentration and the gene expression of BDNF and bFGF in the rat brain . Brain Res 2007; 1179: 
28-34. 
[50] Manta S, El Mansari M, Debonnel G, and Blier P. Electrophysiological and neurochemical effects of long-term vagus 
nerve stimulation on the rat monoaminergic systems. Int J Neuropsychopharmacol 2013; 16: 459-70. 
[51] Hassert DL, Miyashita T, and Williams CL. The effects of peripheral vagal nerve stimulation at a memory-modulating 
intensity on norepinephrine output in the basolateral amygdala. Behav Neurosci 2004; 118: 79-88. 
[52] Belzung C, Willner P, and Philippot P. Depression: from psychopathology to pathophysiology. Curr Opin Neurobiol 
2015; 30: 24-30. 
[53] Anne M. Landau SD, Steen Jakobsen, Aage KO. Alstrup, Albert Gjedde, and Doudet DJ. Acute vagal nerve stimulation 
lowers α2 adrenoceptor occupancy: Possible mechanism of therapeutic action. Brain Stimul 2015: in press. 
[54] Dorr AE and Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission . J 
Pharmacol Exp Ther 2006; 318: 890-8. 
[55] Manta S, El Mansari M, Debonnel G, and Blier P. Electrophysiological and neurochemical effects of long-term vagus 
nerve stimulation on the rat monoaminergic systems. Int J Neuropsychopharmacol 2012: 1-12. 
[56] Groves DA, Bowman EM, and Brown VJ. Recordings from the rat locus coeruleus during acute vagal nerve stimulation  
in the anaesthetised rat. Neurosci Lett 2005; 379: 174-9. 
[57] Florin-Lechner SM, Druhan JP, Aston-Jones G, and Valentino RJ. Enhanced norepinephrine release in prefrontal cortex 
with burst stimulation of the locus coeruleus. Brain Res 1996; 742: 89-97. 
 105 
 
[58] He W, Jing XH, Zhu B, Zhu XL, Li L, Bai WZ, and Ben H. The auriculo-vagal afferent pathway and its role in seizure 
suppression in rats. BMC Neurosci 2013; 14: 85. 
[59] Swartz JB and Weinreich D. Influence of vagotomy on monosynaptic transmission at second-order nucleus tractus 
solitarius synapses. J Neurophysiol 2009; 102: 2846-55. 
[60] Glaum SR and Miller RJ. Metabotropic glutamate receptors depress afferent excitatory transmission in the rat nucleus 
tractus solitarii. J Neurophysiol 1993; 70: 2669-72. 
[61] Liu Z, Chen CY, and Bonham AC. Metabotropic glutamate receptors depress vagal and aortic baroreceptor signal 
transmission in the NTS. Am J Physiol 1998; 275: H1682-94. 
[62] Cedarbaum JM and Aghajanian GK. Afferent projections to the rat locus coeruleus as determined by a retrograde 
tracing technique. J Comp Neurol 1978; 178: 1-16. 
[63] Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 2002; 59: S3-14. 
[64] Vandermaelen CP and Aghajanian GK. Electrophysiological and pharmacological characterization of serotonergic dorsal 
raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 1983; 289: 109-19. 
[65] Baraban JM and Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-
adrenoceptor antagonists. Neuropharmacology 1980; 19: 355-63. 
[66] Svensson TH, Bunney BS, and Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the 
alpha-adrenergic agonist clonidine. Brain Res 1975; 92: 291-306. 
[67] Naritoku DK, Terry WJ, and Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant 
stimulation of the vagus nerve. Epilepsy Res 1995; 22: 53-62. 
[68] Gieroba ZJ and Blessing WW. Fos-containing neurons in medulla and pons after unilateral stimulation of the afferent 
abdominal vagus in conscious rabbits. Neuroscience 1994; 59: 851-8. 
[69] Cunningham JT, Mifflin SW, Gould GG, and Frazer A. Induction of c-Fos and DeltaFosB immunoreactivity in rat brain by 
Vagal nerve stimulation. Neuropsychopharmacology 2008; 33: 1884-95. 
[70] Leger L and Descarries L. Serotonin nerve terminals in the locus coeruleus of adult rat: a radioautographic study. Brain 
Res 1978; 145: 1-13. 
[71] Slattery DA and Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc 
2012; 7: 1009-14. 
[72] Porsolt RD, Le Pichon M, and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments . Nature 
1977; 266: 730-2. 
[73] Krahl SE, Senanayake SS, Pekary AE, and Sattin A. Vagus nerve stimulation (VNS) is effective in a rat model of 
antidepressant action. J Psychiatr Res 2004; 38: 237-40. 
[74] Annelies Grimonprez RR, Jeanelle Portelli, Ine Dauwe, Lars Emil Larsen, Charlotte Bouckaert, Jean Delbeke, Evelien  
Carrette, Alfred Meurs, Veerle De Herdt, Paul Boon, Kristl Vonck. The antidepressant-like effect of vagus nerve stimulation 
is mediated through the locus coeruleus. Journal of Psychiatric research 2015; 68: 1-7. 
[75] Pineyro G and Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999; 
51: 533-91. 
[76] Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13: 57-
66. 
[77] Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, and Young SN. Mood-lowering effect of tryptophan depletion. 
Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994; 51: 687-97. 
[78] Carpenter LL, Anderson GM, Pelton GH, Gudin JA, Kirwin PD, Price LH, Heninger GR, and McDougle CJ. Tryptophan 
depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 1998; 19: 26-35. 
[79] Knott VJ, Howson AL, Perugini M, Ravindran AV, and Young SN. The effect of acute tryptophan depletion and 
fenfluramine on quantitative EEG and mood in healthy male subjects. Biol Psychiatry 1999; 46: 229-38. 
[80] Wong ML and Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001; 2: 343-51. 
[81] Wainwright SR and Galea LA. The neural plasticity theory of depression: assessing the roles of adult neurogenesis and 
PSA-NCAM within the hippocampus. Neural Plast 2013; 2013: 805497. 
[82] Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry 2004; 56: 140-5. 
[83] Fuchs E, Czeh B, and Flugge G. Examining novel concepts of the pathophysiology of depression in the chronic 
psychosocial stress paradigm in tree shrews. Behav Pharmacol 2004; 15: 315-25. 
[84] Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, and Gage FH. Neurogenesis in the 
adult human hippocampus. Nat Med 1998; 4: 1313-7. 
[85] Duman RS, Nakagawa S, and Malberg J. Regulation of adult neurogenesis by antidepressant treatment . 
Neuropsychopharmacology 2001; 25: 836-44. 
[86] Hanson ND, Owens MJ, and Nemeroff CB. Depression, antidepressants, and neurogenesis: a critical reappraisal. 
Neuropsychopharmacology 2011; 36: 2589-602. 
[87] Zhao C, Deng W, and Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132: 645-60. 
[88] Sheline YI, Wang PW, Gado MH, Csernansky JG, and Vannier MW. Hippocampal atrophy in recurrent major depression . 
Proc Natl Acad Sci U S A 1996; 93: 3908-13. 
[89] Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, and Charney DS. Hippocampal volume reduction in major 
depression. Am J Psychiatry 2000; 157: 115-8. 
 106 
 
[90] Vermetten E, Vythilingam M, Southwick SM, Charney DS, and Bremner JD. Long-term treatment with paroxetine 
increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003; 54: 
693-702. 
[91] Jayatissa MN, Bisgaard C, Tingstrom A, Papp M, and Wiborg O. Hippocampal cytogenesis correlates to escitalopram-
mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology 2006; 31: 2395-404. 
[92] Jayatissa MN, Bisgaard CF, West MJ, and Wiborg O. The number of granule cells in rat hippocampus is reduced after 
chronic mild stress and re-established after chronic escitalopram treatment. Neuropharmacology 2008; 54: 530-41. 
[93] van der Hart MG, Czeh B, de Biurrun G, Michaelis T, Watanabe T, Natt O, Frahm J, and Fuchs E. Substance P receptor 
antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus 
and hippocampal volume. Mol Psychiatry 2002; 7: 933-41. 
[94] Lehmann K, Butz M, and Teuchert-Noodt G. Offer and demand: proliferation and survival of neurons in the dentate 
gyrus. Eur J Neurosci 2005; 21: 3205-16. 
[95] Revesz D, Tjernstrom M, Ben-Menachem E, and Thorlin T. Effects of vagus nerve stimulation on rat hippocampal 
progenitor proliferation. Exp Neurol 2008; 214: 259-65. 
[96] Zuo Y, Smith DC, and Jensen RA. Vagus nerve stimulation potentiates hippocampal LTP in freely-moving rats. Physiol 
Behav 2007; 90: 583-9. 
[97] Clark KB, Krahl SE, Smith DC, and Jensen RA. Post-training unilateral vagal stimulation enhances retention performance 
in the rat. Neurobiol Learn Mem 1995; 63: 213-6. 
[98] Clark KB, Smith DC, Hassert DL, Browning RA, Naritoku DK, and Jensen RA. Posttraining electrical stimulation of vagal 
afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat. Neurobiol Learn 
Mem 1998; 70: 364-73. 
[99] Clark KB, Naritoku DK, Smith DC, Browning RA, and Jensen RA. Enhanced recognition memory following vagus nerve 
stimulation in human subjects. Nat Neurosci 1999; 2: 94-8. 
[100] Biggio F, Gorini G, Utzeri C, Olla P, Marrosu F, Mocchetti I, and Follesa P. Chronic vagus nerve stimulation induces 
neuronal plasticity in the rat hippocampus. Int J Neuropsychopharmacol 2009; 12: 1209-21. 
[101] Gebhardt N, Bar KJ, Boettger MK, Grecksch G, Keilhoff G, Reichart R, and Becker A. Vagus nerve stimulation 
ameliorated deficits in one-way active avoidance learning and stimulated hippocampal neurogenesis in bulbectomized rats. 
Brain Stimul 2013; 6: 78-83. 
[102] Ibanez CF. Neurotrophic factors: from structure-function studies to designing effective therapeutics. Trends 
Biotechnol 1995; 13: 217-27. 
[103] Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007; 12: 1079-88. 
[104] Malberg JE, Eisch AJ, Nestler EJ, and Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat 
hippocampus. J Neurosci 2000; 20: 9104-10. 
[105] Memberg SP and Hall AK. Proliferation, differentiation, and survival of rat sensory neuron precursors in vitro require 
specific trophic factors. Mol Cell Neurosci 1995; 6: 323-35. 
[106] Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, and Bertschy G. Low brain-derived neurotrophic factor 
(BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet 
reactivity. Biol Psychiatry 2005; 57: 1068-72. 
[107] Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, and Aubry JM. Decreased serum brain-derived neurotrophic 
factor levels in major depressed patients. Psychiatry Res 2002; 109: 143-8. 
[108] Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, 
and Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without 
antidepressants. Biol Psychiatry 2003; 54: 70-5. 
[109] Nibuya M, Morinobu S, and Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive 
seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-47. 
[110] Chen B, Dowlatshahi D, MacQueen GM, Wang JF, and Young LT. Increased hippocampal BDNF immunoreactivity in 
subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-5. 
[111] Mallei A, Shi B, and Mocchetti I. Antidepressant treatments induce the expression of basic fibroblast growth factor in 
cortical and hippocampal neurons. Mol Pharmacol 2002; 61: 1017-24. 
[112] Furmaga H, Carreno FR, and Frazer A. Vagal nerve stimulation rapidly activates brain-derived neurotrophic factor 
receptor TrkB in rat brain. PLoS One 2012; 7: e34844. 
[113] Rantamaki T, Hendolin P, Kankaanpaa A, Mijatovic J, Piepponen P, Domenici E, Chao MV, Mannisto PT, and Castren E. 
Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce 
phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 2007; 32: 2152-62. 
[114] Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasalo A, Nawa H, Aloyz R, 
Ernfors P, and Castren E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required 
for antidepressant-induced behavioral effects. J Neurosci 2003; 23: 349-57. 
[115] Jayatissa MN, Henningsen K, West MJ, and Wiborg O. Decreased cell proliferation in the dentate gyrus does not 
associate with development of anhedonic-like symptoms in rats. Brain Res 2009; 1290: 133-41. 
[116] Sahay A and Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007; 10: 1110-5. 
[117] Sousa N, Lukoyanov NV, Madeira MD, Almeida OF, and Paula-Barbosa MM. Erratum to "Reorganization of the 
morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement". 
Neuroscience 2000; 101: 483. 
 107 
 
[118] Vyas A, Mitra R, Shankaranarayana Rao BS, and Chattarji S. Chronic stress induces contrasting patterns of dendritic 
remodeling in hippocampal and amygdaloid neurons. J Neurosci 2002; 22: 6810-8. 
[119] McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci 1999; 22: 105-22. 
[120] Price JL and Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010; 35: 192-216. 
[121] Loy R, Koziell DA, Lindsey JD, and Moore RY. Noradrenergic innervation of the adult rat hippocampal formation. J 
Comp Neurol 1980; 189: 699-710. 
[122] Kulkarni VA, Jha S, and Vaidya VA. Depletion of norepinephrine decreases the proliferation, but does not influence the 
survival and differentiation, of granule cell progenitors in the adult rat hippocampus. Eur J Neurosci 2002; 16: 2008-12. 
[123] Rizk P, Salazar J, Raisman-Vozari R, Marien M, Ruberg M, Colpaert F, and Debeir T. The alpha2-adrenoceptor 
antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule 
cells. Neuropsychopharmacology 2006; 31: 1146-57. 
[124] Jhaveri DJ, Mackay EW, Hamlin AS, Marathe SV, Nandam LS, Vaidya VA, and Bartlett PF. Norepinephrine directly 
activates adult hippocampal precursors via beta3-adrenergic receptors. J Neurosci 2010; 30: 2795-806. 
[125] Brezun JM and Daszuta A. Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular 
zone of adult rats. Neuroscience 1999; 89: 999-1002. 
[126] Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, and 
Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9. 
[127] Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, Zhang YJ, Nestler EJ, and Duman RS. Regulation of 
neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci 2002; 22: 
3673-82. 
[128] Chadi G, Tinner B, Agnati LF, and Fuxe K. Basic fibroblast growth factor (bFGF, FGF-2) immunoreactivity exists in the 
noradrenaline, adrenaline and 5-HT nerve cells of the rat brain. Neurosci Lett 1993; 160: 171-6. 
[129] Palmer TD, Markakis EA, Willhoite AR, Safar F, and Gage FH. Fibroblast growth factor-2 activates a latent neurogenic 
program in neural stem cells from diverse regions of the adult CNS. J Neurosci 1999; 19: 8487-97. 
[130] Chen MJ, Nguyen TV, Pike CJ, and Russo-Neustadt AA. Norepinephrine induces BDNF and activates the PI-3K and 
MAPK cascades in embryonic hippocampal neurons. Cell Signal 2007; 19: 114-28. 
 
 
 
 
 
 
 108 
 
  
 109 
 
 
 
 
 
 
 
Chapter 4 
Optimization of the stimulation parameters 
 110 
 
  
 111 
 
 
 
 
 
 
 
 
Chapter 4 - study 4 
Intensity-dependent modulatory effects of vagus nerve stimulation 
on cortical excitability 
 
 
 112 
 
Study 4: Optimization of the stimulation parameters 
 
The optimal stimulation parameters for effective VNS are still unknown. However, optimizing the 
stimulation paradigm is an indispensable step towards the achievement of a better clinical outcome. 
The stimulation parameters used currently in experimental studies and in clinical practice are based 
on what is known to be safe and tolerable and are therefore not evidence based but rather 
empirically determined. As the efficacy of VNS is dependent on the adequate activation of the vagal 
A- and B-fibers, the stimulation parameters should be optimized to activate these fibers. The 
activation threshold of the A- and B-fibers is lower than the output currents used in experimental 
settings and in clinical practice and therefore we hypothesize that VNS output currents lower than 
those used today, are sufficient and at least equally effective in reducing cortical excitability as VNS 
at higher output currents. This hypothesis was tested in the motor cortex stimulation rat model.  
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Abstract 
Objectives: Vagus nerve stimulation (VNS) is an effective treatment for refractory epilepsy. It remains 
unknown whether VNS efficacy is dependent on output current intensity. The present study 
investigated the effect of various VNS output current intensities on cortical excitability in the motor 
cortex stimulation rat model. The hypothesis was that output current intensities in the lower range 
are sufficient to significantly affect cortical excitability. 
Material and methods: VNS at 4 output current intensities (0.00 mA, 0.25 mA, 0.50 mA and 1.00 mA) 
was randomly administered in rats (n = 15) on 4 consecutive days. Per output current intensity, the 
animals underwent 5 one-hour periods: (1) baseline, (2) VNS1, (3) wash-out1, (4) VNS2 and (5) wash-
out2. After each one-hour period, the motor seizure threshold (MST) was measured and compared 
to baseline (i.e. ∆MSTbaseline, ∆MSTVNS1, ∆MSTwash-out1, ∆MSTVNS2 and ∆MSTwash-out2). Finally, the mean 
∆MSTbaseline, mean ∆MSTwash-out1, mean ∆MSTwash-out2 and mean ∆MSTVNS per VNS output current 
intensity were calculated.  
Results: No differences were found between the mean ∆MSTbaseline, mean ∆MSTwash-out1 and mean 
∆MSTwash-out2 within each VNS output current intensity. The mean ∆MSTVNS at 0.00 mA, 0.25 mA, 0.50 
mA and 1.00 mA was 15.3 ± 14.6 µA, 101.8 ± 23.5 µA, 108.1 ± 24.4 µA and 85.7 ± 18.1 µA 
respectively. The mean ∆MSTVNS at 0.25 mA, 0.50 mA and 1.00 mA were significantly larger compared 
to the mean ∆MSTVNS at 0.00 mA (p=0.002 for 0.25 mA; p=0.001 for 0.50 mA; p=0.011 for 1.00 mA). 
Conclusions: This study confirms efficacy of VNS in the motor cortex stimulation rat model and 
indicates that, of the output current intensities tested, 0.25 mA is sufficient to decrease cortical 
excitability and higher output current intensities may not be required.  
 115 
 
Introduction 
Vagus nerve stimulation (VNS) is an efficacious and widely applied neurostimulation modality for 
patients with medically or surgically refractory epilepsy [1, 2]. The left vagus nerve is stimulated in 
the neck area by means of a helical stimulation electrode connected to a subclavicular implanted 
pulse generator. The clinically available stimulation parameters include output current intensity 
(range: 0.25 - 3.50 mA), frequency (range: 20 - 30 Hz), pulse width (range: 250 - 500 µsec) and duty 
cycle (range ON time (sec) / OFF time (min): 30/5, 30/3, 30/1.8, 30/1.1, 21/0.8, 14/0.5) which can all 
be modified in order to reach maximum therapeutic efficacy [3]. It has been demonstrated that VNS 
has both an acute effect on seizures, i.e. it is able to interrupt ongoing seizure activity, as well as 
having a more chronic seizure preventative effect following long-term treatment [2, 4, 5].  
The antiepileptic mechanism of VNS remains incompletely understood. Previous experimental 
research showed that VNS exerts its antiepileptic effect by stimulating the afferent fibers of the 
vagus nerve [6-8]. The afferent fibers originate from the nodose and jugular ganglion and primarily 
project to the nucleus of the solitary tract (NTS). The NTS in turn has widespread projections to 
numerous areas in the brain including the locus coeruleus (LC), which is the major brain source of 
noradrenaline, and important areas for epileptogenesis such as the amygdala and the thalamus. 
Furthermore the NTS, LC and thalamus have many diffuse cortical connections. Different 
neurochemical and neuromodulatory changes affecting cortical excitability seem to play a role in the 
mode of action of the acute and chronic effects of VNS [9-12]. 
One clinical drawback of current VNS therapy is the variable therapeutic outcome [13-15]. Currently, 
VNS is successful in about half of treated patients [16]. It is routine clinical practice to uptitrate 
output current intensity in order to reach seizure control over several weeks/months. So far, analysis 
of large patient series have not demonstrated a correlation between output current intensities and 
seizure control. Several experimental studies in animals and humans using functional imaging and c-
fos however, do suggest that lower output current intensities are sufficient to induce significant 
intracerebral effects [17-19]. 
A study by De Herdt et al. showed efficacy of acute VNS in the motor cortex stimulation rat model 
using an output current intensity of 0.75 mA [11]. In this rat model, the threshold for evoking focal, 
motor seizures is determined by electrical stimulation of the motor cortex in unanaesthetized rats 
[20, 21]. VNS significantly increased the threshold for evoking focal, motor seizures.  
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The present study investigated the effect of various VNS output current intensities on cortical 
excitability in the motor cortex stimulation rat model. The hypothesis was that output current 
intensities in the lower range are sufficient to significantly affect cortical excitability. 
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Material and methods 
 
Animals 
Fifteen male Wistar rats (Harlan, The Netherlands) weighing 250 - 275 g were used. Animals were 
treated according to the guidelines approved by the European Ethics Committee (decree 
86/609/EEC). The study protocol was approved by the Animal Experimental Ethical Committee of 
Ghent University Hospital (ECP 08/47). All animals were kept under environmentally controlled 
conditions (12h light/dark cycles, 20-23°C and 50% relative humidity) with food and water intake ad 
libitum. 
Surgery 
Rats were anesthetized with Isoflurane (induction: 5%; maintenance: 1 - 2%). An incision was made 
over the left anterior cervical region. The left cervical vagus nerve was carefully dissected from the 
aortic sheet and a custom-made silicone spiral cuff electrode with two platinum contacts (3 mm² 
area each, with 1 mm space between them) was implanted around the vagus nerve with the anode 
placed caudally and the cathode placed rostrally. The cuff electrode leads were tunneled under the 
skin over the back of the neck towards an incision made over the skull. Animals were then placed in a 
stereotactic frame (Bilaney Consultants, Düsseldorf, Germany), the skull was exposed and eight holes 
were drilled to insert electrodes and anchor screws. For stimulation of the motor cortex, two 
epidural stainless steel screw electrodes were stereotactically positioned over the motor area of the 
left and right frontal cortex (coordinates relative to bregma: dorsoventral -1.0 mm; mediolateral ± 
3.0 mm). Four epidural stainless steel screw electrodes were implanted bilaterally on the parietal 
cortex; three of them were used for electroencephalogram (EEG) recording, the fourth was used as a 
reference/ground electrode. Two anchor screws were implanted bilaterally on the parietal cortex. 
The leads of the epidural electrodes and the leads of the cuff electrode were assembled in a head 
cap on the skull of the rat using acrylic cement. To minimize post-operative pain, Buprenorphine 
(Temgesic®, 0.03 mg/kg) was subcutaneously administered and a 2% Xylocaine gel was applied to the 
incision wounds. Animals were allowed to recover from surgery under an infrared lamp. Correct 
positioning of the cuff electrode around the left vagus nerve was verified post-mortem.  
EEG monitoring, cortical stimulation and VNS 
One week after surgery, rats were placed in neuromonitoring cages. Rats were connected via an 
electrical swivel (Plastics One, Roanoke, USA) to (i) a custom-made digital EEG monitoring system for 
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EEG recording, which was used to confirm the focal character of the induced seizures and (ii) two 
external constant-current stimulators (DS4, Digitimer Ltd., Hertfordshire, England) for cortical 
stimulation and for delivering VNS. Rats were allowed to move freely in their cages. 
Cortical stimulation 
Cortical stimulation was performed using a ramp-shaped pulse train with biphasic, rectangular pulses 
(1000 µs, 50 Hz) with increasing amplitude (0 - 10 mA). The maximum duration of the cortical 
stimulation train was 150 s (i.e. 1.3 µA increments every pulse). The cortical stimulation train was 
interrupted when the first symptoms of a focal seizure were detected on visual inspection. The 
clinical expression of a focal seizure was typically a forelimb clonus. The motor seizure threshold 
(MST) was then defined as the current intensity corresponding to the first clinical symptoms of a 
focal seizure.  
VNS 
The effect of one hour of VNS (30 Hz, 250 µsec, 30 sec ON / 1.8 min OFF) at 4 different output 
current intensities (0.00 mA, 0.25 mA, 0.50 mA and 1.00 mA) on the MST was evaluated. These VNS 
parameters are typically used in clinical practice. 
Experimental design 
The experimental design is represented in figure 1 and detailed below. VNS was administered in each 
rat on 4 consecutive days. On each day, VNS was given at one of the 4 output current intensities (see 
higher) in a random order. Per VNS output current intensity, the animals underwent 5 one-hour 
periods: (1) baseline, (2) VNS 1, (3) wash-out 1, (4) VNS 2 and (5) wash-out 2 (on any given day, VNS1 
and VNS2 represent the same VNS intensity). Immediately after each one-hour period ended, the 
MST was measured (i.e MSTbaseline, MSTVNS1, MSTwash-out1, MSTVNS2 and MSTwash-out2). Prior to baseline, 
the impedance between the two vagus nerve electrode contacts was measured. 
Part 1: Outlasting effect of VNS 
Per rat and per VNS output current intensity, the ∆MSTbaseline (i.e. MSTbaseline minus MSTbaseline), 
∆MSTwash-out1 (i.e. MSTwash-out1 minus MSTbaseline) and ∆MSTwash-out2 (i.e. MSTwash-out2 minus MSTbaseline) 
were calculated. Finally, the mean ∆MSTbaseline, mean ∆MSTwash-out1 and mean ∆MSTwash-out2 per VNS 
output current intensity were calculated. 
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Part 2: Effect of various VNS output current intensities on the MST 
Per rat and per VNS output current intensity, the ∆MSTVNS1 (i.e. MSTVNS1 minus MSTbaseline) and 
∆MSTVNS2 (i.e. MSTVNS2 minus MSTbaseline) were calculated. Finally, the mean ∆MSTVNS per VNS output 
current intensity was calculated as the mean of all ∆MSTVNS1 and ∆MSTVNS2 values. 
 
Figure 1. Schematic representation of the experimental design. Vagus nerve stimulation (VNS) at four 
output current intensities was administered randomly in each rat on four consecutive days. Per 
output current intensity, ﬁve-one-hour periods were conducted and the motor seizure threshold 
(MST) was determined after each period. ΔMST values were obtained by comparing the MST values 
with the baseline MST value. 
 
Statistical analysis 
A generalized linear mixed model and post-hoc Bonferroni for multiple comparisons was used to 1) 
compare the mean ∆MSTwash-out1 and the mean ∆MSTwash-out2 with the mean ∆MSTbaseline within each 
VNS output current intensity and 2) to compare the mean ∆MSTVNS at 0.25 mA, 0.50 mA and 1.00 mA 
with the mean ∆MSTVNS at 0.00 mA. Statistical analyses were performed using SPSS 20 for Windows. 
Data are expressed as mean ± standard error of the mean. The significance level for demonstrating 
differences was set at α = 0.05.  
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Results 
The impedance between the vagus nerve electrode contacts showed normal values in all rats during 
all experiments (1 - 4 kOhm). Within each VNS output current intensity, no differences were found 
between the mean ∆MSTbaseline, the mean ∆MSTwash-out1 and the mean ∆MSTwash-out2, showing that VNS-
induced changes in MST were transient and returned to baseline in the inter-stimulus periods. 
The mean ∆MSTVNS as a function of VNS output current intensity is plotted in figure 2. The mean 
∆MSTVNS at 0.00 mA, 0.25 mA, 0.50 mA and 1.00 mA was 15.3 ± 14.6 µA, 101.8 ± 23.5 µA, 108.1 ± 
24.4 µA and 85.7 ± 18.1 µA respectively. The mean ∆MSTVNS at 0.25 mA, 0.50 mA and 1.00 mA were 
significantly larger compared to the mean ∆MSTVNS at 0.00 mA (p = 0.002 for 0.25 mA; p = 0.001 for 
0.50 mA and p = 0.011 for 1.00 mA). 
 
Figure 2. Effect of 
various vagus nerve 
stimulation (VNS) 
output current 
intensities on the 
motor seizure 
threshold (MST). The 
mean ΔMSTVNS (SEM) 
is plotted as a 
function of the VNS 
output current 
intensity. 
 
 
No electro-encephalographic, epileptiform discharges were observed in the parietal cortical areas 
during any epileptic seizure, indicating that the elicited epileptiform activity was restricted to the 
motor cortex. Furthermore, no afterdischarges were observed on the EEG after cessation of cortical 
stimulation. 
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Discussion 
The main findings of our study in the motor cortex stimulation rat model are that (i) VNS at 0.25 mA, 
0.50 mA and 1.00 mA significantly increases the threshold for evoking focal, motor seizures 
compared to stimulation at 0.00 mA and (ii) effects of one hour VNS are no longer present one hour 
later.  
A previous study by our group showed that acute VNS at 0.75 mA in the motor cortex stimulation rat 
model is effective in decreasing cortical excitability [11]. The findings of De Herdt et al. and our 
findings are in agreement with the reported direct and indirect acute effects of VNS on cortical 
excitability in preclinical and clinical experiments [7, 9, 22].  
In our study, significant effects of acute VNS on cortical excitability in rats were already observed at 
0.25 mA. Also in other types of preclinical and clinical research, significant effects of low-intensity, 
acute VNS were found. Acute VNS at 0.25 mA in conscious rats increased staining for c-fos, an 
indirect marker of neuronal activity, in the NTS and many regions that receive its projections [19]. In 
a functional neuroimaging study by our group, acute VNS, using an output current intensity of 0.25 
mA, induced significant cerebral blood flow changes in the human brain, particularly in the thalamus 
and the limbic system [17]. These findings were confirmed in a human imaging study by Vonck et al. 
[18]. 
Our observation, together with the observation of De Herdt et al. [11], that VNS at 0.25 mA, 0.50 mA, 
0.75 mA and 1.00 mA in rats significantly increased the MST supports the theory that vagal afferent 
fibers with low-to-moderate activation thresholds (i.e. A- and B-fibers) may be responsible for the 
antiepileptic effect of VNS. The vagus nerve contains three types of fibers (A-, B- and C-fibers), 
distinguished by their diameter and conduction velocity. In rats, recruited at the lowest threshold 
(0.02-0.20 mA) are the large, myelinated A-fibers. At thresholds of 0.04-0.60 mA, smaller, myelinated 
B-fibers are recruited. C-fibers are small, unmyelinated fibers with the highest stimulation threshold 
of above 2.00 mA [23, 24]. Initially, it was thought that the antiepileptic effect of VNS was directly 
related to the extent of C-fiber activation [6]. This theory was discarded after Krahl et al. 
demonstrated seizure suppression in rats even following selective destruction of C-fibers using 
capsaicin [8]. Furthermore, the group of Bunch concluded that therapeutically effective stimulation 
levels are below the threshold for C-fiber activation [24]. In an electrophysiological study by Evans et 
al., a C-fiber response was identified in 4 out of 8 patients using therapeutic VNS parameters [25]. 
However, because the C-fiber response (i) was apparent in 2 of the 4 patients only with 2.00 or 3.00 
mA stimulation (which is at the upper limit of intensities used clinically) and (ii) was not measured 
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consistently, the authors concluded that C-fiber activation is probably not necessary for the 
antiepileptic effect of VNS.  
Additional support that low-to-moderate output current intensities are sufficient to reduce seizure 
activity comes from a study of Woodbury and Woodbury, in which VNS at 0.20-0.50 mA already 
reduced chemically-induced seizures in rats [6]. In vivo intracellular recordings in the temporal 
association cortex in rats showed that stimulus intensities that predominantly activate myelinated 
vagal fibers (≤ 0.20 mA) were already effective in reducing the excitability of pyramidal neurons [26]. 
Our low effective current values are even more impressive considering that the authors above used a 
500 µsec pulse width, which, according to the classical strength-duration relationship and according 
to Takaya et al. [27], is expected to require about half the current to yield the same effect as a 250 µs 
pulse. Lower output current intensities also seemed to be effective in the antidepressant activity of 
VNS in rats [28], in the effect of VNS on recognition memory in rats and humans [29, 30] and in the 
effect of VNS on human tolerance for pain [31].  
A modeling study on the neurophysiology of the human vagus nerve suggested an output current 
level between 0.75 and 1.75 mA to reach optimal seizure control [32]. A direct comparison with the 
results of our study is not possible due to a large number of factors including: 1) experimental rats 
versus humans; 2) much smaller diameter of rat vagus nerve; 3) different electrodes (cuff versus 
helicoidal); 4) the model does not take surgical neurotrauma into account; 5) structural irregularities 
such as the presence of different nerve vessels modify thresholds but are not modeled; 6) tissue 
conductivities and geometry have a significant influence but are only rough approximations in a 
model. Both the study of Helmers et al. and our study however give insight in appropriate ways to 
optimize the therapeutic output current intensity and save battery-life. Our study in particular 
suggests that output current intensity quickly reaches a saturation level in therapeutic effectiveness 
and that higher output current intensities are not required to reach significant effects on cortical 
excitability. This idea may be extrapolated to human clinical practice in future clinical trial design. 
Due to the lack of prospective clinical trials comparing the effects of lower and higher output current 
intensities on seizure control, it is, even with the knowledge of our study, too early to defend 
convincingly the benefit of lower stimulation currents, although it would save battery life and 
decrease adverse events. However, it is worthwhile to extrapolate the implications of our findings to 
human VNS therapy. Combination of VNS and recording of vagal nerve compound action potentials 
could help to decide at what level this change in strategy should be applied in individual patients 
[33].  
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Taken together, this study confirms efficacy of VNS in the motor cortex stimulation rat model, and 
indicates that, of the VNS output current intensities tested, 0.25 mA is sufficient to decrease cortical 
excitability and higher output current intensities may not be required. Further research is needed to 
determine if even lower output current intensities are sufficient. Preliminary results in our rats, using 
vagal compound action potential recordings with single VNS pulses and a short pulse width, indicate 
that fiber recruitment may reach a saturation level at output current intensities lower than 0.25 mA. 
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Chapter 4 – Study 5  
Laryngeal motor-evoked potentials mark vagus nerve activation: a 
preclinical study 
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Study 5: Optimization of the stimulation parameters 
Two major problems in VNS therapy are that (1) optimal stimulation parameters are unknown and 
(2) about one third of patients do not benefit from the treatment (non-responders). It is possible that 
the vagus nerve of some non-responders is not adequately activated, for multiple reasons such as 
lead failure, poor electrode contact or nerve damage. To date, there is no tool to test this hypothesis 
in an experimental setting nor in clinical practice. Previous studies from our lab have shown that the 
activation of the Aα-motor fibers of the recurrent laryngeal nerve, as measured by laryngeal motor-
evoked potentials or LMEPs, is reflective of the activation of the vagus nerve. Therefore, LMEPs could 
provide us with valuable information to deduct optimal stimulation parameters and to identify 
ineffective stimulation of the vagus nerve leading to non-response. The techniques used in previous 
studies required invasive surgery or the use of special VNS electrodes for simultaneous stimulation 
and recording. The aim of the following study was to investigate the feasibility and reliability of LMEP 
recordings using a minimally invasive, easy-to-use tool in a chronic experimental setting. 
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Abstract  
Vagus nerve stimulation (VNS) is a treatment for refractory epilepsy and depression. Previous studies 
using invasive recording electrodes showed that VNS induces laryngeal motor-evoked potentials 
(LMEPs) through the co-activation of the recurrent laryngeal nerve and subsequent contractions of 
the laryngeal muscles. The present study investigates the feasibility of recording LMEPs in chronically 
VNS-implanted rats, using a minimally-invasive technique, to assess effective current delivery to the 
nerve and to determine optimal VNS output currents for vagal fiber activation.  
Three weeks after VNS electrode implantation, signals were recorded using an electromyography 
electrode in the proximity of the laryngeal muscles and a reference electrode on the skull. The VNS 
output current was gradually ramped up from 0.10 mA to 1.00 mA in 0.10 mA steps.  
In 13/27 rats, typical LMEPs were recorded at low VNS output currents (median 0.30 mA, IQR 0.20 - 
0.30 mA). In 11/27 rats, significantly higher output currents were required to evoke 
electrophysiological responses (median 0.70 mA, IQR 0.50 - 0.70 mA, p<0.001). The latencies of these 
responses deviated significantly from LMEPs (p<0.05). In 3/27 rats, no electrophysiological responses 
to simulation were recorded. 
Minimally-invasive LMEP recordings are feasible to assess effective current delivery to the vagus 
nerve. Furthermore, our results suggest that low output currents are sufficient to activate vagal 
fibers. 
 
Keywords 
Vagus nerve stimulation, stimulation parameters, responders, electromyography, laryngeal motor-
evoked potentials 
 
 
 
 
 
 
 131 
 
Introduction  
Vagus nerve stimulation (VNS) consists of the electrical stimulation of the left vagus nerve at the 
cervical level by means of an implantable electrode and a programmable pulse generator. This 
neuromodulation technique has been used since 1988 as an add-on therapy for the treatment of 
refractory epilepsy [1, 2]. Despite the abundant experience with VNS, one third of patients do not 
benefit from the treatment and optimal stimulation parameters remain elusive [2, 3]. More recently, 
VNS has also been approved for refractory depression[4-13] and is currently under investigation for 
the treatment of several other conditions including chronic heart failure, Alzheimer’s disease, pain, 
tinnitus, obesity and anxiety disorders [14-16]. Considering the chronic nature of these diseases and 
the fact that the use of VNS for these indications is still in the experimental phase, long-term 
preclinical VNS studies are required. Effective delivery of electrical current to the vagus nerve is a 
prerequisite to obtain reliable experimental results. To date, there is no technique available in a 
chronic experimental setting to assess whether the electrical current is effectively delivered to the 
nerve and the vagal fibers are subsequently effectively activated.  
The recurrent laryngeal nerve branches off from the vagus nerve at the level of the aortic arch, 
ascends next to the trachea and carries low threshold vagal Aα-motor fibers to the larynx, the 
pharynx and the vocal cords. Effective delivery of current to the vagus nerve at the cervical level, co-
activates the recurrent laryngeal nerve and induces contractions of the laryngeal muscles and the 
vocal cords. In this context, we have previously recorded VNS-induced far field laryngeal motor-
evoked potentials or LMEPs in an acute intra-operative setting using invasive electrodes [17]. Nerve 
lesions and neuromuscular blocking agents confirmed that these electrophysiological responses were 
LMEPs, induced by the co-activation of the Aα-motor fibers of the recurrent laryngeal nerve. These 
LMEPs were characterized by an initial negative peak wave with a latency of 2.88 ± 0.27 ms after the 
stimulation pulse. Based on these results, a 95% confidence interval for LMEP latencies can be 
calculated (2.34 ms - 3.42 ms), which can be used to differentiate between LMEPs and muscle-
evoked potentials or MEPs resulting from other sources such as direct muscle activation due to 
current spill-over. This study, aiming at a future chronic and clinical applicability has minimized 
invasiveness and exploits ‘clinical VNS’ stimulation parameters at the cost of stronger artifacts and 
limited verifications. Our LMEP source identification is based on replication and congruency of 
previously obtained results from our lab, where experiments were conducted to clearly identify the 
recorded potential sources [17]. 
To allow for chronic VNS studies, a less invasive, reliable technique for LMEP recordings is required to 
exclude rats where electrical current delivery to the vagus nerve is doubtful, to identify the optimal 
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moment for initiation of the experiment and to determine the optimal stimulation output current to 
activate the relevant fibers without inducing stimulation-related side effects. The aim of this study 
was therefore to investigate the feasibility and reliability of LMEP recordings by acute testing after 
recovery from VNS electrode implantation, using a minimally invasive commonly available 
electromyography (EMG) technique. 
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Methods 
Animals 
Male Wistar rats (n=27, Harlan, The Netherlands) weighing 200 – 250 g were used. Animals were 
treated according to the guidelines approved by the European Ethics Committee (decree 
86/609/EEC). The study protocol was approved by the Animal Experimental Ethical Committee of 
Ghent University medical department. All animals were kept under environmentally controlled 
conditions: 12 hour light/dark cycles, temperature and relative humidity were kept at 20 - 23°C and 
50% respectively. Food and water were provided ad libitum. 
 
Surgery 
The animals were anesthetized with a mixture of Isoflurane (5% for induction, 2% for maintenance) 
and medical O2. A lack of hind leg withdrawal upon toe-pinching was used a criterion to ensure that 
the animal was fully anesthetized. Body temperature was maintained using a heating pad. A dose of 
Buprenorphine (0.025 mg/kg, subcutaneously) was administered preoperatively. For the VNS 
electrode placement, the skin of the ventral cervical region was shaved and disinfected. An incision 
was made over the anterior cervical region. The skin and muscles were retracted and the left vagus 
nerve was carefully dissected from the aortic sheet. Subsequently, a custom-made bipolar silicone 
cuff electrode was wrapped around the nerve. The leads of the electrode were tunneled 
subcutaneously to an incision in the scalp and were fixed to the skull using anchor screws and acrylic 
cement. Xylocaine gel and Neobacitracine gel were applied to the incision wounds to minimize pain 
and to reduce the risk for postoperative infections respectively. Metacam (1 mg/kg, subcutaneously) 
was given to the animals postoperatively and every 24 hours after surgery for 2 days. Animals were 
allowed to recover from surgery for 2 - 3 weeks. 
 
Recording and stimulation 
The animals were anesthetized with a mixture of Isoflurane (5% for induction, 2% for maintenance) 
and medical O2. A lack of hind leg withdrawal upon toe-pinching was used a criterion to ensure that 
the animal was fully anesthetized. Body temperature was maintained using a heating pad. The 
impedance of the VNS electrode was verified before each recording session and remained low in all 
animals (< 10 kOhm). For placement of the EMG recording electrode, the skin of the ventral cervical 
region was shaved and disinfected. A small skin incision of approximately 2 mm was made over the 
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left cervical region to facilitate the subcutaneous insertion of the tip of an EMG electrode in the 
proximity of the laryngeal muscles (figure 1). This EMG electrode consisted of a custom-made 
monopolar needle electrode, made from an 18 gauge needle of which the tip was blunted and 
bended to obtain a non-traumatic hook electrode. Signals were recorded referred to a distant 
epidural electrode which consisted of a standard stainless steel skull screw. Signals were recorded 
using a distant epidural electrode on the skull as a reference. The VNS electrode was connected to a 
constant current stimulator and the left vagus nerve was stimulated with biphasic, charge-balanced 
square-wave pulses of 250 µs per phase. The intensity of the stimulation pulses was gradually 
ramped up from 0.1 to 1.0 mA in incremental steps of 0.1 mA. For each intensity, 20 sweeps were 
recorded to improve the signal to noise ratio and to assess the reproducibility of the signals. There 
was a 1-second interval between every sweep. At this frequency (1 Hz), no fatigue of the muscles is 
expected [18]. Each recorded sweep covered 1000 ms including a 100 ms pre-stimulus period. The 
zero time for MEP latency measurements was defined as the end of the stimulus duration of 250 µs. 
For each intensity, two sets of recordings were performed. For one set, the negative (cathodal) phase 
was given first at the proximal electrode contact. For the other set, the stimulation polarity was 
inversed, i.e. the negative phase was given first at the distal electrode contact. The succession order 
of these two types of stimuli was randomized. Signals were amplified using a High Performance AC 
Preamplifier Model P511 (Grass Technologies). The amplifier gain was set at 2000, the sampling rate 
was 100 kHz, with 16 bit resolution. The filters -3 dB bandpass limits were set at 3 Hz and 3 kHz. The 
data was digitized using a National Instruments acquisition board (NI USB 6259) and stored locally on 
a personal computer. Data acquisition and subsequent analysis was performed with Matlab 2007a 
(the MathWorks, Natick, Massachusetts). 
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Figure 1: Schematic representation of the anatomy of the left cervical vagus nerve and the 
experimental setup for the recording of VNS-induced signals. 
 
Definition of variables and statistical analysis 
A VNS-induced MEP was defined as the initial negative peak wave appearing after the stimulation 
artefact, which had the same shape and polarity despite stimulation polarity inversion and was 
reproducibly recorded in all 20 sweeps at a specific stimulation output current. The latency was 
defined as the time between the onset of the stimulation pulse and the initial negative peak wave of 
the MEP in the averaged trace. The threshold stimulation current was defined as the lowest current 
at which a MEP could clearly and reproducibly be identified visually on the EMG recordings. For a 
MEP to be defined as an LMEP, the latency of the negative peak wave needed to be within the 
expected range, i.e. the 95% confidence interval for LMEP latencies (2.34 ms - 3.42 ms, as 
determined in a previous study from our lab), using both stimulation polarities. Statistical analyses 
were performed using Sigmaplot. The threshold stimulation currents to evoke LMEPs versus MEPs 
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were compared. As this data was not normally distributed, a non-parametric Mann–Whitney U test 
was used and results were expressed as median and interquartile range (IQR). Furthermore, the 
threshold stimulation currents to evoke LMEPs were compared between both stimulation polarities, 
using a non-parametric Wilcoxon Signed Rank Test. Again, results were expressed as median and IQR. 
The latency of the LMEPs at the threshold stimulation current was compared between both 
stimulation polarities using a paired t-test. As this data was normally distributed, the results were 
expressed as mean ± standard deviation. Statistical significance was considered at p<0.05. 
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Results 
When the initial negative phase of the VNS pulse was given at the proximal electrode contact, VNS-
induced MEPs were reproducibly recorded in 24/27 rats. Figure 2 shows a typical VNS-induced MEP, 
recorded using both stimulation polarities. The overlay of 20 sweeps demonstrates the low variability 
and high reproducibility of the signals and suggests that the recording of 5 to 10 sweeps is sufficient 
to assess reproducibility in future experiments. The MEPs were characterized by a negative peak 
wave with a mean latency of 2.76 ± 1.25 ms. The threshold stimulation current for evoking MEPs 
ranged from 0.1 mA to 0.8 mA. In 13/24 rats, MEPs were identified as LMEPs, as their latency at the 
threshold output current was within the expected interval for LMEP latencies. In the other 11/24 
cases, the latency of the MEP was significantly higher (in 4/24 rats) or lower (in 7/27 rats) than 
expected for LMEPs (p<0.05). The threshold stimulation current to evoke LMEPs was significantly 
lower than the threshold stimulation current to evoke MEPs: median 0.3 mA, IQR 0.2 - 0.3 mA versus 
median 0.7 mA, IQR 0.5 - 0.7 mA for LMEPs and MEPs respectively (p<0.001). In 3/24 cases, no 
response to VNS was recorded.  
When the initial negative phase of the VNS pulse was given at the distal electrode contact (reversed 
stimulation polarity), the stimulation artifact was indeed reversed while the shape and polarity of the 
MEP remained unchanged, thereby confirming that these MEPs were not merely a part of the 
stimulation artifact. With this reverted stimulus polarity, VNS-induced MEPs were reproducibly 
recorded in the same 24/27 rats. The MEPs were characterized by a negative peak wave with a mean 
latency of 2.81 ± 1.18 ms. The results for the threshold stimulation current and the fraction of rats 
displaying MEPs, LMEPs and no recordable signals were the same as when the negative phase of the 
VNS pulse was given at the proximal electrode contact. Table 1 shows the individual results. Once a 
MEP was recorded at the threshold stimulation current, it remained present for all the following 
incremental stimulation currents. At higher stimulation currents however, additional high amplitude 
components became visible on the EMG recordings, potentially due to co-activation of cervical 
muscles as suggested by visible contractions. The threshold stimulation current to evoke LMEPs did 
not differ significantly between both stimulation polarities: median 0.3 mA, IQR 0.2 - 0.3 mA versus 
median 0.3 mA, IQR 0.2 - 0.3 mA for the initial negative phase of the pulse at the proximal and the 
distal electrode contact respectively, p>0.05. Furthermore, the latency at the threshold stimulation 
current to evoke LMEPs did not differ significantly between both stimulation polarities: 2.80 ± 0.23 
ms versus 2.78 ± 0.23 ms for the initial negative phase of the VNS pulse at the proximal and the distal 
electrode contact respectively, p>0.05.  
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Figure 2: Example of a typical VNS-induced MEP. A. The overlap of 20 sweeps. B. The averaged signal. 
The upper and lower panel of the figure show VNS-induced MEPs when the initial negative phase of 
the VNS pulse is given at the proximal or distal electrode contact respectively. The bipolar stimulation 
artifact of the VNS pulse is observed at 100 ms. This is followed by a MEP that is characterized by an 
initial negative peak wave at 2.76 ± 1.25 ms or 2.81 ± 1.18 ms after the pulse artifact when the initial 
negative phase of the VNS pulse was given at the proximal or distal electrode contact respectively.  
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Table 1: Individual latencies (ms) of the negative peak wave of the MEP for all stimulation currents. 
The rats are arranged in the table according to increasing threshold stimulation currents. For each 
rat, the latency values are given for both stimulation polarities; the upper and the lower line show 
the latency values for the stimulation polarity where the initial negative phase was given at the 
proximal or distal electrode contact respectively. Each value is the average of 20 recordings. A dash (-
) indicates the absence of a MEP. Dotted boxes indicate that a MEP was recorded using one 
stimulation polarity but not the other. The second last column shows the threshold stimulation 
current. The last column repeats the latency of the MEP at the threshold stimulation current. Gray 
shades in this column depict latencies that lay within the previously established 95% confidence 
interval for LMEP latencies.  
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Discussion 
Our results demonstrate that it is feasible to record VNS-induced MEPs using a minimally invasive, 
easy-to-use EMG tool. MEPs were reliably recorded in the majority (24/27) of our chronically VNS-
implanted rats. However, in less than half of the rats (13/27), the MEPs were identified to be LMEPs, 
resulting from the co-activation of the recurrent laryngeal nerve and the subsequent contraction of 
the laryngeal muscles. In this case, the latency of the MEP is expected to be within the previously 
established 95% confidence interval for LMEP latencies[17, 19]. LMEPs occurred at low VNS output 
currents, i.e. median 0.3 mA, IQR 0.2 - 0.3 mA .  
Significantly higher latencies of the MEPs were recorded in 4/27 rats and could be due to an 
incomplete recovery of the vagus nerve after surgery. Indeed, it has been shown previously that the 
implantation of cuff electrodes causes an initial loss of myelination, with a subsequent regeneration 
of the myelin sheath over several weeks to months[20]. In animals with more damage to the myelin 
sheath, a longer postoperative recovery period before initiating a VNS experiment is warranted. In a 
previous study from our lab using dedicated electrodes for simultaneous stimulation and recording, 
13/21 rats displayed a recordable LMEP 2 - 4 weeks after surgery. In the remaining rats, a post-
surgical recovery period up to 7 weeks was required before an LMEP could be recorded. Once an 
LMEP was present, it remained stable during the entire follow-up period of two months [19]. It would 
be very interesting to use the presented non-invasive method to follow-up LMEP stability over time 
in future experiments. The total absence of a MEP in 3/27 rats, could likewise result from a 
dysfunctional nerve. Consequently, rats with longer latency LMEPs or without LMEPs should have 
longer recovery periods or should be excluded from the experiment, as the adequate delivery of 
current to the nerve is doubtful in these animals, while this is obviously a prerequisite to obtain 
reliable experimental results. 
The significantly lower MEP latency in 7/27 rats most likely results from electrical current spillover 
and subsequent direct muscle activation[14]. Such direct muscle activation occurred at higher 
stimulation intensities (≥ 0.5 mA) and was easily identified as the appearance of high amplitude MEPs 
on the EMG recordings and as the visual observation of cervical muscle twitches. This VNS-induced 
contraction of the cervical muscles at higher VNS output currents occurred in 18/27 tested rats and 
most likely results in the frequently observed stimulation-related side effects in awake animals, e.g. 
head nodding or scratching the neck at the implantation side during the ON-phase of the stimulation. 
These stimulation-related side effects may cause stress and discomfort in the animals and may 
consequently confound the results of preclinical VNS studies.  
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Consistent with our findings, there is a large body of evidence both in animals and humans 
suggesting that low or moderate VNS output currents are sufficient and optimal to achieve 
therapeutic effects [21-28]. This hypothesis is further supported considering the anatomy of the 
vagus nerve. The nerve consists of A-, B- and C-fibers. The A- and B-fibers are myelinated and have a 
large and intermediate diameter respectively. The C-fibers are unmyelinated and have a small 
diameter. Subsequently, the A-, B- and C-fibers have a low (< 0.2 mA), intermediate (< 0.4 mA) and 
high (> 2.0 mA) threshold for activation respectively[24]. The earliest animal studies suggested that 
the antiepileptic potential of VNS was directly related to the fraction of vagal afferent C-fibers 
stimulated[22, 29]. However, Krahl et al. demonstrated that the effect of VNS on PTZ-induced 
seizures is still present following selective destruction of the C-fibers using capsaicin in rats[30]. 
Based on this and other studies[31-34], it is conceivable that the A- and B-fibers are responsible for 
the therapeutic effects of VNS and subsequently, low and intermediate output currents should be 
sufficient to evoke therapeutic responses. Apart from the fiber characteristics and the VNS output 
current, nerve fiber activation during stimulation depends on other important factors. Fibers located 
closer to the perimeter of the nerve and thereby closer to the VNS electrode are exposed to a 
stronger electric field and are easier to excite compared to fibers located deeper in the nerve. Also, 
fibrous tissue encapsulation at the site of the electrode can increase resistance, altering the electric 
field and resulting in increased voltage requirements for fiber excitation[35, 36]. These factors 
suggest individual variations and therefore, one optimal VNS output current cannot be defined. This 
is reflected in our results by the fact that the output currents required to evoke LMEPs are variable 
and range from 0.1 to 0.3 mA, and even to 0.5 mA in one animal displaying LMEPs.  
 
LMEP recordings represent an indirect monitoring tool in the sense that it records the activity of the 
low threshold Aα-motor fibers, while the therapeutic effects of VNS are believed to be mediated by 
higher threshold A- and B-fibers. Nevertheless, it is well-known that physiological features such as 
fiber diameter, activation sensitivity to electrical stimulation, action potential conduction velocity 
and function are all closely related[37]. When the threshold to one specific fiber type can be reliably 
recorded, it can be used as an indicator to determine the expected threshold for all other fibers. The 
threshold stimulation strength to produce LMEPs is thus directly related to the required therapeutic 
VNS stimulus strength. The value of the ratio between both stimulus strengths still has to be 
established and will be part of our future work. However, given that the variation in activation 
sensitivity with fibre diameter is rather limited in the large diameter range[38], we expect to find a 
ratio value close to unity between the LMEP threshold stimulation current and efficient therapeutic 
VNS output current. 
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LMEPs result from efferent stimulation, while the therapeutic effects of VNS are believed to be 
mediated through the activation of the afferent fibers. Both in experimental studies and in clinical 
practice, one is trying to selectively stimulate the afferent fibers by administering the initial negative 
phase at the proximal electrode contact. It is hoped that anodal block, i.e. a conduction block due to 
hyperpolarization of the nerve, at the level of the distal electrode contact, will occur. Consequently, 
this would limit efferent effects of VNS, e.g. hoarseness, cardiac and pulmonary side effects. 
However, this study shows that LMEPs are recorded at the same output current and have the same 
latency irrespective of the stimulation polarity configuration and thus, that anodal block does not 
occur. In practice, anodal block is indeed only observed using high output currents and long 
pulses[39, 40], while it is not the case using clinically relevant stimulation parameters[41-43]. 
 
In conclusion, the main findings of this study are that VNS-induced LMEPs are reproducibly recorded 
in about half of the animals 2 - 3 weeks after surgery and that these LMEPs occurred at low 
stimulation intensities. At higher stimulation intensities, the MEPs had significantly higher or lower 
latencies than expected for an LMEP, pointing at nerve damage and direct muscle activation due to 
current spill-over respectively. These results suggest that low stimulation currents are sufficient to 
achieve therapeutic effects, while high stimulation currents can lead to significant stimulation-
related side effects. Apart from reducing stimulation-related side effects, stimulating the vagus nerve 
with a lower output current density would be beneficial in the sense that it would save battery life, 
thereby postponing the surgical procedure and costs for battery replacement. Furthermore, we 
suggest that this minimally invasive, easily-applicable method is a valid tool in an experimental 
setting to identify non-responders due to ineffective activation of the vagus nerve and to determine 
individual post-operative recovery periods. 
 
Future steps in this research field should focus on the optimization of this technique in awake 
animals, the relationship between Aα- and other A- and B-fiber activation thresholds, the correlation 
of LMEP recordings with therapeutic responses and the translation of this technique to clinical 
practice. Although VNS is well-established in clinical practice, one third of patients are classified as 
non-responders [2, 3]. Potential causes for non-response that could be further investigated using 
LMEP recordings are lead failure, a poor nerve-electrode contact due to scar tissue and nerve 
damage such as demyelination. Optimal stimulation parameters required for effective activation of 
the pertinent vagus nerve components are still unknown. For this purpose as well, LMEP recordings 
in a clinical population could optimize the therapeutic approach with VNS. 
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Chapter 4 - study 6 
Laryngeal motor-evoked potentials as an indicator of vagus nerve 
activation: a clinical pilot trial 
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Study 6: Optimization of the stimulation parameters 
 
In clinical practice, one third of patients are non-responders and optimal stimulation parameters 
required to effectively activate the vagus nerve are still unknown. The therapeutically applied 
stimulation intensity is typically the highest output current tolerated by the individual patient. This is 
obviously not an evidence-based way to determine the individual, optimal output current for vagal 
fiber activation. Research should therefore be directed towards finding a non-invasive method that 
can guide individual titration of the stimulation parameters. Such biomarker for effective delivery of 
VNS pulses to the nerve could support the choice for individual stimulation parameters in a more 
rational way. To date, no such technique is available for clinical use in chronically VNS-implanted 
patients. In a previous study from our lab, it was shown that it is feasible to record VNS-induced 
laryngeal muscle-evoked potentials or LMEPs in chronically VNS-implanted experimental rats using a 
non-invasive electromyography technique. LMEPs are indicative of the effective delivery of electrical 
current to the cervical fibers of the vagus nerve and could subsequently be used to identify non-
responders due to ineffective activation of the nerve and to determine individual optimal stimulation 
parameters to activate the vagal fibers. The aim of the presented study was to translate this 
technique to clinical practice. 
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Abstract 
Rationale: Vagus nerve stimulation (VNS) is an adjunctive therapy for patients with medically 
refractory epilepsy and depression. However, one third of patients do not benefit from the treatment 
and optimal stimulation parameters remain elusive. To date, a non-invasive technique to assess 
whether the vagus nerve is effectively activated by the applied stimulation parameters is lacking. We 
have recently demonstrated in a preclinical setting that VNS-induced laryngeal motor-evoked 
potentials (LMEPs) can serve as indicators of effective activation of the cervical vagal fibers. The aim 
of this study is to investigate the feasibility and applicability of recording VNS-induced LMEPs in 
patients treated with VNS.  
Methods: To record LMEPs, six surface EMG electrodes were placed in the cervical region of the 
patients (n = 2) according to 3 perpendicular axes around the larynx. The VNS parameters were set at 
a pulse width of 250 μs, a frequency of 10 Hz and a duty cycle of 7 s ON / 18 s OFF. The VNS output 
current was gradually ramped down from the patients’ usual output current to 0.00 mA, in steps of 
0.25 mA. Subsequently, the output current was gradually ramped up again to the patient’s usual 
settings. For each output current, the responses to two 7-second VNS trains were recorded. LMEP 
amplitude and latency were analyzed by two independent investigators. 
Results: VNS-induced LMEPs were recorded in both patients with high reproducibility. The LMEPs 
were already observed at low output currents (0.25 - 0.50 mA) and the amplitude of the signals 
reached a plateau at 0.75 - 1.00 mA. The LMEP latency remained constant for each stimulation 
intensity. LMEP amplitude and latency were very reproducibly assessed across stimulation trains and 
for the two observers. 
Conclusion: Our study demonstrates that it is feasible to record VNS-induced LMEPs in a 
reproducible, easy and non-invasive way in chronically VNS-implanted patients. Furthermore, our 
results suggest that output currents of 0.75 – 1.00 mA are sufficient to activate the Aα-motor fibers 
of the vagus nerve. VNS-induced LMEPs may help neurologists to choose the optimal stimulation 
parameters in a more objective way and to identify non-responders due to ineffective stimulation of 
the vagus nerve. 
 
 
 
 149 
 
Introduction 
Vagus nerve stimulation (VNS) is an effective treatment for patients suffering from refractory 
epilepsy and depression. A small pulse generator is surgically implanted subcutaneously in the left 
thoracic area and delivers intermittent electrical pulses via an electrode that is partially wrapped 
around the left vagus nerve in the mid-cervical region. The afferent signals are further processed in 
the nucleus tractus solitarius and relayed to various regions of the brain [1]. Although VNS is well-
established in clinical practice, there are still some drawbacks associated with the treatment. One 
third of patients do not benefit from the therapy and are classified as non-responders [2, 3]. 
Potential causes for non-response are a poor electrode contact due to gliotic tissue and nerve 
damage such as demyelination. Optimal stimulation parameters required to effectively activate the 
vagus nerve are still unknown. In clinical practice, the therapeutically applied stimulation intensity is 
typically the highest output current tolerated by the individual patient. A biomarker for effective 
delivery of VNS pulses to the nerve could support epileptologists in their choice for individual 
stimulation parameters in a more rational way. To date, no such technique is available for clinical use 
in chronically-implanted patients receiving VNS treatment. 
 
Recently, we have shown that it is feasible to record VNS-induced laryngeal muscle-evoked potentials 
or LMEPs in chronically implanted experimental rats using a non-invasive electromyography (EMG) 
technique [4]. These LMEPs result from contractions of the laryngeal muscles which are induced by 
the co-activation of the Aα-motor fibers of the recurrent laryngeal nerve, which branches off from 
the vagus nerve at the level of the aortic arch. LMEPs are thus indicative of the effective delivery of 
electrical current to the cervical fibers of the vagus nerve and could subsequently be used to identify 
non-responders due to ineffective activation of the nerve and to determine optimal stimulation 
parameters. In humans, VNS-induced LMEPs have also been recorded using acute intra-operative 
vocal cord EMG, endotracheal tubes with electrodes and laryngoscopy [5-7]. The intra-operative 
measurement of LMEPs may provide a marker for effective activation of the vagal fibers by VNS, but 
remains invasive, prolongs the implantation procedure and provides no information on the effective 
activation of the vagal fibers in the chronic phase of VNS treatment. Therefore, the aim of the 
present study was to evaluate whether it is feasible to reliably record VNS-induced LMEPs in 
chronically implanted awake patients, using a non-invasive, easy-to-use EMG tool. 
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Methods 
 
Patients 
To date, two patients (1 male, 1 female, mean age 37 years), suffering from refractory epilepsy and 
implanted with a VNS device (Cyberonics, Houston, TX, USA) were recruited for the study. The study 
took place in the Reference Center for Refractory Epilepsy at Ghent University Hospital, Ghent, 
Belgium. Patients were included in the study if they met the following criteria: 1) at least 18 months 
of treatment with VNS for refractory epilepsy; 2) older than 18 years and 3) a VNS electrode 
impedance below 10 kOhms. The main clinical characteristics of the patients and their usual VNS 
parameters are summarized in table 1. The study was approved by the ethics committee of Ghent 
University Hospital. After a full description of the procedure was provided and explained, both 
patients gave written informed consent. 
 
 
 
Table 1: The main clinical characteristics of the patients and their usual VNS parameters. Response 
was defined as a seizure frequency reduction of ≥ 50%.  
 
 
VNS-induced LMEP recordings 
At the beginning of the study, the VNS electrode impedance was checked and the body length of the 
patient was measured. Subsequently, 8 surface electrodes were placed on the skin of the patient 
(see figure 1). Six Ag/AgCl (Kendall H92SG ECG electrodes, Ø 35 mm) recording electrodes were 
placed in the neck according to 3 perpendicular axes around the larynx. Electrode pair 1a-1b, 2a-2b 
and 3a-3b were placed according to the sagittal, horizontal and vertical axes respectively. 
Furthermore, a grounding electrode (G1) and a common reference electrode (rb) were placed on the 
forehead and the sternum respectively. EMG was recorded using Micromed System Plus (Micromed, 
Mogliano, Italy).  
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Figure 1: Schematic representation of the electrode placement. 
 
For the duration of the experiment, the frequency of the VNS pulse was set at 10 Hz in order to avoid 
overlap of the stimulation artifacts and the electrophysiological responses. Furthermore, the pulse 
width and the duty cycle were set at 250 µs and 7 s ON / 18 s OFF respectively in all patients to 
assure reproducibility and to limit the time of the procedure respectively. Using the handheld 
computer, the stimulation output current was gradually ramped down from the usual output current 
(2.25 mA and 1.25 mA for patient 1 and 2 respectively) to 0.00 mA, in steps of 0.25 mA. For each 
intensity, the response to 2 stimulation trains was recorded to assess the reproducibility of the 
signals (see figure 2). Subsequently, the stimulation output current was gradually ramped up again 
from 0.00 mA to the usual output current, in incremental steps of 0.25 mA. Again, two trains per 
stimulation intensity were recorded (not shown in the figure). The signals were digitized online with a 
sampling frequency rate of 1024 Hz, an antialiasing filter of 250 Hz, a gain of 50 dB and a resolution 
of 16 bits. The signals were analyzed offline using BrainVision Analyzer 2.0. Two stimulation trains per 
output current level and five pulses per stimulation train were analyzed and this was done in duplo 
by two independent investigators. Apart from the fact that the pulses could not be disturbed by the 
electrocardiogram, the pulses were chosen at random. One investigator analyzed the signals from 
the ramp down condition, the other investigator analyzed the signals from the ramp up condition. 
Therefore, 20 pulses per output current were analyzed in total. The results were compared to check 
reproducibility. After the experiment, the pulse generator was programmed back to the usual 
stimulation parameters of the patient.  
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Figure 2: Schematic representation of the ramping down part of the protocol.  
 
 
Definition of variables 
An LMEP was defined as the initial positive peak that was reproducibly recorded after each 
stimulation artifact. The threshold stimulation current was defined as the output current at which an 
LMEP could be reproducibly identified in the recorded EMG signals. The latency was defined as the 
time between the negative peak of the stimulation pulse and the peak of the first positive deflection 
of the LMEP above noise level. The amplitude of the LMEP was defined as the difference in amplitude 
between the first positive and the following negative peak of the LMEP. Input-output curves were 
drawn for the amplitude of the LMEPs and the amplitude of the stimulation artifact. All graphs were 
drawn with Sigmaplot.  
 
 
 
 
 
 
 
 
 153 
 
Results 
 
LMEPs were very reproducibly recorded in both patients (figure 3, upper part panel A and B). 
Although LMEPs were clearly identified in all three derivations (1a-1b, 2a-2b and 3a-3b), they had the 
biggest amplitude in 3a-3b and 1a-1b for patient 1 and 2 respectively. In patient 1, LMEPs were 
recorded at the lowest output current (0.25 mA) and their amplitude increased until it reached a 
plateau at an output current of 0.75 - 1.00 mA (figure 3, lower part panel A). In patient 2, LMEPs 
were recorded from 0.50 mA onwards and the amplitude of these LMEPs also reached a plateau at 
an output current of 0.75 - 1.00 mA (figure 3, lower part panel B). The latency of the LMEPs was 9.76 
ms and 8.60 ms for patient 1 and 2 respectively. LMEP amplitude could be assessed very reproducibly 
between the two observers working respectively on the ramping up and ramping down data (see 
figure 3, lower part panel A and B). The amplitude of the stimulation artifact kept on increasing with 
the intensity of the output current (figure 4), while the LMEP amplitude reached a plateau around 
0.75 - 1.00 mA in both patients. This finding provides strong evidence that the recorded LMEP signals 
are not merely part of the stimulation artifact but are true electrophysiological responses. 
 
Figure 3: Panel A, B and C show the results for patient 1, patient 2 and the overlap of patient 1 and 2 
respectively. In the upper part of panel A and B, the overlay of 10 LMEP recordings at an output 
current of 1.00 mA is shown for patient 1 and 2 respectively. The stimulation artifact is seen at 0 ms, 
followed by an LMEP at 9.76 ms and 8.60 ms for patient 1 and 2 respectively. The lower part of panel 
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A and B depict the amplitude of the LMEP in function of the output current for patient 1 and 2 
respectively. For both patients, the overlay of the analysis of the two independent investigators is 
shown. The upper part of panel C shows the overlay of the averaged signal of patient 1 and 2. The 
lower part of panel C depicts the overlay of the amplitude in function of the output current of patient 
1 and 2.  
 
 
Figure 4: Amplitude of the stimulation artifact in function of the output current for both patients. 
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Discussion 
 
The results from this pilot trial show that LMEPs can be reproducibly recorded in patients chronically 
treated with VNS, using a non-invasive EMG approach. These LMEPs result from contractions of the 
laryngeal muscles which are induced by the co-activation of the Aα-motor fibers of the recurrent 
laryngeal nerve upon VNS. In a recent study by Kim et al., LMEPs were recorded upon direct 
stimulation of the recurrent laryngeal nerve, using invasive stimulation and recording needle 
electrodes. The mean latency of the responses was 1.98 ± 0.26 ms when the stimulation electrode 
was placed 3 cm below the lower margin of the cricoid cartilage [8]. Considering a conduction delay 
of around 1 ms for neuromuscular transmission at the end plate [9], the conduction velocity in that 
study can be estimated at 31 m/s. In the present clinical pilot trial, the mean LMEP latency was 9.18 ± 
0.82 ms. Based on the knowledge that the mean length of the left recurrent laryngeal nerve in 
humans is 13.7 cm [10], that the VNS electrode is implanted approximately 8 cm above the clavicle 
[11] and that the recurrent laryngeal nerve branches off from the vagus nerve approximately 5 cm 
under the clavicle, a total estimated distance of 26.7 cm can be calculated from the VNS electrode to 
the laryngeal muscles. This distance value, the 1-ms conduction delay and the mean LMEP latency of 
9.18 ± 0.82 ms obtained in our study, lead to an approximate conduction velocity of about 33 m/s. 
The very similar conduction velocities estimated from the study of Kim et al. [8] and the present 
clinical pilot trial, support the hypothesis that the signals recorded are of the same origin, i.e. the 
activation of the Aα-motor fibers of the recurrent laryngeal nerve and subsequent contraction of the 
laryngeal muscles. Obviously, the conduction velocities calculated here are merely approximations 
and future studies should assess the true conduction velocity of the fibers by recording signals from 
two locations on the laryngeal nerve at a known distance from each other. 
In clinical practice, the therapeutically used stimulation intensity is typically the highest output 
current tolerated, with a median value of 1.75 mA (ranging from 0.75 mA to 3.50 mA) after long-term 
treatment [12]. However, as the efficacy of VNS is dependent on the adequate activation of the low 
(< 0.20 mA) and moderate (< 0.40 mA) threshold vagal A- and B-fibers [13-15], the currently used 
stimulation output currents are probably much higher than what is required to achieve therapeutic 
effects. In both patients included in the present study, LMEPs, reflecting Aα-fiber activation, were 
already recorded at low VNS output currents, i.e. 0.25 and 0.50 mA in patient 1 and 2 respectively. 
These results are consistent with the findings from the invasive study by Ardesch et al., where the 
effect of VNS on the vocal folds was already present at VNS output currents of 0.25 - 0.50 mA, 
without necessarily causing VNS-induced hoarseness [7]. In the present study, the amplitude of the 
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LMEPs increased until it reached a plateau at an output current of 0.75 - 1.00 mA in both patients. 
The lack of further LMEP amplitude increase at higher output currents, most likely reflects the fact no 
additional Aα-fibers are recruited at higher VNS output currents and subsequently suggests that 
stimulating the vagus nerve at higher output currents will not results in an additional therapeutic 
effect. However, it must be acknowledged that one general optimal stimulation current cannot be 
defined. That is, individual thresholds for the activation of vagal A- and B-fibers will vary as a result 
from differences in the anatomy of the vagus nerve, i.e. the relative position of fibers within the 
nerve, electrode contact position and local tissue gliosis. It was shown by Helmers et al. that the 
presence of 110 µm of fibrotic tissue can decrease fiber activation by 50% [1]. Furthermore, LMEP 
recordings may underestimate the VNS output current required to achieve therapeutic efficacy as it 
records the activity of the low threshold Aα-motor fibers, while the therapeutic effects of VNS are 
believed to be mediated by the slightly higher threshold A- and B-fibers. Nevertheless, it is known 
from physiological studies in all nerves and in all species that physiological features such as fiber 
diameter, activation sensitivity to electrical stimulation and action potential conduction velocity are 
all closely related [16]. If the threshold to one specific type of fiber can be measured, it can be used 
as a correction coefficient to determine the expected threshold for all other fibers. Given that the 
variation in threshold intensity with fiber diameter is rather limited in the large diameter range [17], 
we expect to find a ratio value close to unity between the LMEP threshold stimulation current and 
efficient therapeutic VNS parameters. Therefore, we suggest that the presented non-invasive LMEP 
recording technique could be used to guide individual titration of the stimulation parameters.  
Another important problem in VNS therapy is the high non-responder rate and the lack of 
explanation for this fact. It is possible that the vagus nerve of some non-responders is not adequately 
activated, for multiple reasons such as lead failure, poor electrode contact or nerve damage. Even 
general conditions such as diabetes can lead to neuropathy of the vagus nerve [18]. A temporary 
paresis of the vocal cords after VNS surgery has previously been described in humans [19-21]. This 
indicates that the surgical procedure and implantation of the electrode can cause nerve damage such 
as demyelination and a transient failure of the vagus nerve, hence requiring a recovery period before 
becoming functional again [22]. To allow recovery of the nerve, a delay of two weeks is usually 
foreseen between the implantation of the system and the start of VNS. The duration of this delay is 
determined rather empirically, while an individualized approach, based on the recovery of the nerve 
could be beneficial. The absence of an LMEP at reasonable stimulation currents or a prolonged 
latency of the LMEP could indicate incomplete recovery of the nerve. In that case, a further rest 
period might be beneficial for the nerve and more easily accepted then unsuccessful trials. Future 
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studies should include LMEP recordings starting immediately after surgery, to follow-up the recovery 
of the nerve.  
Furthermore, we suggest that the lack of LMEPs could be used to identify non-response resulting 
from inefficient activation of the vagus nerve. Of course, non-response could also result from the 
heterogeneity of the underlying pathophysiological mechanisms or the variability in characteristics of 
more central structures in the neural pathway involved in VNS. In this regard, genetic differences in 
neurotransmitter systems could be an example of hypotheses to consider. Therefore, the presence of 
LMEPs is not an identifier of response nor is it a biomarker for the anti-epileptic or antidepressant 
efficacy of VNS but rather an indication that the nerve is effectively stimulated, which is an essential 
step to achieve therapeutic response. This is reflected in our data by the fact that both patients 
display LMEPs while only one of them is a responder. Non-response in the other patient despite the 
proper activation of the vagus nerve as reflected by the presence of LMEPs, could result from 
upstream problems such as an impaired noradrenergic signaling. 
In conclusion, the results from this pilot trial show that VNS-induced LMEPs can be recorded very 
reproducibly in chronically VNS-implanted patients using a non-invasive EMG approach. 
Furthermore, our results suggest that low to moderate output currents are sufficient to activate the 
vagal fibers and therefore to achieve therapeutic responses. We hypothesize that LMEPs could be 
used for the identification of ineffective stimulation leading to non-response and for the 
individualization of post-operative recovery delays. However, long-term longitudinal studies in a 
bigger sample of patients are needed to confirm these hypotheses. 
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Conclusions 
 
 
Proof-of-concept and mechanism of action 
 
From this thesis, we can conclude that: 
1. Chapter 3 – Study 1| The kainic acid (KA) rat model for temporal lobe epilepsy presents 
anhedonia, as demonstrated by a significant decrease in saccharin preference. The reduced 
saccharin preference in the KA-treated rats was not caused by an altered taste perception, as 
the aversion towards quinine was unaltered. Two weeks of VNS decreased the anhedonic 
state in the KA rats, as indicated by a significant increase in saccharin preference. No effects 
were found in the other groups (KA-SHAM, SAL-VNS and SAL-SHAM). Furthermore, VNS nor 
SHAM treatment had an effect on taste perception, as shown in the quinine aversion test. 
Our findings demonstrate the antidepressant-like effect of VNS in the KA rat model for 
temporal lobe epilepsy and comorbid anhedonia. 
 
2. Chapter 3 – Study 2| We confirmed that VNS has an antidepressant-like effect based on a 
significant reduction of the immobility time in the rat forced swim test. The antidepressant-
like effect of VNS was completely abolished when the noradrenergic axons arising from the 
locus coeruleus (LC) were eliminated using the selective noradrenergic neurotoxin DSP-4. To 
rule out the possibility that the effects in the forced swim test were caused by an overall 
change in locomotor activity, the animals were tested in an open field. No significant 
differences in locomotor activity were found between groups. Furthermore, the immobility 
in the forced swim test did not correlate with the locomotor activity in the open field test, 
ruling out a mere locomotor effect as an explanation for the observed forced swim test 
results. Our results confirm the key role of the noradrenergic LC neurons in the 
antidepressant-like mechanism of action of VNS. 
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Optimization of the stimulation parameters 
 
From this thesis, we can conclude that: 
1. Chapter 4 – Study 4| VNS is effective in reducing cortical excitability in the motor cortex 
stimulation rat model. A low VNS output current (0.25 mA) is sufficient to reduce cortical 
excitability, while higher output currents (0.50 mA and 1.00 mA) do not result in an 
additional therapeutic effect and may therefore not be required. These results suggest that 
the effect of VNS on cortical excitability is mediated through the low and moderate threshold 
A- and B-fibers and not through the high threshold C-fibers. 
2. Chapter 4 – Study 5|VNS-induced LMEPs can be recorded reproducibly in chronically VNS-
implanted experimental rats, using a minimally invasive, easy-to-implement 
electromyography (EMG) technique. 
3. Chapter 4 – Study 5|In experimental rats, LMEPs occurred at low stimulation intensities 
(median 0.2 mA, IQR 0.2 - 0.3 mA). At higher stimulation intensities (median 0.7 mA, IQR 0.5 - 
0.7 mA), the muscle-evoked potentials had significantly higher or lower latencies than 
expected for an LMEP, pointing at nerve damage and direct muscle activation due to current 
spill-over respectively. These results suggest that low stimulation currents are sufficient to 
activate the vagus nerve, while higher stimulation currents can lead to significant 
stimulation-related side effects. Furthermore, we suggest that this technique can be used 
to identify non-response due to ineffective activation of the vagus nerve and to determine 
the individual post-operative recovery periods. 
4. Chapter 4 – Study 6| VNS-induced LMEPs were recorded in two chronically VNS-implanted 
patients with very high reproducibility.  
5. Chapter 4 – Study 6| These LMEPs were already present at low output currents (0.25 - 0.50 
mA) and the amplitude of the signals reached a plateau around 0.75 - 1.00 mA. These results 
suggest that low to moderate output currents are sufficient to activate the vagal fibers in 
humans. VNS-induced LMEPs may help neurologists to choose the optimal stimulation 
parameters in a more objective way and to identify non-responders due to ineffective 
stimulation of the vagus nerve. 
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Discussion and future perspectives 
 
 
Proof-of-concept and mechanism of action 
 
The promising results from the proof-of-concept study encourage further studies in the KA rat model 
for temporal lobe epilepsy and comorbid depression. First, studies should focus on identifying the 
pathophysiological processes underlying this comorbidity. The frequent co-occurrence of epileptic 
seizures and depressive symptoms in chronic epilepsy models, suggests that these symptoms may 
share common underlying pathophysiological mechanisms. Although the specific mechanisms have 
not been identified to date, emerging evidence shows that there is a remarkable overlap in the 
abnormalities found in epilepsy and depression models, the two most important ones being 
imbalances in neurotransmitter systems [1] and changes in neural plasticity [2, 3]. Therefore, future 
studies should include neurochemical experiments in order to characterize potential abnormalities in 
neurotransmitter balances and the investigation of the role of aberrant neural plasticity. In a second 
phase, experimental studies should focus on unraveling the mechanism of action of VNS in animal 
models for temporal lobe epilepsy and comorbid depressive symptoms. This mechanism of action 
most likely results from a complex interplay between the different mechanisms that underlie the 
pathophysiology of both diseases, i.e. the correction of dysfunctional neurotransmitter circuits and 
the promotion of neural plasticity.  
As the LC and its neurotransmitter noradrenaline are convincingly involved in the treatment of 
depression [4, 5] and VNS-induced noradrenaline release from the LC has been shown in several 
experiments [6-8], we hypothesized that the antidepressant-like effect of VNS in the KA model for 
temporal lobe epilepsy and comorbid depression would be abolished when the LC axons are lesioned 
using the very selective noradrenergic neurotoxin DSP-4. However, in a pilot trial we found that 
lesioning the LC axons in KA-treated animals is a lethal intervention. As noradrenaline also has potent 
antiepileptic effects [9], we hypothesize that our KA-treated animals developed a refractory status 
epilepticus after DSP-4 injection, eventually leading to their death. Consistent with this hypothesis, it 
has previously been shown that DSP-4 potentiates pilocarpine- [10], iron- [11] and bicuculline-
induced seizures [12]. Although this was not the focus of this thesis, it would be interesting to setup 
an experiment involving video-EEG monitoring to test this hypothesis in the future. 
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To assess whether the LC plays a key role in the antidepressant-like mechanism of action of VNS, we 
searched literature for an alternative model to test our hypothesis in. Such an animal model was 
found in the publication of Krahl et al. were it was shown that VNS is effective in the rat forced swim 
test, which is a validated test for behavioral despair [13]. The abolishment of the antidepressant-like 
effect of VNS after lesioning the noradrenergic LC axons, confirmed the hypothesis that this effect is 
mediated through the activation of this brainstem nucleus and the subsequent release of 
noradrenaline. 
In previous LC lesioning studies, it was demonstrated that an intact LC is required for the antiepileptic 
and the antinociceptive effects of VNS [14-17]. Considering the total loss of therapeutic efficacy of 
VNS for several disorders after the selective destruction of LC axons, we hypothesize that the LC 
functions as a gateway structure, by primarily releasing noradrenaline which can then trigger other 
mechanisms important in several conditions. A hypothesis to consider for depression is the 
enhancement of other neurotransmitter systems such as the serotonergic and the dopaminergic 
neurotransmission, two monoaminergic systems which are implied in the pathophysiology and the 
treatment of depression [18, 19] and have been shown to be enhanced by VNS [20-24]. It was 
previously demonstrated that the enhancing effect of VNS on serotonergic neuronal firing is 
indirectly mediated by the noradrenergic LC neurons through the enhanced activation of the 
excitatory α1-adrenoreceptors located on dorsal raphe nucleus serotonergic cell bodies [20]. It would 
be interesting to investigate in future experiments, whether the effect of VNS on the dopaminergic 
system is also indirectly mediated through the enhanced noradrenaline release from the LC. In a next 
step, experiments using selective agonists and antagonists for the different adrenergic receptor 
subtypes (α1-, α2-, β-receptors), could provide valuable information on which receptor subtypes are 
involved in this effect. Previous studies showed that direct LC stimulation elicits burst firing of the 
dopaminergic ventral tegmental neurons through the excitatory α1-adrenoreceptors [25-27], 
suggesting that VNS could indeed also activate the dopaminergic system via binding to these 
receptors. Furthermore, studies using selective serotonergic and dopaminergic neurotoxins should 
be performed to assess the individual roles of these neurotransmitter systems in the antidepressant-
like effect of VNS.  
 
Another plausible hypothesis is that VNS produces its antidepressant-like effect through increasing 
neural plasticity, especially in the hippocampus, a structure important in mood regulation. As the 
hippocampus is rich in noradrenergic LC innervation [28] and noradrenaline has proven neuroplastic 
effects [29-31], it is tempting to hypothesize that these effects of VNS are also indirectly mediated 
though the activation of the LC and the subsequent release of noradrenaline in the hippocampus. 
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The rationale for the neural plasticity hypothesis of depression originates from the knowledge that 
stressful events, such as forced swimming in rodents, lead to a significant reduction in neural 
plasticity, while several antidepressants increase neural plasticity [32]. A growing body of evidence 
suggests that VNS also produces its antidepressant-like effect through increasing neural plasticity [8, 
33-36]. However, only two experimental animal studies have correlated VNS-induced changes in 
neural plasticity to antidepressant-like effects in behavioral testing paradigms. Only the study of 
Gebhardt et al. found an association between the VNS-induced increased progenitor proliferation 
and its restorative effects on cognition [35]. However, as an association does not imply a causative 
relationship between the observed phenomena, the results should be interpreted with caution. That 
is, the possibility exists that the neuroplastic effects of VNS are merely an epiphenomenon of other, 
more important processes leading to sustained antidepressant effects. The dissociation between the 
presence of neuroplastic effects and the lack of behavioral effects in the study of Biggio et al. [34], 
supports this hypothesis. Consequently, future studies should focus on investigating the potential 
causal relationship between VNS-induced neuroplastic changes and antidepressant-like effects, for 
example using x-ray irradiation techniques to ablate hippocampal cell proliferation. Another 
shortcoming of the studies performed so far, is that none of them have investigated whether the 
newborn progenitor cells differentiate into mature neurons and integrate functionally into the 
cortico-limbic networks important in depression. Therefore, future studies should determine the 
phenotype of the newborn cells using specific markers for mature neurons, such as NeuN (neuronal 
nuclei) or NSE (neuron specific enolase). Furthermore, connectivity studies should be performed to 
confirm the hypothesis that the newborn neurons restore the disturbed cortico-limbic networks in 
depressed subjects. 
 
Animal models are indispensable for investigating the etiology of diseases, as well as for developing 
and optimizing therapeutics for these diseases. However, it must be acknowledged that all animal 
models have limitations. For example, animals cannot observe feelings of sadness, guilt or suicidal 
thoughts, depressive symptoms mainly limited to humans [37, 38]. Therefore, it is indispensable to 
assess whether our findings translate to human subjects treated with VNS. In a previous study by 
Harden et al., it was found that VNS induces mood improvements in epilepsy patients [39] supporting 
the findings from our preclinical study. However, there are multiple factors confounding the study of 
Harden et al. First, this study was not randomized nor placebo-controlled. Consequently, patients in 
the VNS group were different from patients in the control group with respect to both baseline 
seizure frequency and mood scale scores. Second, there might have been a placebo effect in the VNS 
group, simply resulting from the fact that patients in this group chose to be proactive in treating their 
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epilepsy. Third, patients in the VNS group were seen much more frequently for the adjustment of 
VNS settings compared to control patients. It is therefore possible that non-specific effects of 
physician contact accounted for the observed mood improvements. Lastly, although it is well-known 
that antiepileptic drugs can contribute to mood disturbances [40], drug levels were not 
systematically measured during this study [39]. 
To assess whether VNS has a true antidepressant effect in epilepsy patients suffering from comorbid 
depression, a randomized sham-controlled, double-blind clinical trial should be conducted. First, all 
patients should be implanted with a VNS device. Subsequently, patients should be randomized in a 
matched VNS- or sham-treated group. The output current of the patients in the VNS group should be 
gradually ramped-up, while it should be kept at 0.00 mA in the patients of the sham group. However, 
patients in both groups should be approached in exactly the same way. That is, they should be seen 
by a physician as frequently in both groups and similarly as in the VNS group, the physician should 
make adjustments to the parameters settings of the patients in the sham group, albeit sham 
adjustments. Furthermore, concomitant drug therapy should be closely monitored and matched. To 
minimize or even avoid the confounding influences of interactions between different medication 
groups, anti-epileptic and antidepressant drugs could be down-titrated to a stable monotherapy 
regime prior to the start of the study. Naturally, for ethical reasons, the output current of the 
patients in the sham group should be ramped-up after the initial sham-controlled phase of the study. 
If the results from such clinical trial confirm the results from our preclinical study, VNS could be 
suggested as a standard treatment for patients suffering from comorbid epilepsy and depression. 
Furthermore, clinical studies assessing the role of the LC and noradrenaline in the antidepressant 
mechanism of action of VNS should be conducted. As lesioning the LC in patients is not feasible for 
obvious ethical reasons, confirming the causal relationship between the VNS-induced activation of 
the LC and the antidepressant effect of VNS is impossible in a clinical population. This stresses the 
importance of the use of animal models for this purpose. To date, non-invasive techniques to directly 
measure noradrenaline in the human brain are lacking. However, an increase in noradrenaline can be 
indirectly evaluated through parameters which are modulated by the central noradrenergic 
signalization, such as the pupil diameter or the P300 component of event-related potentials. A recent 
study from our lab showed that VNS induces a significant increase of the P300 amplitude at the 
parietal midline electrode, in VNS responders only. This finding suggests that the VNS-induced 
activation of the noradrenergic LC system is associated with the therapeutic response to VNS in 
patients with epilepsy [41]. It would be very interesting to assess in a future study, whether this 
relationship between the VNS-induced effect on the P300 and the therapeutic response also exists 
for depressive patients treated with VNS. 
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Optimization of the stimulation parameters 
 
Electrical pulses applied in VNS therapy are defined by the following stimulation parameters: 
frequency (Hz), pulse width (µs), ON/OFF time or duty cycle (s, min) and output current (mA) [42]. 
The parameters currently applied in clinical practice and in experimental animal studies are based on 
a limited number of studies showing their safety and tolerability. Agnew et al. demonstrated that 
stimulation of the vagus nerve in rats with a low frequency (20 Hz), induces less damage compared to 
VNS with high frequencies (50 – 100 Hz) [43]. A pulse width of 250 µs instead of 500 µs was shown to 
increase tolerability in patients treated with VNS [44]. The use of a duty cycle saves battery life and 
reduces stimulation-related nerve damage [45]. Furthermore, it has been demonstrated that the 
effect of the stimulation outlasts the stimulus duration [46-48]. In clinical practice, the 
therapeutically used output current is typically the highest stimulation intensity tolerated. The 
output currents used in preclinical experimental studies are determined rather empirically and vary 
considerably between experiments. The lack of evidence-based data for VNS output currents in 
combination with the lack of efficacy in a substantial number of VNS-treated subjects, demonstrates 
the need for studies optimizing the VNS output current both in clinical practice and in preclinical 
experimental studies. 
In a previous study from our laboratory by De Herdt et al., it was shown that 1 hour of VNS at an 
output current of 0.75 mA is effective in lowering cortical excitablity in the motor cortex stimulation 
rat model [49]. This model allows repeated testing of the threshold for motor seizures in a 
standardized manner by means of applying a ramp-shaped stimulation pulse train with increasing 
intensity to the motor cortex [49, 50]. In the experiment presented in this thesis, we used this model 
to further finetune and investigate the dose-response relationship by measuring the effects of 
different VNS output currents on cortical excitability, i.e. 0.25, 0.50 and 1.00 mA. We found that VNS 
at 0.25 mA is sufficient to significantly decrease cortical excitability, while higher output currents 
(0.50 and 1.00 mA) do not result in an additional therapeutic effect. Our results suggest that the 
output current intensities may quickly reach a saturation level in terms of therapeutic effectiveness 
and that higher output current intensities are not required to reach significant effects on cortical 
excitability. Considering the previous study from our lab by De Herdt et al. [49], the VNS-induced 
reduction in cortical excitability in the motor cortex stimulation rat model has proven to be very 
reproducible. Therefore, future VNS studies in this model are warranted. Follow-up studies should 
assess whether even lower output currents (< 0.25 mA) are sufficient to reduce cortical excitability. 
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Other stimulation parameter settings including the stimulation frequency, pulse width and duty cycle 
could be optimized using this model.  
The results from our preclinical study raise the hypothesis that low VNS output current intensities 
could be equally sufficient in reducing cortical excitability in humans. However, a direct translation of 
these output currents to clinical practice is hampered by several factors, including the much smaller 
diameter of the rat vagus nerve compared to the human nerve and the use of different electrode 
types, i.e. cuff versus helical electrodes in rats and humans respectively. Therefore, a clinical trial 
should be performed to assess the effect of different VNS output currents on cortical excitability. 
Similarly as in the motor cortex stimulation rat model, cortical excitability of the motor cortex can be 
assessed in humans. However, instead of using electrical currents as is being done in rats, 
transcranial magnetic stimulation (TMS) can be applied to assess cortical excitability in humans. TMS 
stimuli are delivered through a coil placed over selected scalp locations overlying the primary motor 
cortex. These stimuli mainly activate pyramidal neurons transsynaptically, which produces indirect 
waves descending along the corticospinal fibers. Applied over the motor cortex, these discharges 
produce a twitch in the corresponding muscles. This muscle activity, referred to as a motor-evoked 
potential (MEP), can be recorded using electromyography (EMG) from many muscles, including the 
small muscles of the hand [51, 52]. Future prospective clinical studies using TMS and comparing high 
versus low VNS output current intensities are required to confirm the hypothesis that low output 
currents are sufficient to reduce cortical excitability, eventually leading to antiepileptic effects in 
humans. 
Additional evidence supporting the hypothesis that low output currents are sufficient to activate the 
vagus nerve, was found in the LMEP studies presented in this thesis. Effective delivery of current to 
the vagus nerve at the cervical level, co-activates the Aα-fibers of the recurrent laryngeal nerve and 
induces contractions of the laryngeal muscles and the vocal cords. In this context, a previous study 
from our laboratory has recorded LMEPs in rats in an acute intra-operative setting using invasive 
electrodes [53]. For chronic VNS studies, a less invasive, reliable technique for LMEP recordings is 
required (i) to determine the optimal stimulation output current to activate the relevant fibers, (ii) to 
exclude rats where electrical current delivery to the vagus nerve is doubtful and (iii) to identify the 
optimal moment for initiation of the experiment. Therefore, we aimed at investigating in a chronic 
experimental setting, the feasibility and reliability of LMEP recordings using a minimally invasive, 
easy-to-use EMG tool. In a second phase, we aimed at translating this technique to clinical practice.  
We found that VNS-induced LMEPs can be reproducibly recorded in chronically VNS-implanted 
experimental rats and that these LMEPs occur at low stimulation intensities (median 0.2 mA, IQR: 
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0.2-0.3 mA). At significantly higher stimulation intensities (median 0.7 mA, IQR 0.5-0.7 mA, p<0.001), 
the responses had significantly higher or lower latencies than expected for an LMEP, pointing at 
nerve damage and direct muscle activation due to current spill-over respectively. In chronically VNS-
implanted patients as well, LMEPs were recorded with very high reproducibility. These LMEPs were 
already present at low output currents (0.25 - 0.50 mA) and the amplitude of the signals reached a 
plateau around 0.75 - 1.00 mA. Combined, these results again support the hypothesis that low to 
moderate stimulation currents are sufficient to activate the vagal fibers. There is a growing body of 
evidence, both from preclinical and clinical studies that further supports this hypothesis. Cunningham 
et al. found that VNS at 0.25 mA in rats significantly increases staining for c-fos, an indirect marker 
for neuronal activity, in the nucleus tractus solitarius and many other regions that receive projections 
from the vagus nerve [54]. Furthermore, Woodbury and Woodbury showed that VNS at 0.20 - 0.50 
mA reduces chemically-induced seizures in rats [55]. Moreover, in vivo intracellular recordings in the 
temporal association cortex of rats, showed that VNS output currents of 0.20 mA or less, are 
effective in reducing the excitability of pyramidal neurons [56]. Interestingly, it was shown that VNS 
at 0.25 mA and 0.30 mA significantly increases the firing rate of the serotonergic neurons of the 
dorsal raphe nucleus [20] and of the noradrenergic neurons of the LC [57] respectively. In clinical 
studies as well, it was shown that low VNS output currents are sufficient to achieve intracerebral 
effects. In functional neuroimaging studies by our own group, acute VNS at an output current of 0.25 
mA, induced significant cerebral blood flow changes, particularly in the thalamus and the limbic 
system [58, 59]. Furthermore, it was shown that VNS at low output current intensities is effective in 
enhancing recognition memory in humans [60] and in the effect on human tolerance for pain [61]. 
Moreover, analyses of large patient series have not demonstrated a positive correlation between 
output current intensities and seizure control. More specifically, it was shown by Bunch et al. that 
many VNS-treated patients respond to VNS at low output currents (< 1.00 mA) while higher output 
currents (≥ 1.00 mA) do not necessarily lead to a greater reduction in seizure frequency. On the other 
hand, 20% of the initial non-responders from that study became responders when the VNS output 
current was increased [62]. However, the possibility exists that this improvement did not result from 
the increase in output current, but rather from neuromodulatory changes that require time to 
establish. A retrospective study by Labar et al. evaluated the effect of output current on seizure 
frequency in 269 patients who had not changed their antiepileptic medication over a 1-year period. 
Output currents were classified as low (0.25 - 1.00 mA), medium (1.25 - 2.00 mA) or high (≥ 2.25 mA). 
Patients receiving VNS at high output currents experienced a smaller reduction in seizure frequency 
(median 38%) than those with low (median 64%) or medium (median 61%) output currents. The 
results from this study again suggest that low and moderate output currents are sufficient or even 
beneficial to achieve therapeutic effects [63]. However, this study could be confounded by the fact 
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that initial responders are less likely to undergo an increase in output current compared to non-
responders. Therefore, future randomized controlled clinical trials of sufficient duration (e.g. 1 year 
of follow-up), comparing high versus low to moderate output current intensities are required to 
confirm the hypothesis that low to moderate output currents are sufficient or even beneficial in 
exerting therapeutic effects in humans. 
This large body of evidence both in animals and humans suggesting that low or moderate VNS output 
currents might be sufficient to achieve therapeutic effects, is consistent with the knowledge on the 
anatomy of the vagus nerve. The nerve contains three types of fibers, i.e. A-, B- and C-fibers, 
distinguished by their diameter and conduction velocity. The A- and B-fibers are myelinated and have 
a large and intermediate diameter respectively. The C-fibers are unmyelinated and have a small 
diameter. Subsequently, the A-, B- and C-fibers have a low (< 0.20 mA), intermediate (< 0.40 mA) and 
high (> 2.00 mA) threshold for activation respectively [57]. The earliest animal studies suggested that 
the antiepileptic potential of VNS was directly related to the fraction of vagal afferent C-fibers 
stimulated [55, 64]. However, the theory supporting C-fiber involvement was discarded after Krahl et 
al. demonstrated VNS-induced seizure suppression in rats following selective C-fiber destruction [65]. 
Based on this and other studies [6, 46, 62, 66], it is conceivable that the A- and B-fibers are 
responsible for the therapeutic effects of VNS and subsequently, low and intermediate output 
currents should be sufficient to evoke therapeutic responses. Apart from reducing stimulation-
related side effects, stimulating the vagus nerve with a lower output current density would be 
beneficial in the sense that it would save battery life, thereby postponing the surgical procedure and 
costs for battery replacement. 
However, it must be acknowledged that one general optimal stimulation current cannot be defined. 
This is reflected in our results by the fact that the output currents required to evoke LMEPs in rats 
are variable and range from 0.10 to 0.30 mA, and even to 0.50 mA in one animal. Individual 
thresholds for the activation of vagal A- and B-fibers will vary as a result from differences in the 
anatomy of the vagus nerve, i.e. fibers located closer to the perimeter of the nerve and thus closer to 
the VNS electrode are exposed to a stronger electrical field and are easier to excite compared to 
fibers located deeper in the nerve. Also, fibrous tissue encapsulation at the site of the electrode can 
increase resistance, altering the electric field and resulting in increased voltage requirements for 
fiber excitation [67, 68]. It was shown by Helmers et al. that the presence of 110 µm of fibrotic tissue 
can decrease fiber activation by 50% [68]. Furthermore, LMEP recordings may underestimate the 
VNS output current required to achieve therapeutic efficacy as it reflects the activity of the low 
threshold Aα-motor fibers, while the therapeutic effects of VNS are believed to be mediated by 
higher threshold A- and B-fibers. Nevertheless, it is well-known that physiological features such as 
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fiber diameter, activation sensitivity to electrical stimulation, action potential conduction velocity 
and function are all closely related [69]. When the threshold to one specific fiber type can be reliably 
recorded, it can be used as an indicator to determine the expected threshold for all other fibers. The 
threshold stimulation strength to produce LMEPs is thus directly related to the required therapeutic 
VNS stimulus strength. The value of the ratio between both stimulus strengths still has to be 
established, for example by correlating LMEP recordings with intracerebral effects, i.e. unit 
recordings from the LC. However, given that the variation in activation sensitivity with fibre diameter 
is rather limited in the large diameter range [70], we expect to find a ratio value close to unity 
between the LMEP threshold stimulation current and efficient therapeutic VNS output currents. 
Therefore, we suggest that the presented non-invasive LMEP recording technique could be used to 
guide individual titration of the stimulation parameters.  
Furthermore, we suggest that this minimally invasive, easily-applicable method could be a valid tool 
to identify non-responders due to ineffective activation of the vagus nerve and to determine 
individual post-operative recovery periods. It is possible that the vagus nerve of some non-
responders is not adequately activated, for multiple reasons such as lead failure, poor electrode 
contact or nerve damage. It has previously been shown that the implantation of cuff electrodes in 
rabbits causes an initial loss of myelination, with a subsequent regeneration of the myelin sheath 
over several weeks to months [71]. In animals with more severe damage to the myelin sheath, a 
longer postoperative recovery period before initiating VNS is warranted. However, the usually 
applied recovery delays in experimental studies are determined rather empirically and are typically 
the same for all animals in one study. In a previous study from our lab, 13/21 rats displayed a 
recordable LMEP 2 to 4 weeks after surgery. In the remaining rats, a post-surgical recovery period of 
up to 7 weeks was required before an LMEP could be recorded [72]. In the presented preclinical 
LMEP trial, significantly higher latencies of the LMEPs were recorded in 4/27 rats, which suggests an 
incomplete recovery of the vagus nerve after surgery in these animals. Furthermore, the total 
absence of an LMEP in 3/27 rats, could likewise result from a dysfunctional nerve. Consequently, rats 
with longer latency LMEPs or without LMEPs should be excluded from the experiment, as the 
adequate delivery of current to the nerve is doubtful in these animals, while this is obviously a 
prerequisite to obtain reliable experimental results. In clinical practice as well, a temporary paresis of 
the vocal cords after VNS surgery [73-75] indicates that the surgical procedure and implantation of 
the electrode can cause nerve damage and a transient failure of the vagus nerve, hence requiring a 
recovery period before becoming functional again [72]. To allow recovery of the nerve, a delay of 
two weeks is usually foreseen between the implantation of the system and the start of VNS. Again, 
the duration of this delay is determined rather empirically, while an individualized approach, based 
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on the recovery of the nerve could be beneficial. The absence of an LMEP at reasonable stimulation 
currents or a prolonged latency of the LMEP could indicate incomplete recovery of the nerve. In that 
case, a further rest period might be beneficial for the nerve and more easily accepted then 
unsuccessful trials. Of course, non-response could also result from the heterogeneity of the 
underlying pathophysiological mechanisms or the variability in characteristics of more central 
structures in the neural pathway involved in VNS. In this regard, genetic differences in 
neurotransmitter systems could be an example of hypotheses to consider. Therefore, the presence of 
LMEPs is not an identifier of response nor is it a biomarker for the anti-epileptic or antidepressant 
efficacy of VNS but rather an indication that the nerve is effectively stimulated, which is an essential 
step to achieve therapeutic response. This is reflected in our data by the fact that both patients 
display LMEPs while only one of them is a responder. Non-response in the other patient despite the 
proper activation of the vagus nerve as reflected by the presence of LMEPs, could result from 
upstream problems such as an impaired noradrenergic signaling. 
In conclusion, VNS-induced LMEPs can be recorded very reproducibly both in chronically VNS-
implanted rats and patients using a non-invasive EMG approach. Furthermore, our results suggest 
that low to moderate output currents are sufficient to activate the vagal fibers. Moreover, LMEPs 
could be used for the identification of ineffective stimulation leading to non-response and for the 
individualization of post-operative recovery delays. 
Future studies should focus on the optimization of this technique in awake animal models for 
depression, epilepsy or the comorbidity of both disorders, as there might be an effect of general 
anesthetics on axonal excitability [76]; the expansion of our sample size in the clinical epilepsy pilot 
trial; a clinical trial in a patient population suffering from refractory depression; the identification of 
the ratio between the output current threshold for Aα- and other A- and B-fiber activation and the 
correlation of LMEP recordings with therapeutic responses both in epileptic and depressed 
experimental animals and human subjects. 
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Summary 
 
Epilepsy and depression are two highly prevalent disorders, that frequently occur together. Despite 
the availability of an abundance of both antiepileptic and antidepressant drugs, up to one third of 
patients fail to respond adequately to standard medication and are classified as refractory. 
Furthermore, current treatment options for patients suffering from both epilepsy and depression are 
limited by the fact that antiepileptic drugs can contribute to mood disturbances, while 
antidepressant drugs can increase seizure susceptibility. The lack of success with current 
pharmacological interventions for patients suffering from refractory epilepsy, depression or the 
combination of both diseases, highlights the importance of optimizing non-pharmacological, 
neuromodulatory treatments such as vagus nerve stimulation (VNS) for this patient population. 
VNS is an extracranial form of neurostimulation which consists of stimulating the left vagus nerve in 
the neck through an implanted electrode and a pulse generator. Since the first patient was implanted 
with a VNS device in 1988, more than 100.000 patients worldwide have been treated with VNS. 
Although VNS appears to be an efficacious and safe treatment, some unresolved questions remain to 
counteract its full therapeutic potential. First, mood improvements in epilepsy patients treated with 
VNS, irrespective of the effects on seizure frequency, provided the initial rational for using VNS for 
the treatment of refractory depression. However, randomized controlled trials confirming the 
antidepressant effect of VNS in epileptic subjects are lacking. Furthermore, the mechanism of action 
is still unknown, optimal stimulation parameters remain elusive and about one third of patients do 
not benefit from the treatment (non-responders). Therefore, the research presented in this thesis 
focused on assessing the antidepressant potential of VNS in an animal model for temporal lobe 
epilepsy and comorbid depression, unraveling its antidepressant mechanism of action and optimizing 
the stimulation parameters, which could all contribute to improving clinical outcome in the long run. 
The first experimental study consisted of a proof-of-concept experiment in which the antidepressant 
effect of VNS was confirmed in the post status epilepticus kainic acid rat model for temporal lobe 
epilepsy and comorbid anhedonia, the latter being a key symptom of major depression. Future 
clinical studies should be performed to assess whether our findings can be translated to patients. 
Confirmation of the pre-clinical results in patients could lead to the choice of VNS as a preferred 
treatment for patients suffering from comorbid epilepsy and depression. 
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The second study was designed to unravel the antidepressant mechanism of action of VNS. Since the 
1960s, there has been a strong emphasis on the role of the locus coeruleus (LC) and its 
neurotransmitter noradrenaline in the mechanism of action of several antidepressants. There is 
extensive evidence demonstrating that like antidepressants, VNS enhances the noradrenergic 
neurotransmission through the activation of the LC. Therefore, we tested the hypothesis that the 
VNS-induced antidepressant effect in the rat forced swim test is mediated through the activation of 
the LC. For this purpose, the noradrenergic LC neurons were lesioned using the highly selective 
neurotoxin DSP-4. The complete abolishment of the antidepressant effect of VNS in DSP-4-treated 
rats, confirmed the key role of the LC in the antidepressant mechanism of action of VNS. Future 
studies are warranted to unravel the upstream mechanisms by which the VNS-induced activation of 
the LC exerts its antidepressant effect. Hypotheses to consider are the upregulation of hippocampal 
neuroplasticity and the secondary enhancement of other neurotransmitter systems involved in 
depression, i.e. the serotonergic and dopaminergic neurotransmission. 
 
With regards to the stimulation parameters, we found that VNS at an output current of 0.25 mA is 
sufficient to decrease cortical excitablity in rodents, while higher output currents (0.50 and 1.00 mA) 
do not result in an additional therapeutic effect. Further evidence supporting the hypothesis that low 
to moderate output currents are sufficient to activate the vagus nerve and produce therapeutic 
effects, came from the laryngeal motor-evoked potential or LMEP studies. VNS-induced LMEPs – 
reflecting effective activation of the vagal fibers – were recorded very reproducibly both in 
chronically VNS-implanted rats and patients using a non-invasive electromyography approach. In 
rats, these LMEPs occurred at low stimulation intensities (median 0.20 mA, IQR 0.20 - 0.30 mA). At 
higher stimulation intensities (median 0.70 mA, IQR 0.50 - 0.70 mA), the responses had significantly 
higher or lower latencies than expected for an LMEP, pointing at nerve damage and direct muscle 
activation due to current spill-over respectively. In a pilot trial in patients, LMEPs were already 
recorded at low output currents (0.25 - 0.50 mA). Consistent with our findings, there is a growing 
body of evidence, both in animals and in humans, suggesting that low to moderate output currents 
are sufficient to achieve intracerebral effects. However, future prospective studies comparing low 
versus high output current intensities are required to confirm this hypothesis. Furthermore, we 
suggest that LMEP recordings could be used for the identification of ineffective stimulation of the 
vagus nerve, leading to non-response. To test this hypothesis, future studies should correlate LMEP 
recordings with therapeutic responses both in experimental animals and in human subjects. 
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Samenvatting 
 
Epilepsie en depressie zijn twee aandoeningen met een hoge prevalentie, die bovendien frequent 
samen voorkomen. Ondanks het correct gebruik van anti-epileptica en antidepressiva, blijft één 
derde van de patiënten epileptische aanvallen en/of depressieve symptomen ervaren. Deze 
patiënten lijden aan moeilijk behandelbare of refractaire epilepsie of depressie. Bovendien zijn de 
behandelingsmodaliteiten die vandaag beschikbaar zijn voor patiënten die zowel lijden aan epilepsie 
als depressie, beperkt door het feit dat anti-epileptica een negatieve invloed kunnen hebben op het 
gemoed, terwijl antidepressiva de gevoeligheid voor epileptische aanvallen kunnen verhogen. Het 
gebrek aan succes met de beschikbare farmacologische behandelingen voor patiënten die lijden aan 
refractaire epilepsie, depressie of de comorbiditeit van beide aandoeningen, onderstreept het belang 
van het optimaliseren van niet-farmacologische, neuromodulatoire behandelingen zoals nervus 
vagus stimulatie (NVS). 
NVS is een extracraniële vorm van neurostimulatie waarbij de linker nervus vagus in de nek 
gestimuleerd wordt via een geïmplanteerde elektrode en een pulsgenerator. De eerste NVS 
implantatie bij een epilepsiepatiënt vond plaats in 1988. Sindsdien worden wereldwijd reeds meer 
dan 100.000 patiënten behandeld met deze therapie. Ondanks de bewezen doeltreffendheid en 
veiligheid van NVS, dienen nog een aantal aspecten rond deze therapie opgehelderd te worden. Zo 
merkte men op dat NVS in epilepsiepatiënten een positief effect heeft op het gemoed, onafhankelijk 
van het effect op de epileptische aanvallen. Deze bevinding heeft geleid tot het gebruik van NVS voor 
de behandeling van refractaire depressie. Tot op heden zijn er echter nog geen gerandomiseerde, 
gecontroleerde studies voor handen die aantonen dat NVS daadwerkelijk een antidepressief effect 
heeft in epilepsiepatiënten. Bovendien zijn het werkingsmechanisme en de optimale 
stimulatieparameters nog steeds niet gekend. Daarenboven ervaart één derde van de patiënten geen 
therapeutisch voordeel van de behandeling (non-responders). Dit proefschrift richt zich op het 
onderzoeken van het antidepressief effect van NVS in een diermodel voor epilepsie en comorbide 
depressie, het ontrafelen van het antidepressief werkingsmechanisme en het optimaliseren van de 
stimulatieparameters, met als uiteindelijk doel het verbeteren van de klinische uitkomst. 
  
In de eerste experimentele studie werd bevestigd dat NVS een antidepressief effect heeft in het 
kainaat rat model voor temporale kwab epilepsie en comorbide anhedonie, een kernsymptoom van 
majeure depressie. Prospectieve klinische studies zijn nodig om na te gaan of deze bevinding vertaald 
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kan worden naar patiënten. De bevestiging van de preklinische resultaten in patiënten zou ertoe 
kunnen leiden dat NVS als standaard behandeling wordt gebruikt voor patiënten die lijden aan de 
comorbiditeit van epilepsie en depressie. 
 
De tweede studie van dit proefschrift onderzocht het antidepressief werkingsmechanisme van NVS. 
Sinds de jaren ‘60 ligt een sterke nadruk op de rol van de locus coeruleus (LC) en zijn voornaamste 
neurotransmitter noradrenaline, in het werkingsmechanisme van verschillende antidepressiva. Er zijn 
sterke aanwijzingen dat de LC en noradrenaline ook een belangrijke rol spelen in het 
werkingsmechanisme van NVS. Daarom werd nagegaan of het antidepressief effect van NVS in de 
“rat forced swim test” gemedieerd wordt door de activatie van de LC. Om dit te onderzoeken werd 
een selectieve laesie gemaakt in de noradrenerge neuronen van de LC met behulp van het selectief 
neurotoxine DSP-4. Het volledig verdwijnen van het antidepressief effect van NVS in DSP-4-
behandelde dieren, bevestigt de rol van de LC in het werkingsmechanisme van NVS. Toekomstige 
studies zijn nodig om te onderzoeken welke mechanismes upstream van de NVS-geïnduceerde LC 
activatie verantwoordelijk zijn voor het antidepressief effect van NVS. Plausibele hypotheses zijn de 
opregulatie van hippocampale neuroplasticiteit en van andere neurotransmitters die belangrijk zijn in 
de pathofysiologie en de behandeling van depressie, bvb. serotonine en dopamine.  
Met betrekking tot de stimulatieparameters, kon besloten worden dat NVS aan een intensiteit van 
0.25 mA volstaat om de corticale exciteerbaarheid significant te verlagen in het motor cortex 
stimulatie rat model, terwijl hogere stimulatie intensiteiten (0.50 en 1.00 mA) niet resulteren in een 
additioneel therapeutisch effect. Verdere evidentie dat lage tot matige NVS-intensiteiten voldoende 
zijn om de nervus vagus te activeren en therapeutische effecten te bekomen, komt van de “laryngeal 
motor-evoked potential of LMEP” studies. NVS-geïnduceerde LMEPs – die de efficiënte activatie van 
de vagale vezels reflecteren – werden op een zeer reproduceerbare, niet-invasieve manier gemeten 
zowel in ratten als in patiënten. In ratten werden deze LMEPs reeds gemeten bij zeer lage stimulatie 
intensiteiten (mediaan 0.20 mA, IQR 0.20 - 0.30 mA). Bij hogere stimulatie intensiteiten (mediaan 
0.70, IQR 0.50 - 0.70 mA), werden de responsen gekarakteriseerd door significant hogere of lagere 
latenties dan men zou verwachten voor een LMEP. Deze afwijkende latenties wijzen respectievelijk 
op zenuwschade en directe spieractivatie door lekstroom. Ook in een klinische piloot studie werden 
LMEPs gemeten bij lage NVS-intensiteiten (0.25 – 0.50 mA). Deze bevindingen worden ondersteund 
door verschillende dierexperimentele en humane studies die suggereren dat lage tot matige NVS-
intensiteiten voldoende zijn voor het bekomen van positieve effecten in de hersenen. Om deze 
hypothese te bevestigen zijn prospectieve klinische studies nodig die het effect van lage versus hoge 
NVS-intensiteiten vergelijken. De resultaten van de gepresenteerde LMEP-studies suggereren dat 
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LMEP-metingen in de toekomst zouden kunnen gebruikt worden voor het identificeren van 
inefficiënte activatie van de nervus vagus, wat leidt tot non-response. Om deze hypothese te testen 
zijn studies verreist die LMEP-metingen correleren met de therapeutische respons van NVS, zowel in 
proefdieren als in patiënten.  
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Résumé 
 
 
L'épilepsie et la dépression sont des maladies très prévalentes, qui peuvent fréquemment se 
présenter simultanément. Malgré la disponibilité des traitements antiépileptiques et 
antidépresseurs, un tiers des patients continuent à avoir des crises d’épilepsie ou des symptômes 
dépressifs. Ces patients sont considérés ‘réfractaires au traitement’. En outre, les médicaments 
utilisés dans la prise en charge de chacune de ces pathologies peuvent avoir une influence négative 
l’un sur l’autre: les médicaments antiépileptiques peuvent aggraver la dépression, tandis que les 
antidépresseurs peuvent diminuer le seuil épileptogène. Vu l’efficacité limitée des traitements 
pharmacologiques sur les patients souffrant d’épilepsie et/ou de dépression réfractaire, il est 
important d’optimiser d’autres modalités thérapeutiques non-pharmacologiques. En particulier la 
stimulation du nerf vague (SNV), afin d’améliorer la qualité de la prise en charge de ces maladies. 
La SNV est une forme de neurostimulation extra-crânienne, qui consiste à stimuler le nerf vague au 
niveau cervical, au moyen d'une électrode de stimulation reliée à un générateur d'impulsions. Le 
premier implant humain a été réalisé en 1988. De nos jours, plus de 100.000 patients bénéficient de 
ce traitement dans le monde. Malgré l'efficacité et la sécurité établie de la SNV, certaines questions 
spécifiques au sujet de ce traitement restent non résolues. Tout d'abord, l'amélioration de la qualité 
de vie des patients épileptiques traités avec la SNV, indépendamment des effets sur la fréquence les 
crises, a fourni la justification de l'utilisation de cette technique pour le traitement de la dépression 
réfractaire. Toutefois, des études randomisées contrôlées confirmant l'effet antidépresseur de la SNV 
chez les sujets épileptiques, ne sont pas encore disponibles. En outre, le mécanisme d'action et les 
paramètres d’une stimulation optimale ne sont pas encore définis. En effet, environ un tiers des 
patients ne réagissent pas au traitement (‘non-responders’). Cette thèse a pour but d’évaluer le 
potentiel antidépresseur de la SNV dans un modèle animal présentant une pathologie comorbide 
reflétant l’épilepsie et la dépression, de comprendre le mécanisme impliqué dans l’action 
antidépressive et d’optimiser les paramètres de stimulation afin de contribuer à l’amélioration des 
résultats cliniques. 
 
Dans notre première étude expérimentale, l'effet antidépresseur de la SNV a été confirmé dans le 
modèle de rat à acide kaïnique pour la comorbidité épilepsie et anhédonie, celle-ci étant un 
symptôme de la dépression majeure. Cependant, des essais cliniques devront être effectués afin de 
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déterminer si ces résultats peuvent être utilisés dans la prise en charge des patients. Si cela devait 
être le cas, la SNV pourrait être proposée comme traitement standard pour les patients souffrant 
d'épilepsie et de dépression de façon comorbide. 
 
La deuxième étude avait pour but de mieux comprendre le mécanisme d’action de la SNV. Depuis les 
années 1960, de nombreuses recherches ont été effectuées, évaluant le rôle du locus coeruleus (LC) 
et son neurotransmetteur la noradrénaline, dans le mécanisme d'action de plusieurs 
antidépresseurs. En effet, plusieurs données de la littérature soutiennent qu’au même titre que les 
antidépresseurs, la SNV améliore la neurotransmission noradrénergique grâce à l'activation du LC. 
Par conséquent, nous avons testé l'hypothèse que l'effet antidépresseur de la SNV dans le ‘rat forced 
swim test‘ est médié par l'activation du LC. Dans ce cadre, les neurones noradrénergiques du LC ont 
été lésés en utilisant le DSP-4, une neurotoxine hautement sélective. Dans les rats traités avec le 
DSP-4, l’effet antidépresseur de la SNV était supprimé, confirmant le rôle très important du LC dans 
le mécanisme d'action antidépresseur de la SNV. Des études complémentaires sont nécessaires afin 
de comprendre les mécanismes d’action, par lesquels l'activation du LC induite par la SNV, exerce son 
effet antidépresseur. Plusieurs hypothèses peuvent être émises comme l’augmentation de la 
neuroplasticité hippocampique et le renforcement secondaire d'autres neurotransmetteurs 
impliqués dans la dépression, par exemple la neurotransmission sérotoninergique ou 
dopaminergique. 
 
En ce qui concerne les paramètres de stimulation, nous avons constaté que la SNV à 0.25 mA est 
suffisante pour diminuer l’excitabilité corticale chez les rats, tandis que les intensités de courant plus 
élevées (0.50 et 1.00 mA) n’avaient aucun effet thérapeutique supplémentaire. Par ailleurs, des 
études dans lesquelles on a enregistré des potentiels laryngés évoqués moteur (ou des LMEPs) 
soutiennent l’hypothèse que des courants faibles à modérés sont suffisants pour activer le nerf 
vague et produire des effets thérapeutiques. Les LMEPs, qui reflètent l’activation efficace des fibres 
vagales, ont été enregistrés de manière reproductible chez les rats et les patients en utilisant une 
approche d'électromyographie non-invasive. Chez les rats, ces LMEPs étaient enregistrés à des 
intensités de stimulation faibles (médiane 0.20 mA, IQR 0.20 – 0.30 mA). A des intensités de 
stimulation plus hautes (médiane 0.70 mA, IQR 0.50 - 0.70 mA), les réponses avaient des latences 
significativement plus élevées ou plus basses que prévu pour un LMEP, témoignant respectivement 
de lésions du nerf vague ou de l'activation musculaire directe. Ces résultats expérimentaux sont 
soutenus par un essai clinique pilote, ou les LMEPs ont pu être enregistrés à des intensités faibles 
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(0.25 – 0.50 mA). Nos résultats concordent avec ceux déjà réalisés tant sur les modèles animaux que 
chez les humains, ce qui soutient l’hypothèse que des intensités de stimulation faibles à modérés 
sont suffisantes pour obtenir un effet intracérébral. Pour confirmer cette hypothèse, des essais 
cliniques prospectifs comparant différentes intensités seront nécessaires. En outre, nous suggérons 
que les enregistrements d’LMEPs pourraient être utilisés afin d’identifier la stimulation inefficace du 
nerf vague, qui pourrait résulter en une non-réponse. Pour tester cette hypothèse, des futures 
études devront corréler l’enregistrement d’LMEPs à des réponses thérapeutiques dans des modèles 
animaux et chez des sujets humains. 
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Dankwoord 
 
 
Het dankwoord, wellicht het favoriete stuk van deze thesis voor velen. Maar hoe begin je daar in 
godsnaam aan? Ik zou een extra thesis kunnen schrijven over alle mensen die op een of andere 
manier hebben bijgedragen aan het tot stand komen van dit werk, want een thesis schrijf je niet 
alleen. Ik kan me niet herinneren hoeveel mensen mij gedurende de voorbije vier jaar gevraagd 
hebben: “en hoe gaat het met je onderzoek, vlot het een beetje?”. Al kan ik onmogelijk al deze 
mensen opnoemen, ik wil hen allemaal van harte bedanken, want deze blijken van interesse hebben 
me enorm veel deugd gedaan!  
In het bijzonder wil ik graag mijn promotor en co-promotor, Prof. Dr. Paul Boon en Prof. Dr. Kristl 
Vonck bedanken voor de kans die ik kreeg om onderzoek te doen in het LKEN3. Prof. Boon, ik 
herinner mij ons eerste gesprek nog alsof het gisteren was. Ik had net een super thesisjaar achter de 
rug en was dan ook dolenthousiast toen u mij vroeg of ik het zag zitten om nog een jaartje of vier 
verder te doen. U vertelde er onmiddellijk bij dat doctoreren niet de gemakkelijkste weg is om in te 
slaan. Eerlijkheidshalve dacht ik op dat moment dat het wel nog zou meevallen, maar het werd me al 
snel duidelijk dat u gelijk had. Bedankt dat ik deel mocht uitmaken van uw onderzoeksteam! Prof. 
Vonck, de kritische inbreng op de peer reviews, het vele nalees- en verbeterwerk, het beantwoorden 
van de talloze mails en de nodige duwtjes in de rug hebben in grote mate bijgedragen aan het 
eindresultaat. Zonder u was het mij niet gelukt, een welgemeende dankjewel voor alles wat u voor 
mij gedaan heeft! 
Prof. Robrecht Raedt, bedankt voor de zes voorbije jaren! Al tijdens mijn thesis had ik door dat jij 
een rasechte wetenschapper bent. Ik ken dan ook niemand die wetenschappelijke nieuwtjes zoals 
optogenetics en DREADDs zo sexy vindt als jij. Onze communicatie verliep niet altijd vlekkeloos, maar 
desalniettemin apprecieer ik enorm wat je allemaal voor het labo doet. Bovendien ben ik nog steeds 
verwonderd over de aura die je over je hebt waarbij dingen die maar niet willen lukken plots wel 
lukken wanneer jij erbij staat, ook al deden we net hetzelfde als voordien… Ik ben er dan ook van 
overtuigd dat we nog veel zullen horen over jou. Misschien ooit in het stadhuis van Stockholm? 
Dear Jeanelle, thank you so much for all the support, both intellectually and emotionally. You joined 
the lab at the moment where I had been struggling with the DSP-4 injections for ages. I was at the 
point where I thought it would never work and I started to feel anhedonic myself . You convinced 
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me that I could make it if I didn’t give up… and you were right! I appreciate your bubbly personality, 
your empathy, your determination, your problem solving way of thinking and so much more. Grazzi 
għal kollox! 
 
Prof. Dr. Jean Delbeke, uw enthousiasme en grenzeloze kennis over alles wat met stimulatie en 
elektriciteit te maken heeft, ik heb er geen woorden voor. Dankzij u werd ik geprikkeld door 
elektrofysiologie en werd het LMEP werk terug het leven ingeblazen dat het verdient! U stond altijd 
klaar om al mijn vragen te beantwoorden, zowel in het labo als gezellig in het zonnetje op het terras 
bij u thuis. Bedankt voor alle fijne en leerrijke momenten! Ook Prof. Dr. Wytse Wadman zou ik graag 
bedanken, voor de constructieve input op de vele peer reviews. 
I would like to thank the members of the examination and reading board – Prof. Dr. Luc Martens, 
Prof. Dr. Elinor Ben-Menachem, Prof. Dr. Bert Aldenkamp, Prof. Dr. Chris Baeken, Prof. Dr. Evert 
Thiery, Prof. Dr. Yasin Temel, Dr. Vincent Keereman and Dr. Valentine Martlé, for the time and 
effort they have put in reading and evaluating this thesis. Ook veel dank aan de administratief 
secretaris, Christian Maes en de decaan van onze faculteit, Prof. Guy Vanderstraeten, voor hun 
bijdrage. 
Een woordje van dank voor de dierenarts Dr. Ingrid Van Overbeke, alle medewerkers van het 
animalarium en de dierenverzorgers is hier zeker ook op zijn plaats. Bedankt voor alle goede zorgen 
voor de ratjes, jullie leveren prachtig werk! Een dikke merci ook aan alle medewerkers van het 
secretariaat, in het bijzonder Corine en Elsie, die er steeds voor zorgden dat alles vlotjes verliep. 
bedankt om alle administratieve zaken in goede banen te leiden! Was het nu UGent of UZ? Chapeau 
dat jullie het hoofd zo koel konden houden bij alle bestelbonnen en contracten waar wel eens twijfel 
over bestond. Ook alle andere leden verbonden aan de dienst die op een of andere manier hebben 
bijgedragen aan het tot stand komen van dit werk wil ik bedanken. Evelien, Veerle, Alfred, Marijke, 
Dimitri, Stefanie, Yuliana, Riëm, medisip, de doctoraatstudenten van de K12 … voor het nalezen van 
artikels, constructieve input op de peer reviews, het netjes houden van onze gebouwen, de leuke 
babbels,…. 
En dan zijn we aanbeland bij de beste, liefste, leukste collega’s van de hele wereld. Ik wil jullie stuk 
voor stuk bedanken voor de vier intense jaren die we samen beleefden in het labo en daarbuiten. 
Bregt, aka Bregma, je stond altijd klaar om iedereen te helpen, niets was je ooit te veel! Ook op 
persoonlijk vlak ben je een topkerel, daar ben ik meerdere malen getuige van mogen zijn, onder 
andere in Stockholm (ik zal niet in detail treden ). Ik bewonder je doorzettingsvermogen en je 
positieve ingesteldheid. Het ga je goed in je nieuwe job en ik ben ervan overtuigd dat onze wegen 
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zich nog zullen kruisen! Diego, aka Didi, je leerde ons dat spanbandjes en duct tape niet de oplossing 
zijn voor alle problemen. Je creativiteit bereikte een hoogtepunt toen je een levensgroot pincet 
maakte om iets uit het vloeibaar stikstofvat te vissen. Ik krijg nog steeds de slappe lach als ik daaraan 
terug denk. Ondanks het feit dat je niet meer bij ons werkte, konden we altijd op je blijven rekenen, 
merci daarvoor! Eline, aka Drs. Blankets, wat was ik blij toen ik ontdekte dat er nog eens een 
rasechte West-Vlaamse het LKEN3-team kwam versterken. Hoewel ik moet toegeven dat de andere 
collega’s hun uiterste best doen om onze wereldtaal te begrijpen, en ja, soms zelfs te (proberen) 
spreken, het doet toch deugd om ook op het UZ nog eens echt West-Vlams te keun klappen. Bedankt 
daarvoor! Ine Buffel, aka Indra, je was een crème van een collega waar ik veel leuke herinneringen 
aan overgehouden heb: een dagje shoppen in Brugge, samen spaghetti eten, achtervolgd worden 
door de hond van Jonas, je instuif... Ik vond het echt super dat we getuige mochten zijn van je 
huwelijk en de geboorte van de eerste LKEN3-baby Fenne. Ine Dauwe, aka the Queen of histology, 
met voorsprong het lid van LKEN3 met het grootste oog voor detail. Bedankt voor het nalezen van 
mijn teksten, de vele praktische zaken die je mij geleerd hebt in het labo, de vele leuke babbels en de 
overheerlijke aardbeien! Jeroen, bedankt dat we altijd bij jou terecht konden met onze computer 
vragen! Lars, aka Mr. chicken-white (sorry for that ), you are definitely the coolest, smartest and 
funniest Danish guy I know! I’m so happy we got to develop our personal Dunglish, again an extra 
language to put on our CV! I think you should seriously consider combining your scientific career with 
a singer-songwriter career. I will be on the first row when you play in the Royal Albert Hall and Noel 
Gallagher warms up the audience for you. tak for alt! Leen, aka de mama van Moustache en Tigra, als 
ik een email zie verschijnen van jou, dan weet ik eigenlijk op voorhand al dat ik een luide schaterlach 
zal moeten onderdrukken. Ik ben dan ook super blij dat ik een vrollega zoals jij heb leren kennen . 
Bedankt voor de ontelbare leuke lunch dates, de peptalks, barbecues, ons super weekend in 
Amsterdam, de champagne voor je eerste artikel, de thema feestjes…! Ik ben ervan overtuigd dat er 
een ware event maganer in jou verborgen zit, misschien een ideetje voor een zelfstandig bijberoep 
(je zou alvast 1 vaste klant hebben)? Ik ben er zeker van dat we mekaar in de toekomst nog veel gaan 
zien! Lies, je introduceerde mij tijdens mijn thesis in de wondere wereld van nervus vagus stimulatie. 
Je leerde mij veel, van kooien kuisen tot opereren, bedankt daarvoor. Lisa, aka Lis, ik herinner me 
nog de dag waarop we elkaar leerden kennen in het bureau, toen nog op het tweede. Op dat 
moment vond je me nog uiterst intimiderend door mijn parfum, door het feit dat ik op jouw stoel zat 
en dan ook nog eens zei dat je geen pritt mocht gebruiken in je laboboek . Sinds die dag is het 
alleen maar bergop gegaan en deelden we superveel lachjes en traantjes. Ik denk met een zéér warm 
hart terug aan onze wandelingen in het bosje achter het UZ, waar we mekaar zoveel hebben 
opgekrikt op moeilijke momenten. Niet alleen op het werk hadden we zeer veel aan mekaar, maar 
ook daarnaast, je leerde me onder andere samen met Leen sushi eten en thee drinken. Absurde 
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toneelstukken moet ik nog leren appreciëren, maar ik ben ervan overtuigd dat je ook daarin zult 
slagen. Van 1 ding ben ik zeker, dit is geen afscheid maar het begin van een superlange vriendschap! 
Mathieu, aka Dr. S, ik ken eigenlijk niemand die zo onvermoeibaar is en zo hard kan werken als jij, 
ongelofelijk! Ik denk met een brede lach op mijn gezicht terug aan al onze flauwe mopjes, maar 
vooral die waar Lisa niet echt mee kon lachen, hihi. Ik ben superblij dat ik in jouw team zat! Eén 
minpuntje misschien, ik zou nog steeds graag hebben dat je dan eens uitlegt wat ‘tegenduwen’ nu 
precies inhoudt. Nathalie, je introduceerde de LKEN3 afterwork drinks en ik denk dat we best kunnen 
stellen dat je indrukwekkende drankkast ons een legendarische eerst editie bezorgde. De congresdag 
nadien was echter iets minder aangenaam… Ik volg met grote ogen je avonturen in Amerika, waar je 
als city girl moet overleven in een blokhut omgeven door spinnen en slangen, chapeau! Ook de 
collega doctoraatstudenten van het instituut voor neurowetenschappen, Linsdey, Katja en Stefanie, 
wil ik bij deze graag bedanken voor alle toffe babbels na onze peer reviews! Dankzij jullie weet ik 
ondertussen toch wat een BICs, rTMS, ASTA, … is, vrouwen aan de top zou ik zeggen! Ook de jonkies 
van LKEN3, Sofie C, Sofie D en Wouter zou ik bij deze graag bedanken. Ik ben blij dat ik jullie heb 
mogen leren kennen en ik ben er van overtuigd dat we elkaar nog zullen terugzien op de veeeeeele 
LKEN3 reünies. Jullie gaan een mooie carrière tegemoet ;-). Ik denk dat het duidelijk is, naast de vele 
wetenschappelijke kennis die een doctoraat met zich meebrengt, heb ik hier ook vrienden aan over 
gehouden, daar ben ik super dankbaar voor. Ik kan alvast niet wachten tot onze eerste LKEN3-
reunie!!  
Gedurende de laatste maanden van mijn doctoraat heb ik ook de kans gekregen om te proeven van 
de klinische studies die op onze dienst plaatsvinden. Al was de combinatie met het afwerken van dit 
doctoraat niet altijd even eenvoudig, toch ben ik zeer tevreden met de ervaringen die ik tijdens deze 
periode heb opgedaan. Het was niet alleen een zeer leerrijke ervaring, maar ook hier heb ik de kans 
gekregen om heel was nieuwe, toffe collega’s te leren kennen. Mijn grootste dank gaat hierbij uit 
naar Fien en Liesbeth, jullie hebben mij ingewijd in de wondere wereld van de CRFs, GCP, IWRS, 
CRA’s,… ik begin er eindelijk een beetje mee weg te zijn ;-). Jullie leveren echt prachtig werk en zijn 
beiden topwijven, bedankt voor alles! Ook alle artsen, assistenten, verplegend on onderhouds 
personeel, medewerkers van het onthaal en het secretariaat wil ik bij deze van harte bedanken. 
Ondanks alle drukke agenda’s stond iedereen steeds met de glimlach paraat om mij wegwijs te 
maken op de dienst. Bedankt voor alles, het was een waar genoegen om deel uit te maken van jullie 
team!  
En dan zijn we aanbeland bij mijn allergrootste supporters, mijn vrienden en familie. Liefste vrienden 
van de bende van Rekkem, de girls mansion/flappen, the biomedical chicks, poedn (kniffel), de 
milieubond, …, bedankt voor alle leuke en ontspannende momenten de voorbije 4 (en eigenlijk 27) 
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jaar. Jullie hebben, zonder het misschien te beseffen, in grote mate bijgedragen tot het slagen van dit 
doctoraat. De ontelbare leuke, koffiekletsen, weekends, verrassingsdagen, breinloze reality-tv-
programma-momenten, etentjes, café bezoekjes, wellness weekendjes, epileersessies…. waren 
onontbeerlijk om mijn batterijtjes telkens terug op te laden, bedankt voor alles, we drinken er 
vanavond eens extra op, al wordt het Kidibul voor mij. 
 
Mijn liefste familie, in het bijzonder ma, pa, Tom & Nelke en mémé, respectievelijk maambrie, 
vaambrie, drieltje & Nelke (daar moet verandering in komen ;-)) en mimpel, bedankt voor de 
onvoorwaardelijk steun en het geloof dat jullie in mij gesteld hebben. Ik hoef er geen tekeningetje bij 
te maken dat ik dit zonder jullie nooit had gekund. Ik ben super trots dat jullie ik jullie dochter, zus, 
kleindochter, nichtje ben! Een oprechte merci voor alles!!!  
 
Ook mijn schoonfamilie wil ik bij deze in de bloemetjes zetten, Ann & Renild, Nick, Maaike & Ina, 
Bram, Shari & Daan, respectievelijk Nonna & Nonno, nonkel scampi, meter Maaike & Ina pretty 
ballerina, Nonkel Bram, tante Shari & Danemanski. Bedankt voor de liefdevolle ontvangst in jullie 
warme nest, ik kan me geen betere schoonfamilie wensen. Een speciaal woordje van dank gaat uit 
naar Nick, voor het ontwerp van mijn cover. Voor alle geïnteresseerden, de contactgegevens van de 
CEO van Uruku kunnen bij mij bekomen worden! 
 
Rob aka, pup (en veel andere bijnaampjes, die ik hier best niet allemaal vernoem), we leerden elkaar 
kennen toen we beiden net begonnen waren met ons doctoraat. Ik zou zo durven stellen dat het een 
woelige periode was, waarin mijn faalangst het vaak overnam van de rede. Toch ben je erin blijven 
geloven en heb je mij gesteund door dik en dun, dat zal ik nooit vergeten. Elk weekend kwam je 
zonder morren mee om de ratjes te checken en te handlen, zonder jou had ik dit niet gekund. Ik 
wordt oprecht gelukkig bij de gedachte aan samen oud worden met jou in ons nestkastje, met enkele 
kleine shmutpups en veeel konijntjes erbij. Je bent de man van mijn leven, ankemoon, normale 
technologie ;)! Ik draag dit werk op aan jou. 
 
Annelies, aka analyze 
Gent, 2015 
 
Dit werk kwam tot stand dankzij de financiële steun van het Instituut voor neurowetenschappen. 
188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
Curriculum vitae 
 
Personalia 
 
LAST NAME: Grimonprez 
FIRST NAME: Annelies 
ADDRESS: Roeselarestraat 395, 8560, Wevelgem - België 
DATE OF BIRTH: 14/04/1988 
NATIONALITY: Belgian 
PHONE NUMBER: 0479/46.46.00 
EMAIL: Annelies.Grimonprez@gmail.com 
 
Graduate studies 
 
2006-2011: Master in Biomedical Sciences – Neurosciences – Ghent University 
Graduated with greatest distinction 
Master thesis: Evaluation of vagus nerve stimulation in the motor cortex stimulation rat model 
Selected for the ‘EOS scriptieprijs’ 
 
 
 
 
 
190 
 
Publications in international peer-reviewed journals (A1) 
 
Grimonprez A, Raedt R, Dauwe I, Mollet L, Larsen LE, Meurs A, De Herdt V, Wadman W, Delbeke J, 
Vonck K and Boon P. Vagus nerve stimulation has antidepressant effects in the kainic acid model for 
temporal lobe epilepsy. Brain Stimulation 2015; 8: 13-20. A1 publication, IF: 5.432, Q1 clinical 
neurology, neurosciences 
 
Grimonprez A, Raedt R, Portelli J, Dauwe I, Larsen LE, Bouckaert C, Delbeke J, Carrette E, Meurs A, De 
Herdt V, Boon P and Vonck K. The antidepressant-like effect of vagus nerve stimulation is mediated 
through the locus coeruleus. Journal of Psychiatric Research 2015; 68: 1-7. A1 publication, IF: 4.092, 
Q1 psychiatry 
 
Grimonprez A, Raedt R, Baeken C, Boon P and Vonck K. The antidepressant mechanism of action of 
vagus nerve stimulation: evidence from preclinical studies. Neuroscience and Biobehavioral Reviews 
2015; 56: 26-34.Review, IF: 10.284, Q1 behavioral sciences, neurosciences 
 
Mollet L, Grimonprez A, Raedt R, Delbeke J, El Tahry R, De Herdt V, Meurs A, Wadman W, Boon P and 
K Vonck. Intensity-dependent modulatory effects of vagus nerve stimulation on cortical excitability. 
Acta Neurologica Scandinavica 2013; 128: 391-396. A1 publication, IF: 2.437, Q2 clinical neurology 
 
Grimonprez A, De Taeye L, Delbeke J, Larsen LE, Raedt R, Boon P and Vonck K. Laryngeal motor-
evoked potentials mark vagus nerve activation: a preclinical study. Submitted to International Journal 
of Neural Systems. A1 publication: IF: 6.056, Q1 computer science, artificial intelligence 
 
Grimonprez A and De Taeye L, Delbeke J, Larsen LE, Raedt R, Boon P and Vonck K. Laryngeal motor-
evoked potentials as an indicator of vagus nerve activation: a clinical pilot trial. In preparation. A1 
publication: in preparation. 
 
191 
 
Mollet L, Raedt R, Delbeke J, El Tahry R, Grimonprez A, Dauwe I, DeHerdt V, Meurs A, Wadman W, 
Boon P and K Vonck. Electrophysiological responses from vagus nerve stimulation in rats. 
International Journal of Neural Systems 2013; 23(6): 1350027. A1 publication: IF: 6.056, Q1 
computer science, artificial intelligence 
 
 
Larsen LE, Van Mierlo P, Wadman W, Delbeke J, Grimonprez A, Van Nieuwenhuyse B, Portelli J, Boon 
P, Vonck K and Raedt R. Modulation of hippocampal activity by vagus nerve stimulation in freely 
moving rats. Submitted to Brain Stimulation A1 publication, IF: 5.432, Q1 clinical neurology, 
neurosciences 
 
Abstracts in international journals (C3) 
 
Grimonprez A, Raedt R, Dauwe I, Mollet L, Larsen LE, Meurs A, De Herdt V, Wadman W, Delbeke J, 
Vonck K, and Boon P. Vagus nerve stimulation has antidepressant effects in the kainic acid model for 
temporal lobe epilepsy. Belgian Brain Council, Luik, Belgium. Frontiers in human neuroscience. 
 
Grimonprez A, Raedt R, Dauwe I, Mollet L, Larsen LE, Meurs A, De Herdt V, Wadman W, Delbeke J, 
Vonck K, and Boon P. Vagus nerve stimulation has antidepressant effects in the kainic acid model for 
temporal lobe epilepsy. 11th European congress on Epileptology, Stockholm, Sweden. Epilepsia 2014; 
55: 228-229. 
 
Grimonprez A, De Taeye L, Delbeke J, Larsen LE, Raedt R, Boon P and Vonck K. Dose-dependent 
laryngeal muscle-evoked potentials as an indicator of effective vagus nerve activation. Belgian Brain 
Council, Luik, Belgium. Frontiers in human neuroscience. 
 
Larsen LE, Van Mierlo P, Wadman W, Delbeke J, Grimonprez A, Mollet L, Van Nieuwenhuyse B, 
Portelli J, Boon P, Vonck K and Raedt R. Vagus nerve stimulation decreases hippocampal and 
prefrontal EEG power in freely moving rats: a biomarker for effective stimulation? Frontiers in human 
Neuroscience. 
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Participation in international congresses en meetings 
 
1. Science day. Belgium, Het Pand Ghent, March 2010. 
2. 12th annual international clinical symposium Kempenhaeghe. The Netherlands, 
Kempenhaeghe Heeze, March 2010. 
3. 13th annual international clinical symposium Kempenhaeghe. The Netherlands, 
Kempenhaeghe Heeze, March 2011. 
4. Electrophysiology study day, MRP Neuroscience. Belgium, Het Pand Ghent, October 2011. 
5. Stimulating (the) brain: neuromodulation and cognitive neuroscience, Institute for 
Neuroscience. Belgium, Het Pand Ghent, December 2011. 
6. IUAP Meeting: Molecular and cellular mechanisms of electrical excitability. Belgium, Het 
Pand Ghent, December 2011. 
7. Wetenschappelijke NVS-vergadering. The Netherlands, Heeze, September 2012. 
8. Epilepsy workshop. Belgium, Het Pand Ghent, October 2012. 
9. SWO midwintermeeting. The Netherlands, AMC Amsterdam, February 2012. 
10. 14th annual international clinical symposium Kempenhaeghe. The Netherlands, 
Kempenhaeghe Heeze, March 2013.  
11. Knowledge for Growth. Belgium, ICC Ghent, May 2013. 
12. SWO midwintermeeting. The Netherlands, AMC Amsterdam, February 2014. 
13. 15th annual international clinical symposium Kempenhaeghe. The Netherlands, 
Kempenhaeghe Heeze, March 2014.  
14. Studenten onderzoekssymposium. Belgium, UZ Ghent, April, 29th 2014. 
15. European Congress on Epileptology, Sweden, Stockholm, June-July 2014. 
16. Symposium on affect and cognition, Belgium, Het Pand Ghent, September, 17th 2014.  
17. Belgian Brain Council. Belgium, ICC Ghent, October, 4th 2014.  
18. VNS avond, The Netherlands, Kempenhaeghe Heeze, October 9th 2014.  
19. Belgian society of physiology and pharmacology, autumn meeting, Brussels, October 2014 
20. VNS Pediatric Educational Seminar, Rotterdam, November 6-7th 2014. 
21. Science day. Belgium, Het Pand Ghent, March 2015. 
22. SWO midwintermeeting. The Netherlands, AMC Amsterdam, March 2015. 
23. 16th annual international clinical symposium Kempenhaeghe. The Netherlands, 
Kempenhaeghe Heeze, March 2015.  
24. PhD Day. Belgium, Zebrastraat Ghent, April 2015. 
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Oral presentations 
 
1. Datablitssession: Vagus nerve stimulation has antidepressant potential in the kainic acid 
model for temporal lobe epilepsy. Epilepsy workshop, Belgium, Het Pand Ghent, October 
2012. 
2. Datablitssession: Vagus nerve stimulation has antidepressant potential in the kainic acid 
model for temporal lobe epilepsy. SWO midwintermeeting, The Netherlands, AMC 
Amsterdam, February 2012. 
3. Staff meeting: Vagus nerve stimulation for the treatment of refractory depression and 
epilepsy. Belgium, UZ Ghent, neurology department, March, 2013. 
4. Nervus vagus stimulatie meeting: Nervus vagus stimulatie voor de behandeling van 
stemmingsstoornissen. Kempenhaeghe, Heeze, October, 2014. 
5. International peer review: Vagus nerve stimultion for the treatment of refractory epilepsy 
and depression. UZ Ghent, neurology department, February 2015. 
6. Platform presentation Science day: The antidepressant-like effect of vagus nerve stimulation 
is mediated through the locus coeruleus. Het Pand, Ghent, March 2015. 
 
 
Poster presentations 
 
Mollet L, Grimonprez A, Raedt R, Delbeke J, El Tahry R, De Herdt V, Meurs A, Wadman W, Vonck K, 
Boon P. Modulation of cortical excitability by vagus nerve stimulation in the cortical stimulation 
model. SWO Midwintermeeting, The Netherlands, AMC Amsterdam, February 2012. 
 
Grimonprez A, Raedt R, Portelli J, Dauwe I, Larsen LE, Bouckaert C, Delbeke J, Carrette E, Meurs A, De 
Herdt V, Boon P, Vonck K. Vagus nerve stimulation has antidepressant potential in the kainic acid 
model for temporal lobe epilepsy. Kempenhaege Epilepsy symposium, The Netherlands, Heeze, 
March 2012. 
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Grimonprez A, Raedt R, Portelli J, Dauwe I, Larsen LE, Bouckaert C, Delbeke J, Carrette E, Meurs A, De 
Herdt V, Boon P, Vonck K. Vagus nerve stimulation has antidepressant potential in the kainic acid 
model for temporal lobe epilepsy. Belgian Brain Council, Belgium, Luik, October 2012. 
 
Grimonprez A, Raedt R, Portelli J, Dauwe I, Larsen LE, Bouckaert C, Delbeke J, Carrette E, Meurs A, De 
Herdt V, Boon P, Vonck K. Vagus nerve stimulation has antidepressant potential in the kainic acid 
model for temporal lobe epilepsy. Knowledge for Growth, Belgium, ICC Ghent, May 2013. 
 
Grimonprez A, Raedt R, Portelli J, Dauwe I, Larsen LE, Bouckaert C, Delbeke J, Carrette E, Meurs A, De 
Herdt V, Boon P, Vonck K. Vagus nerve stimulation has antidepressant potential in the kainic acid 
model for temporal lobe epilepsy. Student onderzoekssymposium, Belgium, UZ Ghent, April 2014. 
Grimonprez A, Raedt R, Portelli J, Dauwe I, Larsen LE, Bouckaert C, Delbeke J, Carrette E, Meurs A, De 
Herdt V, Boon P, Vonck K. Vagus nerve stimulation has antidepressant potential in the kainic acid 
model for temporal lobe epilepsy. European Congress on Epileptology, Sweden, Stockholm, June-July 
2014. 
Grimonprez A, De Taeye L, Delbeke J, Larsen LE, Raedt R, Boon P, Vonck K. Dose-dependent laryngeal 
muscle evoked potentials as an indicator of effective vagus nerve stimulation. Belgian Brain Council, 
Belgium, Ghent, October 2014.  
 
Grimonprez A, De Taeye L, Delbeke J, Larsen LE, Raedt R, Boon P, Vonck K. Dose-dependent laryngeal 
muscle evoked potentials as an indicator of effective vagus nerve stimulation. Belgian society of 
physiology and pharmacology, autumn meeting, Brussels, October 2014.  
 
Grimonprez A, Raedt R, Portelli J, Dauwe I, Larsen LE, Bouckaert C, Delbeke J, Carrette E, Meurs A, De 
Herdt V, Boon P, Vonck K. The antidepressant-like effect of vagus nerve stimulation is mediated 
through the locus coeruleus. Kempenhaege Epilepsy symposium, The Netherlands, Heeze, March 
2015. 
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Awards 
 
Master thesis: shortlist EOS scriptieprijs 
Belgian Brain congress 2014: including 10 best posters 
 
Teaching and students 
 
- Hands-on epilepsy workshop on EEG and design of electrodes, 1° Master Students 
Biomedical Sciences 
- Preparation research internship – Lise Troch (2012-2013). 
- Introduction course on epilepsy for master students Biotechnology. 
- Master thesis Lise Troch: The role of the locus coeruleus in the antidepressant effect of 
vagus nerve stimulation (2013-2014) 
- Internship Charlotte Bouckaert: Research on the mechanism of action of vagus nerve 
stimulation (2014-2015) 
- Introduction course on (pre)clinical research, for Biomedical master students 
- Lesson on epilepsy research at Ghent University, for Biology students 
 
 
Courses and varia 
 
- ICH-GCP qualification training course and examination, international survey of regulatory 
requirements concerning clinical research 
- Course in laboratory animal science 
- Basis statistics course in SPSS 19 (January 2011) 
- Advanced Epilepsy course (2012) 
- Advanced statistics course in SPSS 20 (September 2012) 
- Course on power and sample size calculation (November 2012) 
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- Course on Advanced academic English, writing skills. Belgium, UZ Ghent (February-may 
2013) 
- Course on species specific animal welfare in the lab. Ghent, Belgium, Faculty of 
Veterinary Medicine Ghent University (May 2014) 
- Scientific services, reviewer for scientific publication 
- Member of the animal welfare cell of the Ghent University Ethics committee  
 
 
